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SUMMARY
The porphyrias are a group of genetically inherited diseases, each 
characterized by a deficiency of a particular enzyme in the haem biosynthetic 
pathway. The condition may be well tolerated until extra demands are made 
on the pathway. Under such circumstances, the disease may enter an acute 
phase or there may be a worsening of chronic symptoms. The problems 
associated with the porphyrias occur as a result of the excessive production 
of porphyrins and precursors at these times, due to derepression of 5- 
aminolaevulinic acid synthase (ALA-S), the first and rate limiting enzyme in 
the pathway. Porphyria can be accompanied with neurological complications, 
including epilepsy. Seizure control in these patients is difficult because 
many drugs stress the pathway and will precipitate an attack in susceptible 
individuals. Controversy exists as regards which drugs are safe to use for 
control of seizures. This thesis was aimed at resolving if three 
contentious drugs were safe. These were carbamazepine (CBZ), sodium 
valproate (VPA) and phenytoin (DPH). Of further interest was a detailed 
investigation of the effects of CBZ following reports that CBZ treatment 
resulted in a biochemistry typical of acute intermittent porphyria in non- 
porphyric individuals. The nature and possible mechanisms of these effects 
(derepression of ALA-S, depression of porphobilinogen deaminase (PBG-D) 
activity and an altered urinary porphyrin excretion profile) were 
investigated at length in man, rat, cell culture and In vitro.
The first chapter of this thesis provides an introduction to epilepsy, 
the drugs used in its management, the enzymes and intermediates of haem
xiv
biosynthesis and the porphyrias. It concludes with objectives for this 
work. The following chapter describes the various methodologies employed in 
the next six chapters (three to eigbO which contain all the practical results 
and discuss the significance of these.
The results of an assessment of the safety of CBZ, VPA and DPH in the 
management of epilepsy in individuals with porphyria are presented in chapter 
three. This was achieved by examining the effects of these drugs on 
selected aspects of haem biosynthesis in otherwise healthy epileptic patients 
on long-term anti-convulsant monotherapy. CBZ and VPA were found to be
contra-indicated in li^t of the fact that both drugs caused derepression of
ALA-S. There was scxae evidence that in the case of both CBZ and VPA, ALA-S 
was derepressed as a consequence of increased cyt P450 synthesis. VPA also 
caused increased excretion of porphyrins and precursors. This could be
explained by the raised ALA-S activity. CBZ also caused a loss of 5-
aminolaevulinic acid dehydratase (ALA-D, the second enzyme in the pathway) 
activity and a loss of PBG-D activity (third enzyme in the pathway). Both 
of these effects correlated with plasma CBZ levels. However no significant 
departures from normal were found following quantitative and qualitative 
analysis of urinary porphyrins and precursors in individuals on long-term 
CBZ. This disagrees with the findings mentioned earlier. No conclusive 
results could be drawn from the group of patients on DPH. Since all the 
changes found during VPA treatment could be satisfactorily explained, the 
remaining chapters investigated in detail the effects of CBZ treatment on 
selected aspects of the pathway.
Chapter four constituted a more detailed investigation into the effects 
of CBZ treatment on ALA-D, PBG-D and the urinary porphyrin excretion profile
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in man. CBZ treatment produced a slow, irreversible loss of ALA-D activity 
which was related to both plasma "total” CBZ and low activity was the result 
of a reduction in the amount of functionally normal enzyme. The effect of 
CBZ on PBG-D activity noted in chapter three and by earlier workers was shown 
to be an artefact caused by inadequate levels of ALA-D, (required as a 
coupling enzyme for the PBG-D assay). CBZ produced temporary disturbances 
in the urinary porphyrin excretion profile in the initial stages of 
treatment. These changes, described by other workers, were probably related 
to the very hi^ levels of ALA-S found at this time.
Chapter five took these studies a step further by investigating the 
effects of CBZ on haem biosynthesis in rats. These experiments confirmed 
the findings made in chapter four regarding ALA-D and PBG-D and also showed 
that derepression of ALA-S was related to de novo synthesis of the microsomal 
haemoprotein cytodirome P-450. As suggested earlier, this is probably the 
mechanism by which ALA-S activity was derepressed in man during CBZ 
treatment.
Chapter six attempted to elucidate the mechanism whereby ALA-D was 
affected during CBZ treatment. This was done by observing the effects of 
C3BZ and metabolites on erythrocyte ALA-D, rat liver ALA-D and purified bovine 
liver ALA-D jji vitro. Activity was not affected under any of the conditions 
employed, possibly because all of these systems are metabolicailly inert. 
Consequently the effects of CBZ and CBZ-E on ALA-D in cultured human 
lymphocytes were studied in the next chapter (Chapter seven) to try and 
answer the same question as chapter six. Both compounds successfully 
reduced ALA-D activity, both dose-dependently and irreversibly. CBZ-E
XVI
however was mucsh more effective than CBZ. The effects of these compounds on 
the levels of ALA-D activity were not due to cessation of enzyme synthesis. 
Chapter seven also examined the effects of CBZ and CBZ-E on PBG-D activity 
and on the synthesis of porphyrin frcxn added ALA. There was no effect on 
the former but in the case of the latter there was a quantitative (but not 
qualitative) effect: the amount of porphyrin produced was related to the
ALA-D activity remaining. This was taken as further evidence that the 
altered urinary porphyrin excretion profile noted previously was due to 
derepression of ALA-S.
The experiments presented in Chapter ei^t attempted to metabolize or 
activate CBZ to investigate if the effect of CBZ treatment on ALA-D activity 
could be reproduced jji vitro. This was achieved by incubating the drug with 
hepatic drug metabolizing systems in the presence of purified ALA-D. 
Metabolism of either CBZ or CBZ-E was found to produce a selective loss of 
ALA-D activity. The relevance of these findings on the jji vivo situation is 
uncertain. '
Chapter nine is the final chapter in this thesis. It draws together 
the conclusions of the work and discusses the significance of the findings. 
The extent to which the aims set out in Chapter one were met is also 
discussed.
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ABBREVIATIONS
AIP Acute intermittent porphyria
ALA 5-Aminolaevulinic acid
ALA-D 5-Aminolaevulinic acid dehydratase
ALA-S 5-Aniinolaevulinic acid synthase
b.d. twice daily
BSA Bovine serum albumin
CBZ Carbamazepine
CBZ—E Carbamazepine-10,11-epoxide
COPRO Coproporphyrin
COPRO-0 Coproporphyrinogen oxidase
CYTP-450 Cytochrome P-450
DDC 3,5-diethoxycarbonyl-1^4-dihydrocollidine
DHA 4,6-dioxoheptanoic acid
DMAB p-dimethylaminobenzaldehyde
DMSO Dimethyl sulphoxide
DPH Diphenylhydantoin (phenytoin)
DTNB 5,5*-dithiobis (2-nitrobenzoic acid)
DTT Dithiothreitol
EDTA Ethylenediaminote tra-aceti c acid
EP Congenital erythropoietic porphyria
EPP Erythropoietic protoporphyria
PCS Foetal calf serum
FERRO-C Ferrochelatase
GSH Glutathione (reduced form)
GSSG Glutathione (oxidized form)
BBSS Hanks balanced salts solution
HC Hereditary coproprophyria
HgCBZ 10,11-dihydrocarbamazepine
HFLC High performance liquid chromatography
zo • f • o • mixed function oxidase
NADFH Nicotinamide adenine dinucleotide phosphate (reduced form)
NTB 2-nitro-5-thiobenzoic acid
PB Phenobarbitone
PBG Porphobilinogen
PBG-D Porphobilinogen deaminase
PCT Porphyria cutanea tarda (cutaneous hepatic por0iyria)
PROTO Protoporphyrin
PROTO-0 Protoporphyrinogen oxidase
q.i.d. four times daily
RBC Red blood cells
RIA Radioimmunoassay
S.D. Standard deviation
t.d. three times daily
TRANS-CBZ-DICL Trans-10,11 -dihydrodihydroxycarbamazepine
ÜRO Uroporphyrin
URO-D Uroporphyrinogen decarboxylase
VP Variegate porphyria
VPA Valproic acid or its sodium salt
6p-ŒÎC 6p-hydroxy cortisol
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CHAPTER 1
1. INTRODUCTKM
This introductory chapter is divided into four sections. The 
first is devoted to epilepsy and is ccxnprised of a description of 
each of the various forms of the condition. This is followed by a 
section covering each of the anticonvulsant drugs studied in this 
thesis. The third part is concerned with haem biosynthesis and 
includes a review of the knowledge accumulated on each of the enzymes 
in the pathway, a sub-section on the regulation of the pathway and a 
sub-section devoted to disorders of the pathway. The fourth and 
final part of the chapter discusses the objectives of this thesis.
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1.1 EPILEPSY
1.1.1 GENERAL. INTRODUCTION TO EPILEPSY
Epilepsy, which affects 5-6 people per 1000 (Pond, Bidwell and 
Stein, 1960), has been known to man for centuries. As long as 6000 
years ago King Hammurabi of Babylon drew up a code which contained 
laws pertaining to the marriage and employment of epileptics. 
Through the centuries there have been many diverse treatments for the 
disease, ranging from hippopotamus testicles and tortoise blood at the 
time of Hippocrates (400 BC) to castration in the late 19th century. 
Thou^ Hippocrates suggested that epilepsy was due to a disorder in 
the brain almost two and a half thousand years ago, it was not until 
the development of the electroencephalogram in the 1930s that it was 
demonstrated that seizures were caused by abnormal, uncontrolled, 
electrical discharges from neurones throughout the brain. 
Interestingly, such a concept was proposed by DrJîu^lings Jackson in 
the latter part of the 19th century. The pathogenesis of the 
developing fit, however, is still unknown. There is no detectable 
biochemical or physiological abnormality in the brain cells of 
epileptic patients. This has made analysis of the mechanism of 
anticonvulsant drugs, which show great chemical diversity, very 
difficult. Even today the means by which these drugs control 
seizures are still not understood sind the only way of screening new 
euiticonvulsants is by their ability to prevent experimentally induced 
seizures in animals.
1.1.2 CLASSIFICATION OF EPILEPTIC SEIZURES
Epilepsy can generally be divided into two categories: 
generalised and partial epilepsy. Generalised epilepsy symmetrically
involves the whole brain whereas partial epilepsy, as the name 
suggests involves only a part of the brain. These two very broad 
categories can be sub-divided into different classes of seizure and 
the nature of these will be discussed.
All forms of generalised epilepsy are characterized by abnormal 
electrical discharges throughout the cortex of both cerebral 
hemisi^ ieres causing a sudden loss of consciousness. This can take 
the form of a grand mal (or tonic-clonic) or a petit mal (or absence) 
seizure. In a grand mal seizure there is a sudden, ccmplete loss of 
consciousness followed by contraction of all the muscles. This is 
known as the tonic phase and may last from about 30 seconds to 1 
minute. This is followed by the clonic phase, characterized by 
violent contraction and relaxation of all the muscles in the body 
causing a generalised convulsion. These convulsions gradually 
subside as the brain becomes exhausted and the individual may enter a 
state of deep unconsciousness which becomes sleep as consciousness 
returns. On awakening, the individual feels exhausted, is aching all 
over and often has a headache. During the actual convulsion there 
may be incontinence and the patient may bite his tongue. Status 
epilepticus is a condition where one grand mal seizure follows another 
without any rgaining of consciousness between fits. In petit mal 
epilepsy there is only a transient interruption of consciousness 
lasting for up to 30 seconds which often goes unnoticed, as the 
individual does not fall, or is attributed to day-dreaming. The only 
visible sign may be a rapid fluttering of the eyelids. Whereas grand 
mal seizures are commonest in adolescents and adults, petit mal 
seizures occur eLLmost entirely in children.
Partial epilepsy (also known as focal epilepsy) can also be 
divided into two classes - simple or complex partial epilepsy - 
depending on the region of the brain where the disturbance originates 
(the focal point). Simple pairtial epilepsy is an unccxnmon form of 
epilepsy and occurs when the site of abnormal electrical discharge is 
an area of the brain concerned with simple movements such as bending a 
finger, or simple sensations such as heat or cold. An attack occurs 
as a twitch, on one side of the body only, of some part of the body 
corresponding to the focal point of the seizure. This may spread as 
more areas of the brain become involved and may eventually become a 
generalised convulsion with involvement of the entire brain. 
Alternatively the seizure may remain localized and stop. Complex 
partial fits originate in the temporal lobes and for this reason are 
also known as temporal lobe epilepsy. This area of the brain is 
concerned with complex movements involving groups of muscles, for 
example walking and complex sensations such as sound, taste, si^t and 
smell. The temporal lobes sire closely linked to areas of the brain 
controlling autonomic function, emotions, memory and consciousness. 
There is a great variety in the forms ccraplex fits may take, from 
bizarre complex movements to a sensation of strangeness and often 
unpleasant tastes and smells. Due to the proximity of the temporal 
lobes to the aforementioned areas of the brain, these may also become 
involved leading to disturbances of the heart rate, sensations of 
choking or uncomfortable feelings in the gut, memory upsets causing 
feelings of deja vu and emotional involvement leading to feelings of 
rage or fear. There is generally some impairment of consciouness 
which leaves the individual feeling confused after the attack. These 
fits can also develop into generalised convulsions.
The causes of epilepsy can either be termed idiopathic where 
there is no demonstrable brain abnormality» or symptomatic where there 
is a demonstrable brain lesion. However with greater understanding 
of how the brain works, fewer and fewer cases are designated 
idiopathic. The causes of fits may be (a) genetic inheritance of 
some form of brain abnormality - most idiopathic epilepsies fall into 
this category, or (b) brain damage. Brain damage is the commonest 
cause of temporal lobe epilepsy due to the high sensitivity of this 
part of the brain. Brain damage can occur through trauma at birth, 
as a result of an infection of the nervous system such as meningitis, 
as a result of injury to the head, hypoxia, the presence of a tumour 
or the presence of toxic substances, either due to the accumulation of 
endogenous toxic metabolites in diseases such as uraemia or ingestion, 
as in lead poisoning. The commonest precipitating factors of a 
seizure are stress, fever, flashing li^ts and lack of sleep.
For a detailed classification of seizures by clinical and 
electroencêphalo-graphical examination as recommended by the 
International League against Epilepsy, the World Federation of 
Neurology, the World Federation of Neurosurgical Societies and the 
International Federation of Societies for Electroencephalography and 
Clinical NeurojAiysiology see Gas taut (1969). For further detailed 
discussion on all aspects of epilepsy see Laidlaw and Richens, (1982).
1.2 DRUGS USED,IN THE MANAGEMENT OF EPILEPSY
This section provides an introduction to the four most commonly 
prescribed anticonvulsants in this country. The four drugs, 
phenobarbitone, phenytoin, carbamazepine and valproic acid, are 
presented in chronological order of their introduction into the United 
Kingdom. Each is discussed in a separate sub-section. Although 
primidone is now prescribed in preference to phenobarbitone (primidone 
is metabolized to phenobarbitone and another pharmaoologicailly active 
compound) no patients receiving primidone therapy were studied in this 
thesis amd therefore this drug is not discussed here. This section 
discusses the following properties and features of each drug: 
structure; seizures against which it is effective; therapeutic plasma 
levels; absorption; transport; metabolism; half-life; excretion; 
pharmacological interactions; possible mechanisms of action.
1.2.1 PHENOBARBITONE
Phenobarbitone (PB) fig. (1) is a derivative of barbituric acid 
and was one of the first anticonvulsant drugs used in the treatment of 
epilepsy over 70 years ago (Hauptmann, 1912). PB is effective in the 
treatment of generalized tonic-clonic and all forms of partial 
seizures (So and Penry, 1981).
PB differs from other barbiturates in that it's anticonvulsant 
properties are manifest without unacceptable sedation. The 
therapeutic serum levels of PB are 10-40mg/l (43-172pM). The drug is 
40-50$ bound in semM (Goldbaum and Smith 1954; Waddell and Butler, 
1957), principally to albumin. The drug has a relatively long half- 
life of around 96 hours for a single dose (Viswanathan, Booker and
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Welling, 1979). PB is metabolized by the hepatic mixed function 
oxidase (m.f.o) system, but a significant fraction (usually around 
25$) of administered drug is excreted unchanged. (Whyte and Dekaban, 
1977). The major metabolite of the drug is p-hydroxyphenobarbitone 
(HPB), HPB is found in urine and accounts for, on average, 17$ of 
the excreted compound and exists as both free HPB and the glucuronide 
conjugate (Whyte and Dekaban, 1977). The production of HPB is 
important in the detoxification of PB as it is devoid of 
anticonvulsant activity and is rapidly cleared from the circulation 
(Butler, 1956). This is supported by the fact that HPB cannot be 
detected in the plasma of epileptics taking large doses of the drug 
(Alvin al* 1975). Other minor metabolites of PB are known 
(Maynert, 1982).
Drug interactions with phenobarbitone occur at the level of 
biotransformation rather than binding or absorption and are primarily 
due to the powerful induction of hepatic m.f.o activity which PB 
causes. This leads to increased metabolism and consequently shorter 
half-lives of many drugs including carbamazepine (Christiansen and 
Dam, 1973; Christiansen and Dam, 1975) and f^enytoin (Cucinell at 
1965). Due to its long half-life, ccxnpounds which interfere with PB 
metabolism and elimination can cause the drug to accumulate to toxic 
levels. This has been reported to occur with valproate and is 
thought to be due to an inhibitory action of valproate on the 
hepatic m.f,o system (Kapetanovic aL 1980). The phamaoctonetic 
interactions between PB and other drugs have been catalogued by Kutt 
and Paris-Kutt, (1982).
In ocMnmon with the other anticonvulsants to be described» the 
mechanism by which PB acts to prevent seizures is unknown. The most 
plausible mechanism, however, may lie in the effects of the drug on 
synaptic transmission at both pre and post-synaptic levels (Pridiard, 
1982).
1.2.2 PHENYTOIN
Phenytoin, also known as diphenylhydantoin, fig.(2) was 
originally identified as having anticonvulsant properties through its 
ability to prevent experimentally induced seizures in animals (Merrit 
and Putnam, 1938). In humans it has been shown to be effective 
against generalized tonic-clonic seizures and all types of partial 
seizures (So and Penry, 1981),
The drug is principally absorbed by passive diffusion across the 
lumen of the duodenum (Meinardi &L al, 1975) rather than the stomach 
because jAienytoin is not soluble at the pH of gastric juice (Dill 
et al, .1956). The therapeutic range of the drug in serum is 10- 
20mg/l (4G-8C)pM), though departures from this are sometimes necessary 
depending on the individual (in clinical practice values ranging from 
5-50mg/l may be found). Phenytoin in serum is highly protein bound, 
on average, 90$ at 37°C, mostly to albumin (Hooper jgtâL 1973). The 
half-life of the drug in man is, on average, about 22 hours (Arnold 
and Gerber, 1970) following an oral dose. Enormous variations are 
found however because the half-life of the drug is aiffected by many 
parameters including dose (Arnold and Gerber, 1970), concurrent drug 
therapy (see later) and plasma bilirubin (Hooper ai, 1973). The 
drug is extensively metabolized by the mixed function oxidase system 
in the liver and excreted in the urine with less than 5$ of the parent
NH
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drug remaining unchanged (Glazko al» 1969). The principal 
metabolite is 5-(4-hydroxyphenyl)-5-phenyl-hydantoin (HPPH) which 
appears in the urine as a glucuronide conjugate (Maynert, I960; 
Thcmipson at aJj 1973). Recent advances in analytical techniques have 
resulted in the identification of many minor metabolites, (Chang and 
Glazko, 1982).
The observation made in the previous paragraph that the half-life 
of the drug varied with the dose given (the half-life increases as the 
dose increases), is due to the fact that the capacity of the liver to 
metabolize DPH becomes saturated within the range of plasma 
concentrations normally used in seizure control, (Arnold and Gerber, 
1970). The drug is said to display saturation 1d.netics.
Phenytoin interacts extensively with many other drugs (Richens, 
1977; Kutt, 1982), resulting in alterations of the pharmacokinetics of 
either itself or the other ccxnpound. The most common interactions 
occur at the level of protein-binding or biotransfcrmation. Drugs 
which are strongly protein bound, such as salicylates (Fraser sL al;
1980) and valproate (Dahlqv 1st aL 1977), will displace {Aienytoin 
from albumin leading to an increase in the pharmacologically active 
free fraction of the drug, though this may be compensated by an 
increased rate of metabolism. Induction of hepatic mixed function 
oxidase activity may increase the rate of phenytoin metabolism and its 
rate of clearance. Thus phenobarbitone, a potent inducer of the 
mixed function oxidase system, can induce phenytoin metabolism 
(Cucinell al. 1965) though this example can have additional 
complicating factors (Patsalos and Lascelles, 1977). Phenytoin
appears to be autoinducing (i.e. to induce its own metabolism) and can 
also induce the metabolism of other drugs, such as carbamazepine 
(Eichelbaum al.1979).
The mechanism of action of phenytoin is uncertain, but the drug 
is known to have many effects on events associated with the 
transmission of impulses through the synapse (Woodbury, 1982). 
However the most probable mechanism (and the only effect demonstrable 
using therapeutic free serum levels) is that phenytoin limits the hi^ 
frequency, repetitive firing of neurons. This has been shown in cell 
cultures of mouse spinEil cord neurons (Macdonald and McLean, 1982). 
This effect is believed to arise throu#i interference with sodium 
transport across the neuronal membranes, possibly by temporary 
blockage of sodium channels after the neuron has fired, increasing the 
time taken for the action potential to be restored (Matsuki al.
1981).
1.2.3 CARBAMAZEPINE
Carbamazepine (CBZ) fig.(3) was first synthesized in 1954 
(Schindler and Haflinger, 1954). Several years later it was shown to 
have anticonvulsant properties by its ability to suppress 
experimentally induced seizures in animals (Theobold and Kunz, 1963). 
The drug has demonstrated its usefulness in the treatment of partial 
seizures (particularly of the complex form) and generalised tonic- 
clonic seizures (Ctererfiino et al,1974).
CBZ is hi^ily lipid soluble and therefore is rather slowly absor­
bed from the gastro-intestinal tract (Morselli, 1975). The therapeu­
tic range of the drug in serum is 4-10mg/l (17-4^M) though some 
departures from this are occasionally required to achieve satisfactory
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control. CBZ is 70-80% protein bound in serum. Albumin binds the 
drug at only one group of binding sites (Di Salle» Pacifiai and 
Morselli» 1974), but the drug is also bound to other proteins. The 
half-life of CBZ in man varies tremendously and is particularly 
affected by co-medication. CBZ also reduces its own half-life 
(Rapeport &L al? 1983). Half-lives of 26 hours, 12 hours and 8 hours 
were determined for the drug in volunteers, epileptic patients on CBZ 
monotherapy and epileptics taking CBZ in combination with other 
anticonvulscints respectively (Eichelbaum ^ âL?1985). The mechanisms 
of this will be discussed later. CBZ is extensively metabolized, the 
metabolites being excreted in the urine and the faeces (Faigle and 
Feldmann, 1975). The major metabolite found in plasma is 
carbamazepine-10,11-epoxide (CBZ-E), fig.(B), formed through the 
action of hepatic mono-oxygenases on CBZ (Frigerio, Cavo-Briones and 
Belvedere, 1976). This compound accounts for between 10 and 20% 
total CBZ in plasma (Brodie, Forrest and Rapeport, 1983) and has been 
shown to have equipotent anticonvulsant activity with the parent drug 
(Frigerio and Morselli, 1985, Morselli aL 1975). The principle 
excretory metabolite, trans-10,11-dihydrodihydroxycarbamazepine 
(trans-CBZ-diol) fig.(3), is formed by hydrolysis of CBZ-E throu^ the 
action of epoxide hydrase (Oesch,1973). This ccxnpound is found in 
the urine, both free and as the mono-O-conjugated glucuronide, and 
can account for up to 60% of the daily ingested doses of carbamazepine 
(Eichelbaum at al» 1979). Many other minor metabolites and metabolic 
routes have been determined (Faigle and Feldmann 1982).
CBZ is a potent inducer of the hepatic mixBd function oxidase 
(m.f.o) system and as such can significantly effect the
1 1
pharmacokinetics of itself and a number of other drugs. Thus 
prolonged treatment with CBZ results in a reduction of its half-life 
(Eichelbaum, 1985; Rapeport at Sly 1983) and its steady state levels 
(Eichelbaum at Sly 1975). Other drugs known to be affected in this way 
during ccmedication with CBZ include phenytoin (Hansen, Siersback- 
Neilsen and Skorsted, 1971) and valproic acid (Bowdle, Levy and 
Cutler, 1979). Similarly, drugs which induce the hepatic m.f.o. 
system will also reduce the half-life of CBZ (Eichelbaum at a L  
1985). This has been shown to occur with phenytoin and phénobarbital 
(Christiansen and Dam, 1973; Christiansen and Dam, 1975). Compounds 
which inhibit CBZ metabolism will cause elevation of serum levels. 
Such an effect has been demonstrated with cimetidine, an H2  receptor 
antagonist (Macphee at  al* 1984). Levy and Pitick (1982) have 
catalogued pharmacokinetic interactions of CBZ with other drugs.
As for other anticonvulsants, the mechanism of CBZ’s action is 
uncertain, but many workers believe that it has actions similar to 
phenytoin (Suria and Killam 1980). CBZ has been shown to limit hi^ 
frequency sustained repetitive firing of neurons at therapeutic ffee 
serum concentrations (MdLean and Macdonald, 1983). This may occur 
throu^ interference with Na'*’ and trainsport (Schauf sL al* 1974). 
CBZ has also been shown to affect acetylcholine levels (Console, 
Biandii and Ladinsky, 1976), to reduce catecholamine turnover (Maitre 
et al, 1983) and to interact with brain adenosine receptors (Marangos 
âl* 1983; Skerritt, Davies and Johnston, 1983). Each of these may 
have seme beeiring on the anticonvulsant efficacy of CBZ.
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1.2.4 .YAL£ROIÇ AÇIV
Valproic acid is a branched chain fatty acid, fig.(4), first 
synthesized in 1882 (Burton, 1882), but not identified as having 
anticonvulsant activity until 1963 (Meunier sL Sly 1963). It was 
first used in Europe in 1964 (Carraz sL Sly 1964) and in America 14 
years later. The drug is generally prescribed as the sodium salt, 
which has greater water solubility. In man, VPA has been shown to be 
effective in the management of generalized tonic-clonic, absence and 
myoclonic seizures (Pinder ^  al* 1977; Bruni and Wilder, 1979).
VPA is rapidly absorbed following an oral dose and displays no 
site specificity for absorption. Evidence for a therapeutic range is 
sparse, but a target range of 50-100mg/1 (0.33-0.67mM) in serum can be 
used. Toxicity is frequently reported at concentrations in excess 
of this (Mucklow, 1984). The drug is highly protein bound, on average 
about 90% (Patel and Levy, 1979; Bowdle &L al* 1980). As total 
plasma VPA is increased, the free fraction of the drug rises, 
indicating that binding of the drug is a saturable process (Patel amd 
Levy, 1979, Bowdle al* 1980). Albumin is the principal protein 
which binds the drug and has two groups of binding sites (Gugler and 
Mueller, 1978). Most other drugs, including the major 
anticonvulsants, do not affect VPA binding due to the relatively hi^ 
affinity the drug has for albumin. However salicylate cam decrease 
the bound fraction (Schobben, Vree and van der Kleijn, 1978) as can 
free fatty acids (Monks amd Richens, 1979; Patel and Levy, 1979) due 
to competitive inhibition of the binding process. The elimination 
half-life of VPA in man averages about 9 hours (Mattson jgl al 1978), 
though this can be affected by concurrent medication (see later).
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VPA is extensively metabolized primarily by ^-oxidation in extra- 
hepatic tissues (MatsumotOf Kuhara and Yoshino» 1976) and w-oxidation 
involving liver microsomal enzymes (Kochen and Scheffner, 1980). 
This metabolism is what would be expected of a fatty acid and explains 
the many metabolites found in urine and plasma (Kuhara jgi. âi* 1978). 
The major excretory route is in the urine and the major excretory 
product is the glucuronide conjugate of VPA (Vree and van der 
Kleijn» 1977). Less than 4% of an oral dose is excreted as the free
acid (Gugler al* 1977).
VPA frequently interacts with other drugs, affecting the 
pharmacokinetics of VPA 2in(i c>iKer drugs , 19 Ôl). The ti^t binding of
VPA may lead to the displacement of other, less ti^tly bound drugs, 
leading to either an increase in the i^ iarmacologically active free 
fraction of the drug (as may occur with carbamazepine; Mattson, 
Mattson and Gramer, 1982) or a reduction in total concentration due to 
a greater rate of clearance (as occurs with phenytoin; Mattson sL al,
1978). VPA also has inhibitory effects on the hepatic mixed function
oxidase (m.f.o.) system. Hiis could lead to accumulation of drugs 
which have to be metabolized by this pathway sind is believed to be the 
mechanism by which VPA raises phénobarbital levels during co­
medication (Kapetanovic at. al* 1980). VPA does not induce its own 
metabolism or that of other drugs (Mattson at. al* 1978) but many drugs 
which induce hepatic m.f.o. activity accelerate VPA metabolism 
resulting in a more rapid clearance and a reduced half-life (Mihaly at. 
al. 1979; Reunanen et al, 1980).
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The mechanism of action of VPA is unknown but there are three 
basic hypotheses (reviewed by Johnston and Slater, 1982), The first 
suggests that VPA operates by increasing the levels of the inhibitory 
neurotransmitter ^ -amino butyric acid (GABA) in brain by inhibition 
of GABA catabolism ((îodin at Sly 1969; Simmler at al* 1973; Harvey, 
Bradford and Davison, 1975). The second hypothesis proposes that VPA 
exerts its effects by acting on membranes to reduce the excitability 
of the neuron (Slater and Johnston, 1978), while the third hypothesis 
suggests that VPA enhances the response of the GABA receptor in the 
post-synaptic cell to the binding of GABA, potentiating the inhibitory 
effect (Macdonald and Bergey, 1979). There is to date no data to 
favour any one of these hypothesis more than another and it must be 
remembered that much of this work was performed in vitro and as such 
must be interpreted with caution.
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1.3 HAIM BIOSYNTHESIS
The haem biosynthetic pathway is of great interest because of the 
vital metabolic role played by its end-product» haem, in biological 
oxidative processes and oxygen transport. Variations of the basic 
porphyrin nucleus, of which haem is but one, are found in bacteria, 
yeasts and plant cells, as well as in avian and mammalian tissues, 
reflecting the central role played by these ccxnpounds in nature.
The steps leading to the biosynthesis of haem were initially 
elucidated through the use of isotopic tracer studies by Shemin 
(1955). These results laid the foundations for all subsequent 
investigations, as a result of which the pathway is now well 
understood and is illustrated in a typical cell in fig. (5).
As this thesis discusses the effects of drugs on the enzymes of 
haem biosynthesis, a short resume of the knowledge to date on each of 
the enzymes is presented. In general, only mammsilian enzymes will be 
reviewed. The excretion of pathway intermediates, disorders of the 
pathway and the response of the pathway to interference will also be 
covered.
1.3.1 5-AMIN(LAEVULINIC ACID SYNTHASE
(ALA-8; Succinyl CoA: Glycine C Succinyltransferase (decarboxylating); 
E.C.2.3.1.37).
The first and rate-limiting step of haem biosynthesis is the 
condensation of succinyl CoA and glycine to form ALA and is catalysed 
by ALA-8. The structure of ALA is shown in fig.(6). The enzyme is 
located in the mitochondrion, loosely attached to the inner membrane 
(Patton and Beattie, 1973) and requires the cofactor pyridoxal 
phosfdiate (FLP) for activity (8chulman and Richert, 1956) and also 
perhaps as a stabilizing factor (Beattie aL 1985).
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THE HAEM BIOSYNTHETIC PATHWAY
The figure shows the enzymes and intermediates of haem biosynthesis and 
their distribution within the cell.
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STRUCTURES ON THE PORPHYRIN PRECURSORS 
A - 5-Aminolaevulinlo acid (ALA)
B - Porphobilinogen (PBG)
The enzyme is synthesized in the cytoplasm as a precursor and 
then translocated to the mitochondria (Hayashi, Yoda and Kikuchi 
1970), This has recently been demonstrated jja. vitro with the 
suggestion of processing of the enzyme in the course of the 
translocation (Yamauchi, Hayashi and Kikuchi, 1980 (B)).
ALA-S has been purified from rat liver mitochondria and shown to 
be a dimer of 120,000 molecular wei^t, ccxnposed of two identical sub­
units (Paterniti and Beattie, 1979). The cytosolic enzyme has also 
been purified and shown to be immunochemically identical to the 
mitochondrial enzyme (Nakakuki al* 1980). The pH optimum of the 
purified enzyme was 7.5. The enzyme from chick liver has also been 
purified (Whiting and Granick, 1976).
The mechanism of the reaction is that glycine reacts with enzyme 
bound FLP to form a stable Schiff base carbanion. This then reacts 
with succinyl CoA to produce -amino (2-ketoadipic acid which remains 
linked to the FLP-enzyme. There are two possible mechanisms for the 
next step (Ahktar at al* 1976): either a decarboxylation to give an 
ALA-FLP-enzyme complex which is then hydrolysed to release ALA, or 
hydrolysis of the complex yielding -amino p-ketoadipic acid which 
spontaneously decarboxylates to ALA.
ALA-8 is the rate-limiting enzyme of haem biosynthesis and as 
sudi is strictly regulated, principally throu^ feed-back regulation 
of enzyme synthesis by haem. Haem has been shown to inhibit ALA-nS 
synthesis at the transcriptional level (Yamamoto, Hayashi and Kikuchi,
1982) at the translational level (Kikuchi and Hayashi, 1981; 
Yamamoto, Hayashi and Kikuchi, 1983) and at the level of translocation 
of the precursor ALA-S from the cytoplasm into the mitochondria
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(Yamauchi, Hayashi and Kikuchi, 1980 (A), Kikuchi and Hayashi, 1981). 
Haem has also been shown to directly inhibit ALA-S (Whiting and 
Elliot, 1972; Scholnick, Ham maker and Marver, 1972) though the 
physiological relevance of this is doubtful (Wolfson, Bartczak and 
Bloomer, 1979). Steroids are also known to have regulatory effects 
on the levels of enzyme, though the mechanisms by which these occur 
are uncertain (Matsuoka, Yoda & Kikuchi, 1968; Sassa, Bradlow and 
Kappas, 1979). Control of flux throu^ the pathway is also enhanced 
by the short half-life of the enzyme of 1 hour and the low levels of 
activity present in cells, (Granick and Sassa, 1971).
ALA-S activity which is normally low, can be derepressed 
following treatment with drugs and xenobiotics and elevated levels of 
the enzyme are silso found in certain pathological conditions e.g. the 
porphyrigis. The mechanisms by which these effects occur will be 
discussed in sub-section 1.3.9.
1.3.2 5-AMINCLAEVOLINIC ACID DEHYDRATASE
(ALA-D; porphobilinogen synthase; 5-aminolaevulinate hydrolase (adding 
5-aminolaevulinate ard cyclizing) ; E.C. 4.2.1.24)
The next step in the pathway takes place in the cytoplasm. ALA-D 
catalyses the condensation of two molecules of ALA to form the 
monopyrrole porphobilinogen (PBG) with the elimination of two 
molecules of water. The structure of PBG is shown in fig.(6).
ALA-D has been purified from bovine liver (Wu et al, 1974) and 
human erythorocytes (Anderson and Desnick, 1979). Both have been 
shown to be octameric enzymes of molecular wei^ts 285,000 aid 252,000 
respectively and to require Znf* ions for activity. The human 
erythrocyte enzyme binds 8 atoms of Zn^"*" per molecule of native enzyme
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(Gibbs and Jordan, 1981), The enzyme also has essential sulphydryl 
groups which must be maintained in a reduced state for maximum 
catalytic activity using reagents such as dithiothreitol, 
mercaptoethanol and cysteine (Shemin, 1972).
The first step in the condensation reaction is the binding of 
the ALA molecule which will give rise to carbon atcxns 2,3,8,9 and 10 
in the PBG produced to one side of the catalytic site (Jordan and 
Gibbs, 1985). A Sdiiff base is formed with a reactive amino group in 
the active site and a second molecule of ALA then occupies the other 
side of the active site. The series of steps leading to the 
formation of PBG are described by Shemin (1976).
ALA-D is very sensitive to inhibition by a number of compounds. 
Lead is an extremely potent inhibitor of the enzyme, though its 
effects are reversible by treatment with Zn^"*" and sulphydryl reagents 
(Mauras and Allain, 1979; Moore, Meredith and Goldberg, 1980). This 
suggests that inhibition takes place through interaction of lead with 
essential -SH groups, though other factors may be involved (Sakai, 
Yeinagihara and Ushio, 1981). Alcohol also inhibits ALA-D (Moore, 
McColl & Goldberg, 1985) both in human erythrocytes (Krasner al* 
1974) and in human liver (Kondo, Urata & Shimizu, 1984). Succinyl 
acetone, a metabolite produced in abnormal quantities by individuals 
with hereditary tyrosinemia, is a very potent inhibitor of ALA-D 
because it is a non-metabolizable substrate analogue for ALA (Tschudy, 
Hess and Frykholm 1981; Sassa and Kappas, 1983). Inhibition of ALA-D 
by these ccmipounds may be great enough to impair haem biosynthesis and 
consequently lead to an increase in ALA-S activity in the manner 
described in 1.3.9.
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1.3.3 PQfiBiQBJLINOGEN DEAMINASE
(PBG-D; uroporphyrinogen-I-synthase; hydroxymethybilane synthase
porphobilinogen ammonia-lyase (polymerizing); E.C. 4.3.1.8)
and
UROPQRPHYRINOGEN-III-COSYNTHASE 
(URO-CoS NoE.C. Number).
PBG-D and URO-CoS work in concert to produce the asymmetric 
tetrapyrrole uroporphyrinogen III (DROgen III) (fig.(7) from 4 
molecules of PBG with the release of 4 molecules of ammonia. In the 
absence of the cosynthase UROgen I is formed. Both enzymes are 
cytoplasmic. PBG-D activity is normally the rate limiting factor in 
the conversion of PBG to UROgen III.
PBG-D has been purified from human erythrocytes and shown to be a 
monomeric enzyme of molecular wei^t 36,000 -38,000 dal tons and to 
have a pH optimum of 8.2 (Anderson and Desnick, 1980). No 
purifications of the cosynthase are reported.
The mechanism of the reactions is complex. Studies on the 
intermediates using NMR spectroscopy (Burton et al 1979; Scott et al, 
1980) have revealed that PBG-D catalyses a head to tail condensation 
of 4 molecules of PBG to form the linear tetrapyrrole 
hydroxymethylbiliane (HMB, also called preuroporphyrinogen) which is 
the substrate for URO-CoS in the synthesis of the asymmetrical 
tetrapyrrole UROgen III (Jordan al* 1979). In the absence of URO- 
CoS activity, the symmetrical isomer UROgen I is formed throu^ a 
rapid non-enzymatic cyclization of the hi^ly unstable HMB(tV2  = 4.4 
minutes at 37°C and pH 8.25; Burton al* 1979). For further 
discussion of the mechanism and stereochemistry of the PBG-D reaction 
see Jones, Jordan and Ahktar (1984).
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PBG-D has the lowest endogenous activity in the haem biosynthetic 
pathway after ALA-S (Elder, 1982) and it has been suggested for this 
reason that it may be a secondary control point (Brodie ai. al, 
1977(A)), This is of interest because it implies that inhibition of 
PBG-D could seriously disturb flux throu^ the pathway, especially in 
individuals suffering frcxn acute intermittent porphyria where there is 
a genetically inherited deficiency of PBG-D activity (Meyer at. al* 
1972; Strand at. al* 1972). This may precipitate an acute attack as 
described in subsection 1.3.10. With regard to this, sulphonamides 
(Peters at.al* 1980), bilirubin (Kohashi, Tse and Piper, 1984) and 
carbamazepine (Yeung at. al* 1983 (A)) have been reported to inhibit 
PBG-D activity, though the findings of Yeung at. al are disputed and 
will be investigated in detail in this thesis.
1.3.4 UROPORPHYRINOGEN DECARBOXYLASE
(ÜRO-D; uroporphyrinogen carboxy-lyase; E.G. 4.1.1.37).
URO-D, a cytoplasmic enzyme, catalyses the conversion of UROgen 
(an octacarboxylic porphyrinogen) to coproporphyrinogen (COPROgen; a 
tetracarboxylic porphyrinogen) (see fig.7) by 4 sequential 
decarboxylations.
URO-D has been purified from bovine liver (Straka and Kushner,
1983) and from human erythrocytes (Elder, Tovey and Sheppard, 1983; de 
Vemeuil, Sassa and Kappas, 1983 (B)). The enzymes from both species 
are monomeric proteins and have the ability to catalyse each of the 
four decarboxylations which occur in the conversion of UROgen to 
COPROgen. Both enzyme species will convert UROgen III or UROgen I to 
the appropriate COPROgen isomers, thou^ UROgen III is the preferred 
substrate and is more rapidly metabolized. Both appear to have at
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least one essential sulphydryl group for catalytic activity and to 
have at least two active sites. The optimum assay pH in each case is 
6.8. The bovine liver enzyme has a molecular weight of around 57,000 
whilst the human erythrocyte enzyme has a molecular wei^t of 46,000. 
URO-D has also been purified from chicken erythrocytes (Kawanishi, 
Seki and Sano 1983).
Following binding of UROgen to the enzyme, the four 
decarboxylations appear to occur in sequence, the first being the 
rapid removal of the carboxyl group of the cairboxymethyl constituent 
of the D ring, yielding heptacarboxylic (7-COOH) porphyrinogen, 
followed by the slower elimination of the carboxyl groups on the A,B 
and finally C rings to form hexacarboxylic-( 6-COOH), pentacarboxylic- 
(5-COOH) and tetracarboxylic-(COPRO) porphyrinogens respectively 
(Jackson et al. 1976). The structures of these are shown in fig.(7).
URO-D is sensitive to inhibition by pol^ialogenated aromatic 
compounds (Sinclair et al. 1984; Rif kind et al. 1985; Sano, Kawaniski 
and Seki, 1985). Iron also plays a role in the inhibition of this 
enzyme (Smith and Francis, 1983; de Verneuil, Sassa and Kappas, 1983(A); 
Ferioli, Harvey and de Matteis, 1984; Mukerji, Pimstone and Burns,
1984). Liver disease such as is found in alcoholism msiy also lead to 
depressed URO-D activities (Moore, McColl and Goldberg, 1985). All 
of these may produce a cutaneous hepatic porphyria syndrome, 
identical to that found in the inherited deficiency of URO-D except 
that In this case the lesion is confined to the liver whereas in the 
inherited situation it is present in all tissues.
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1.3.5 .CQPRQPORPHYRXNQgEN QXXPAgS
(COPRO-0; coproporphyrinogen: oxygen oxidoreductase (decarboxylating); 
E.C.1.3.3.3).
The pathway now re-enters the mitochondria, where CX)PROgen III 
undergoes two oxidative decarboxylations to produce protoporphyrinogen 
IX. (PROTOgen IX), fig.(7). The reaction is catalysed by COPRO-0, 
sui enzyme located in the inter membrane space of the mit^ondria (Elder 
and Evans, 1978).
The enzyme reaction occurs in two steps (Ahktar fit al* 1976) and 
appears to follow a specific sequence, the propionic acid on the A 
ring being decarboxylated before that on the B ring (Jackson at. al*
1976). The enzyme requires molecular oxygen as a hydrogen acceptor 
for this reaction (Sano and Granick, 1961). COPROgen I is not a 
substrate for the enzyme (Porra and Falk, 1964; Batlle, Benson and 
Rimington, 1965).
1.3.6 PROTOPORPHYRINOGEN OXIDASE
(PROTO-0; protoporphyrinogen IX dehydrogenase; E.C.1.3.3.4).
The reaction catalysed by PROTO-0 is the oxidation of PROTOgen IX 
to protoporphyrin IX (PROTO IX). This reaction can occur 
spontaneously and for this reason it was relatively recently that the 
existence of this enzyme was established. Jackson at. al (1974) 
demonstrated by iso topic labelling studies that the reaction is indeed 
enzyme catalysed in vivo and occurs in a stereospecific manner: 6
hydrogen atoms are removed from one side of PROTOgen IX only. The 
enzyme requires oxygen and is bound to the inner mitochondrial 
membrane (Poulson and Polglase, 1975; Poulson, 1976).
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1.3.7 FERROCHELATASE
(FERRO-C; haem synthetase; protohaem ferro-lyase; B.C. 4,99.1.1.).
The final step in the biosynthesis of haem takes place within the 
mitochondrion and is catalysed by FERRO-C. Ferrous ions (Fe^ '*‘) are 
inserted into PROTO IX with concomitant removal of two hydrogen atoms. 
FERRO-C is attached to the inner mitochondrial membrane (McKay jsL al,
1969) and requires lipid for activity (Simpson and Poulson, 1977; 
Taketani and Tokunaga» 1981).
The enzyme has been purified from rat liver (Taketani and 
Tokunaga» 1981) and from bovine liver (Taketani and Tokunaga, 1982) 
and shown to have molecular weights of approximately 240,000 and 
200,000 respectively and to be oligomers of 4 or 5 identical subunits.
FERRO-C activity is severely inhibited by treatment with 3,5- 
diethoxycarbonyl-1,4-dihydrocollidine (DDC), producing a form of 
porphyria in experimental animals. The actual inhibitor is formed by 
a transmethylation from DDC to the porphyrin moiety of cytochrome P450 
(Ortiz de Montellano, Beilan and Kunze, 1981; Tephly ai; 1980). 
Lead (Campbell ai.âi» 1977) and alcohol (Brodie ai. jai, 1979), also 
reduce FERRO-C activity.
1.3.8 THE EXCRETION OF INTERMEDIATES IN THE HAEM BI0S7NTHETIC PATHWAY
The intermediates of haem biosynthesis, ALA, PEG and the oxidized 
forms of the various porphyrinogens are normally excreted in small 
quantities in urine. The structures of these compounds were shown in 
figs. (6) and (7). Porphyrins found in normal urine are 
predominantly COPRO but traces of URO and the other intermediates are 
also found. Most of the ÜRO-I produced and all of the COPRO-I
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produced is excreted in this way because as explained in 1.3.4 and 
1.3.5, URO-I is a poor substrate for ÜRO-D and COPRO-I is not a 
substrate for COPRO-0.
When the pathway is subjected to stress, for example by 
inhibition of one of the enzymes, an alteration in the excretion 
profile of these precursors is found. Thus lead-poisoning, where 
ALA-D Sind FERRO-C activities are reduced, leads to increased excretion 
of ALA and PROTO, whereas the depression of ÜRO-D scraetimes found in 
alcoholic liver disease may result in an increase in the excretion of 
URO and 7-COOH porphyrins. The porphyrias, genetically inherited 
defects of haem biosynthetic enzymes, also result in alxiormal urinary 
and faecal excretion of porphyrins and precursors. The changes found 
are discussed in detail in 1.3.10.
1.3.9 DEREPRESSION OF 5-AMINXAEVULINATE SYNTHASE
ALA-S, the rate controlling step in haem biosynthesis, can be 
derepressed by treatment with drugs or in pathological conditions 
such as the porphyrias. The primary control of the levels of ALA-S 
activity is throu^ feed-back inhibition of synthesis by haem, as was 
discussed in 1.3.1. The current concept of regulation of this 
process is that the rate of enzyme synthesis is governed by a small, 
rapidly turning-over "free" haem pool within the cell. If this pool 
is depleted through decreased synthesis, increased utilization or 
increased destruction of haem, ALA-S synthesis will be induced. The 
circumstances giving rise to such changes in intracellular haem will 
now be discussed.
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Decreased synthesis of haem can occur when the activity of one or 
more of the enzymes in the pathway is reduced, due to inhibition by 
some factor or a genetically inherited defect. A classic example of 
such inhibition is found in lead-poisoning where ALA-D and FERRO-C 
activities are affected. Genetically inherited defects constitute 
the porphyrias and will be discussed in 1.3.10. In these situations, 
the reduced availability of pathway intermediates after the block 
leads to lower levels of haem output than normal. However, these 
levels, though lower than normal, may be insufficient in themselves to 
trigger derepression of ALA-S and often an additional reduction of 
intracellular haem by either of the remaining mechanisms is required. 
The presence of such a block, however, greatly increases the 
sensitivity of ALA-S to derepression in these circumstances.
Increased utilization of haem is the commonest mechanism by which 
ALA-S activity is increased. Many drugs lead to derepression of ALA-S. 
The vast majority of these are also lipid soluble and metabolized 
prior to excretion by the microscxnal mixed function oxidase system. 
This occurs primarily in the liver (Lu, Kuntzman and Conney, 1976). 
Part of this system is a group of inducible haemoproteins known as the 
cytodirome P450s (see Dus, 1982 for a discussion of the active site 
and Rabin, 1983 for a discussion of the nature and inducibility of cyt 
P450). The synthesis of these proteins utilizes 65% of haem produced 
in the liver (Sassa and Kappas, 1981). The cyt P450s are responsible 
for the actual oxidative metabolism of compounds processed by the 
microscaaal mixed function oxidase system. Some of these drugs, such 
as phenobarbitone, induce de novo synthesis of the apoprotein 
(Hardwick, Gonzalez and Kasper, 1982) which will bind haem and
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consequently reduce the intracellular haem concentration thus 
causing derepression of ALA-S. Others are "suicide substrates", that 
is, they are metabolized by cyt P450 but destroy the haem moiety in 
the process (Ortiz de Montellano et al, 1981; Ortiz de Montellano and 
Correia, 1983) leading to the synthesis of new cyt P450 to replace 
what was lost. This destruction of haem is the third way in which 
intracellular haem is depleted. Two classic examples of compounds 
which lead to derepression of ALA-S throu^ increased haem destruction 
are 2-allyl-2-isopropylacetamide (De Matteis, 1971) and DDC, which has 
already been discussed (1.3.7).
As was mentioned in the discussion on ALA-S in 1.3.1, steroids 
can also cause derepression of ALA-S, not necessarily by mechanisms 
which involve haem (Anderson, Freddara and Kappas 1982; Thompson 
et al; 1984 (A). Fig.(8) summarises the different sites at which drugs 
may act to produce derepression of ALA-S.
Derepression of ALA-S does not present a problem in normal 
individuals, though a sli^t increase in urinary ALA and PEG may be 
detected. However if there exists a block in the pathway as is found 
in the porphyrias or conditions such as lead poisoning, extensive 
accumulation of ALA, PEG and other porphyrins may occur with the 
various clinical problems associated with high levels of these 
compouiKis. The extent of the increase in ALA-S activity is likely to 
be greater in these individuals due to the inherent instability of 
control, leading to even greater production of the porphyrins and 
their precursors. Thus any drug or compound which can cause 
derepression of ALA-S will precipitate an acute attack of porphyria in 
susceptible individuals.
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FIG. (8)
SITES OF INTERACTION OF DRUGS WITO Him BIOSyJIHESIS
Many drugs increase the rate of haem biosynthesis through derepression 
of ALA-S, the rate limiting enzyme of the pathway. This derepression may be 
brought about by a reduction in haem levels which could occur as a direct or 
indirect result of the drugs as shown. Alternatively, certain drugs may 
directly derepress ALA-S. The mechanisms are discussed more fully in sub­
section 1.3.9.
1.3.10 THE PORPHYRIAS
The porphyrias are a group of metabolic disorders characterized 
by over-production and excretion of porphyrins and their precursors. 
They may be conveniently divided into two classes: acute porphyrias
and non-acute porphyrias, the characterization being made on the 
presence of acute generalized neuropathies in the former which are 
absent in the latter. Each of the porphyrias is attributable to a 
particular enzymic deficiency in the haem biosynthetic pathway which 
may be either genetically transmitted or acquired throu^ exposure to 
a foreign agent. Deficiencies for each of the enzymes in the pathway 
from ALA to haem sire known and each gives rise to a particular form of
porphyria. For a review of the defective enzymes see Elder (1983)
and Rimington (1985). Table (1) lists the site of the enzymic lesion 
and classification (acute/non-acute) of each of the porphyrias. The 
abnormal porphyrin and precursor excretion patterns found in all of 
the porphyrias is a consequence of the hi^ levels of ALA-S activity 
found in the tissues of patients with these diseases. This occurs 
because the enzyme deficiency may conpromise haem output, leading to 
derepression of ALA-S (as described in 1.3.9), in an effort to satisfy 
the cell's haem requirements. This derepression of ALA-S probably
occurs in all tissues: in acute intermittent porphyria increased
ALA-S activity has been demonstrated in both liver (Strand et al,
1970) and leucocytes (McColl jaL 1982; Brodie iaib1977 (A). The 
vast majority of the porphyrins and precursors excreted, however, 
originate from the liver.
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The clinical manifestations of the porphyrias varies between the 
two groups: acute and non-acute (see table (D) The acute
porphyrias are characterized by acute attacks during which the patient 
almost always suffers severe abdominal pain, vomiting, constipation 
and tachycardia. There may also be neuropsychiatrie disturbances 
including epilepsy, psychoneurosis and muscle weakness or paralysis. 
Acute attacks can last from several days to several months and are 
usually interspersed with periods of remission during which the 
clinical features subside. Often there are no clinical symptoms 
although biochemical analysis reveals the presence of the disease. 
This is described as latency. The clinical symptoms in the non-acute 
porphyrias are photosensitive skin lesions due to deposition of 
porphyrin in the upper epidermal layer of the skin. The severity of 
these lesions varies between the different porphyrias. There may be 
clinical evidence of liver disease. For further reading on the 
clinical presentation of the porphyrias see Goldberg and Moore (1980), 
and Disler and Moore (1985).
There now follows a short resume of the biochemical features of 
each of the porphyrias. 
fluabQPorphyria
This extremely rare disease, due to low levels of ALA-D activity 
(2% of normal), is inherited in an autosomal recessive manner (Bird 
jgL alf 1979; Doss fit 1982). Recently, de Vemeuil fit fit (1985) 
have demonstrated that low activity is due to a structurally modified 
enzyme. The disease is characterized by excessive production and 
excretion of ALA.
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Acute Intermittent Porphvria (AIP)
The commonest of the acute hepatic porphyrias» AIP is 
characterized by a 50% reduction in the activity of PBG-D, and has 
been shown by familial studies to be inherited as an autosomal 
dominant trait. The enzyme has been shown to be defective in all
tissues studied to date including liver (Strand fit. aX, 1970)» 
erythrocytes (Strand fit aX 1972), epidermal cells (Bickers fit al;
1977), cultured skin fibroblasts (Bonkowsky fit ai» 1975 (B), cultured 
lymphocytes (Sassa, Zalar and Kappas, 1978) and cultured amniotic 
cells (Sassa et al, 1975). Sassa fit al» (1978) demonstrated that the 
low activity is due to a defect in the synthesis of PBG-D rather than 
a defective protein. The disease exhibits a hi^ degree of latency, 
the majority of cases only coming to light when some aggravating 
factor precipitates an acute attack. The most ccxnmon factors are 
drug ingestion and endogenous or exogenous steroid hormones, all of 
which lead to derepression of PL AS. However in both the latent and 
ramission phases of the acute disease, increased urinary excretion of 
ALA, PBG and uroporphyrin (URO) is observed (Doss, 1978; Moore and 
Disler, 1985). In the acute attack all of these are grossly elevated 
as a consequence of derepression of ALA-S. The factors governing 
latency are poorly understood -individuals may have similar 
biochemical profiles to patients in attack, yet can be totally 
asymptomatic.
Congenital Ervthroooietic Porohvria (EP)
This is a very rare porphyria, but was probably the first to be 
discovered (Schultz, 1874). It is characterized by a deficiency of 
URO-CoS (Nordmann and Deybach, 1982) and is inherited as an autosomal
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recessive trait. ALA-S is derepressed but so too is PBG-D (Moore sL 
al» 1978), therefore no precursors accumulate, but very large amounts 
of URO-I and COPRO-I are excreted in the urine (Moore and Disler,
1985).
Porohvria Cutanea Tarda (PCT)
The underlying defect in PCT (or cutaneous hepatic porphyria) is 
a deficiency of URO-D. Three forms of the disease are found: 
familial, sporadic and toxic. Familial PCT is hereditary and the 
deficiency is found in liver and erythrocytes in a pattern consistent 
with autosomal dominant inheritance (Kushner fit fil» 1976). In the 
case of sporadic and toxic PCT, the defect is confined to the liver 
and may be caused by hepatic siderosis, alcoholism or ingestion of 
polyhalogenated aromatic substances (Mukerji, Pi ms tone and Burns, 
1984; Felsher, Jones and Redeker, 1983; McColl fit fil, 1981 ; Sano, 
Kawanishi and SekL, 1985; de Verneuil, Sassa and Kappas, 1983 (A)). 
Total urinary porphyrin excretion is elevated due to the depression of 
ALA-S and to the presence of large amounts of URO and 7-COOH porphyrin 
(Moore and Disler, 1985; Doss, 1978). 
hereditary Coproporphyria (hc)
COPRO-O is the defective enzyme in HC, only 50% of normal 
activities have been found in individuals with the disease ((xrandchamp 
and Nordmann, 1977). The enzyme has been shown to be defective in 
liver (Hawk fit fil» 1978) leucocytes (Brodie fit fil» 1977 (C) cultured 
fibroblasts (Elder et al. 1976) and lymphocytes (Nordmann et al, 1977) 
and to be inherited as an autosomal dominant trait. Individuals with 
50% activity are heterozygous for the defective allele. Homozygosity 
has also been reported where essentially no activity is present 
(Grandchamp, Phung and Nordmann, 1977). Precursor excretion varies
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in remission and in attack and as for AIP, there is a hi^ degree of 
latency. However in attack large quantities of COPRO are found in 
urine and faeces and there is increased excretion of ALA and PBG 
(Doss, 1978; Moore and Disler, 1985).
.Yariemte Porphyria (vp)
The defect in (VP) lies in the oxidation of PROTOgen. PROTO-0 
is reduced to 50% in patients with VP (Brenner and Bloomer, 1980; 
Viljoen fit fil» 1983) and there is evidence that FERRO-C activity may 
also be reduced (Siepker and Kramer, 1985). The condition is 
inherited as an autoscmal dominant trait and as for AIP and HC, the 
disease has acute and remission phases, the usual precipitating 
factors being responsible for induction of an acute attack. In 
attack there is elevated ALA, PBG and urinary porphyrin excretion. 
Faecal protoporphyrin excretion is also grossly elevated (Doss, 1978; 
Moore and Disler, 1985).
Erythropoietic Protoporphyria (EPP)
The defective enzyme in EPP is ferrochelatase and the defect is 
inherited as an autosomal dominant trait. The enzyme defect has been 
demonstrated in hepatocytes (Bonkowsky fit fil» 1975 (A), erythrocytes 
(Bottomley fit. al, 1975), leucocytes (Brodie fit fil» 1977 (D) and 
cultured fibroblasts (Bonkowsky et al, 1975 (A). The disease is 
characterized by very high erythrocyte and faecal protoporphyrin 
(Moore and Disler, 1985). Recent work has suggested an additional 
deficiency of PROTO-0 in this disease (Siepker and Kramer, 1985).
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other conditions \rtiioh mav result in over-produotion 
of porphvrins and precursors
In both lead poisoning and hereditary tyrosinemia there is 
increased ALA excretion (Doss, 1978; Moore and Disler, 1985) due to 
reduced ALA-D activity. Additionally in lead poisoning, as a 
consequence of CX)PR0-0 and FERRO-C inhibition, there is an increase in 
erythrocyte protoporphyrin (Moore and Disler, 1985).
33
1.4 OBJECTIVES OF THIS THESIS
As discussed in sub-section 1.3.10» porphyria can be accompanied 
with neurological complications, including epileptic seizures. 
Seizure control in these patients may be more difficult then in non- 
porphyric individuals because the stimulatory action of many drugs on 
haem biosynthesis upsets the delicate balance which exists in 
porphyria (see sub-section 1.3.9). It is difficult to prescribe a 
drug which will control the epilepsy but which will not aggravate the 
porphyria. Controversy exists as to which drugs are safe and which 
are not, much of the evidence being gathered from non-human systems 
including rat liver, rat hepatocyte culture and chick hepatocyte 
culture. Alternatively evidence may be provided frcm single case 
reports. With regard to the four anticonvulsants discussed earlier 
in this chapter, opinions can be divided. There is a consensus that 
barbiturates such as phenobarbitone, are to be avoided in epileptic 
patients with porphyria due to the extremely marked derepression of 
ALA-S brou^t about by these drugs. However whereas as some authors 
decry the use of carbamazepine (CBZ) (Larson fit. fil» 1978, Reynolds and 
Miska, 1981 ; Bonkowsky, 1981) others advocate it (Lai, 1981, and 
Peters, 1981). Sodium valproate (VPA) is usually not reccmmended 
(Bonkowsky et al, 1980; Reynolds and Miska, 1981; Merino and Lozano, 
1980; Doss et al, 1981) though others disagree (Sergay, 1979 and 
Brodie et al. 1977, B). However no definitive controlled human 
studies have been done. Phenytoin is also not generally reccmmended 
(Larson fit. fil» 1978; Magnussen fit. fil» 1975). More recently McColl 
fit fil (1980) have shown that phenytoin causes derepression of ALA-S in 
man and is therefore unsafe. This thesis was aimed at establishing
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the long term effects of anti convulsant drugs particularly CBZ and 
VP A, on haem biosynthesis in man, to assess the safety of these drugs 
in porphyria. CBZ was of primary interest for the reasons outlined 
below.
Recent reports have announced the appearance of an acute 
intermittent porphyria (AIP) syndrome in non-porphyric individuals 
being treated with CBZ. This was first noted by Yeung et al. (1983) 
in an epileptic patient being treated with the drug. The patient 
exhibited raised ALA-S activity, reduced PBG-D activity, grossly 
elevated excretion of urinary ALA, PBG and porphyrin (particularly 
uroporphyrin) and acute abdqninal pain. These symptcms, which all 
vanished on withdrawal of CBZ, are typical of the acute phase of AIP. 
The interpretations of the findings, particularly as regards PBG-D 
activity, have been disputed by Doss and Shafer, (1983); Rideout 
et al, (1983) and Shanley, (1983). However all these features (with 
the exception of abdominal pain), were reported to occur to a lesser 
extent in volunteer subjects given CBZ (Rapeport fit al, 1984). In 
this case, the overall biochemical picture was the same as that found 
in the latent phase of AIP. "Riis aroused interest in the possible 
use of CBZ treatment as a model for studying AIP. Thus in addition 
to the earlier stated objectives, this thesis was also aimed at 
investigating in more detail the effects of CBZ on haem biosynthesis 
and the mechanisms whereby these occurred. The settling of the 
dispute as regards the effects of CBZ on PBG-D was of particular 
concern. It was also hoped to assess the viability of CBZ treatment 
as a model for studying AIP.
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In order to achieve these objectives haem biosynthesis was 
primarily studied in periiAieral blood cells from epileptic patients 
receiving long-term anticonvulsant therapy. It was assumed that 
enzyme activities in these cells would reflect the levels of the 
corresponding hepatic enzymes which are quantitatively much more 
important. In addition to this, haem biosynthesis was also studied 
in rats, human lymphocyte cell culture and in in vitro systems. The 
effects of anticonvulsants on haem biosynthesis in these systems were 
not studied for their own sake but solely to try and further 
understand the effects of these drugs on haem biosynthesis in man.
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CHAPTER 2
CHAPTER 2
2. MATERIALS AND METHODS
This chapter describes the materials and methods used in this 
thesis and consists of two sections. The first of these covers the 
materials and equipment used and the second describes the methodology. 
In order that a full understanding of what was done is possible, a 
brief summary of each of the methods used is provided, even when the 
technique was performed exactly as referenced. When departures from 
referenced methods were made, the exact experimental details are 
given.
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2.1 MATERIALS AND EQUIPMENT
2.1.1 MATERIALS
Radioisotopes 4-^^C ALA, 2-^^C glycine, 2-keto (5-^ C^) glutaric acid 
and 2,3- C^ succinic acid were obtained from Amersham International 
pic, Amersham, U.K.
Biochemicals ALA, PBG, reduced glutathione, dithiothreitol, 2- 
ketoglutaric acid, succinic acid, 5,5’-dithiobis (2-nitrobenzoic 
acid), dimethyl sulphoxide, NADH, NAD'*’, NADFH, GTP, coenzyme A and 
coproporphyrin standard were obtained from Sigma. Pyridoxal 
phosphate was from Koch Li^t Laboratories. Porphyrin methyl esters 
were obtained from Porphyrin Products, Utah, U.S.A. p- 
Dimethylaminobenezaldehyde was obtained from Merck.
Enzymes Succinyl CoA synthetase was obtained from Boehringer-Mannhiem 
(GMBH). CL-ketoglutarate dehydrogenase was obtained from Sigma.
Drugs CBZ, CBZ-E and H2 ~CBZ were obtained from Geigy Pharmaceuticals. 
Primidone was obtained from Imperial Chemical Industries Ltd. 
Phenobeirbitone was from May and Baker.
Cell Culture Materials RPM1 1640 medium, L-glutamine and Lux tissue 
culture flasks were obtained from Flow Laboratories. Foetal calf 
serum and Penstrep were from Gibco. Phytohaemagglutinin, pokeweed 
mitogen, trypan blue and Histopaque were obtained from Sigma.
All other chemicals and reagents were obtained from BDH. Any 
materials whose origins are not listed here are described in the text.
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2.1.2 .miFHENT USED IN ANALYSES
Routine ar^ a] y,^;j,ct For spectrojgAotcxnetrlc measurements a Pye Unlearn 
SP8-200 UV/VIS double beam spectrophotometer was used and for 
spectrofluorometric detection a Perkin Elmer 3000 Fluorescence 
Spectrometer was used.
Cell Culture Studies All manipulations were carried out in a Hepaire 
vertical laminar flow cabinet. i Cultures were incubated in an LEEC 
automatic COg incubator Model GA2.
HPLC Analyses were carried out on a Hewlett Packard system, 
comprising a 10848 Liquid Chromatograph, a 79831A injector and a 
79850B LC terminal. The method of detection used depended on the 
nature of the analyses. For spectrophotometric detection, the 
aforementioned system was linked to a Kontron Uvikon 7305 LC UV 
spectrophotometer and for spectrofluometric detection to a Perkin 
Elmer 3000 fluorescence spectrometer equipped with a Perkin Elmer LC 
flow cell.
Emit The Emit system used consisted of a Syva CP 5000 Plus Clinical 
Processor linked to a Gilford Stasar III Spectrophotometer.
Equilibrium Dialvsis Dianorm Equilibrium Dialysis system. Diachema, 
Zurich, Switzerland.
Lead Determinations Analyses were performed using a Perkin Elmer 703 
Atomic Absorbtion spectrophotometer controlled by a Perkin Elmer HGA 
500.
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2.2 METHODS FOR DETERMINATION OF ENZYME ACTIVITIES
2.2.1 5-AMINCLAEVÜLINIC ACID SYNTHASE E.C. 2.3.1.37
A number of assays were examined for use in the determination of 
5-aminolaevulinic acid synthase (ALA-S) activity in (i) human 
leucocytes (ii) rat liver eind (iii) cultured human lymphocytes. All 
the assays used were radiochemical and involved incubation of the 
enzyme with a radioactive precursor and then isolation and 
quantification of the radioactive ALA generated. The three assays 
tried in each of the aforementioned systems were as follows:
(a) the substrate was 2-^^C glycine and the method was modified 
from Dowdle» Mustard and Eales (1967) and Freshney and Paul 
(1970);
(b) 2-keto (5-^ C^) glutaric acid was used as substrate using a 
method adapted from Tikerpae, Samson and Lim (1981);
(c) taken from Fitzsimmons (1984) utilising 2,3^^ C succinic acid 
as the radioactive precursor.
In method (a), the assay products were separated by 
electrophoresis. The assay products in method (b) and (c) 
were separated by HPLC following derivativization. For 
each of the tissues studied the three basic methods 
described were assessed and the most suitable assay for each 
adopted for routine use.
(i) Human leucocvte ALA-S
Leucocytes were isolated by centrifuging fresh, 
heparinised whole blood at 2,500g for 30 minutes then 
removing the layer of white cells (the buffy coat) with a 
pipette. Cells were washed twice in ice-cold isotonic 
saline then assayed for ALA-S activity exactly as described
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by Brodie fit fiL (1977 (C)), using method (a). Briefly, 
leucocytes were disrupted by soni cation then incubated for 1 
hour in buffer containing radioactive glycine, sodium malate 
(from which succinyl CÎOA is formed), magnesium chloride and 
EDTA (to inhibit ALA dehydratase) and sucrose, pyridoxal 
phosphate and 2-mercaptoethanol to stabilize the enzyme. 
The reaction was stopping by adding trichloroacetic acid 
containing ALA, Precipitated protein was removed by 
centrifugation, aliquots of supernatant were spotted on to 
chromatography paper and ALA was then separated from glycine 
by hi^ voltage electrophoresis. The ALA and glycine spots 
were identified by reaction with ninhydrin, cut out and 
combusted in a sample oxidizer, collected into scintillation 
fluid and then finally counted in a liquid scintillation 
spectrophotcmeter. Results were expressed as pmoles ALA 
produced/hour/mg protein.
The use of system (c), (^^C succinate), only gave 
appreciable counts when succinyl CoA synthetase was added. 
Unfortunately incorporation of this step led to increased 
background counts, a problem also encountered by De Matteis 
and Hollands (1982) and other workers quoted therein. 
Similar problems were encountered with oL-ketoglutarate.
(ii) Rat Liver ALA-S
After excision and perfusion of livers as described in
2.5.2, 1g of liver was homogenized in 5ml of ice-cold isoto­
nic saline using a Polytron homogenizer. ALA-S was assayed 
in the homogenate as described by Thompson fit. al. (1984(B))
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which was essentially the method quoted for leucocyte ALA-S. 
Results were expressed as pmol ALA produced/hour/mg protein.
Comparable results were found using ot-ketoglutarate and 
succinate as radio-labelled substrates and coupling enzymes 
were not required. However the method described wats used 
as it was convenient to have similar assays for the two 
systems covered so far.
(iii) iLA-S in cultured human ivmnhocvtes
For this assay to be of use, it would be required to 
measure ALA-S activity in 10-15 million cells. Using 
method (a) and double this number of cells, the counts 
incorporated into ALA were barely distinguishable from
background. This method was therefore not suitable. As
was the case with leucocytes, no activity at all was 
detectable using either systems (b) or (c). When coupling 
enzymes were added, (to generate succinylCoA, the substrate 
for the reaction) the background counts became so high that 
it was not possible to ascertain the presenœ of labelled 
ALA. Thus none of the methods were suitable for the 
routine determination of ALA-S activity in cultured human 
lymphocytes. No measurements of ALA-S were made in this 
system.
2.2.2 5-AMINOLAEVULINIC ACID DEHYDRATASE E^ C.^  .4.2,1.24
5-aminolaevulinic acid dehydratase (ALA-D) activity is measured 
by a colorimetric assay, the basis of which is as follows: enzyme is
incubated with ALA, then the reaction is terminated and the amount of
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PBG formed determined by mixing with an equal volume of Ehrlichs 
reagent» para-di methyl am inobenzaldehy de (pDMAB), and measuring the 
extinction, at 555nm, of the coloured PBG-pDMAB complex (€mM=62),
Enzyme activity was determined in (i) human erythrocytes (ii) 
rat liver (iii) mitogen-stimulated human lymphocytes and (iv) in vitro 
studies.
ALA-D activity is readily lost due to oxidation of essential 
thiol groups or loss of Zn^"*" ions, therefore dithiothreitol (DTT) and 
zinc chloride (ZnCl2 ) were routinely included in assays, with the 
exception of assays in human erythrocytes. In this system, activity 
was measured in fresh blood (circulating activity) and in the same 
blood after treatment with these activators (restored activity).
The enzyme is sensitive to inhibition by heavy metal ions, 
therefore all glassware used was acid-washed in 50% nitric acid and 
disposable plastic tubes were used for the assays.
The methods used were modified from the European Standardised 
method (Berlin and Schaller, 1974). Optimum activation or 
restoration of erythrocyte enzyme was achieved by following the 
procedure of Fujita, Orii and Sano (1981). The assay for ALA-D 
activity in mitogen-stimulated lymphocytes also incorporated some 
features described by Sassa (1982).
(i) Human ervthrocvtes
All reagents were equilibrated at 37°C prior to assay. 
Three tubes were required per sample: one blank and two
tests. 0.1ml of whole heparinised blood, kept on ice and 
not more than 3 hours old, was added to each tube and 
haemolysed by adding 0.65ml of water, mixing and incubating
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for 3 minutes at 37°C. The reaction was then started by 
adding to all tubes, 0.5ml sodium phosphate buffer 
(0.1M,pH6.8) to which ALA had been added to give a 10mM 
solution. The blank was terminated immediately with 0.5ml 
of trichloroacetic acid (TCA) solution (10% W/V) containing 
mercuric diloride (HgClg S^mM) and the others were terminated 
in the same way after 30 minutes at 37°C. Precipitated 
protein was removed by centrifu^tion at 1,500g for 15 
minutes, after which the supernatant was decanted and re­
centrifuged. 0.5ml of this final supernatant was mixed with 
0.5ml of Special Ehrlichs solution (2.5g pDMAB and O.lg 
HgCl2  were dissolved in 50ml glacial acetic acid, 24.5ml 
perchloric acid was added, the mixture cooled then made up 
to 100ml with glacial acetic acid). After waiting 5 
minutes for colour development the absorbance at 555nm was 
read against the blank in 1cm path-length semi-micro 
cuvettes, and the amount of PBG produced determined as 
described. Results were expressed as nmoles PBG 
produced/hour/ml erythrocytes.
Assay of restored ALA-D activity was performed by 
adding DTT (lOmM) and ZnCl2(0.1mM) to the water used in the 
haemolysis step and incubating at 37®C for 10 minutes prior 
to assay exactly as described above.
(ii) Rat liver
Livers were removed as described in 2.5.2 and 4g homo­
genized in 10ml of ice cold potassium phosphate buffer, 
(0.15M,pH7.4) containing DTT (ImM), using 5 strokes of a
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motor driven Potter-Elvehjem homogenizer. After 
centrifugation at 1»500g for 10 min at 4®C, the supernatant 
was spun for 25 minutes at 22,500g, also at 4°C. The 
resultant supernatant was assayed for ALA-D activity as 
described previously for restored human erythrocytes except 
that 0.4ml of homogenate was added per tube and 0.35ml of 
water containing DTT and ZnCl2  was used to activate the 
enzyme. Results were expressed as jimoles PBG produced/hour/g 
protein.
(iii) Cultured human Ivmnhnn.vhea
Mitogen-stimulated lymphocytes were prepared as 
described in 2.6. 7.5-10 x 10^  cells were lysed by adding
0.25ml of water containing DTT (lOmM) and ZnCl2  (ImM) and 
incubating for 1 minute at 37°C. 0.25ml of lOmM ALA in
50mM potassium phosphate buffer, (final pH=6.3), was added 
and the mixture incubated in a covered water bath at 37°C 
for 1 hour, after which the reaction was terminated with 
0.25ml of TCA (10% W/V) containing HgCl2(5mM). Tubes were 
left in the dark for 10 minutes to allow complete 
precipitation of protein, then spun at 1,500g for 15 
minutes. 0.6ml of the supernatant was mixed with 0.6ml 
modified Special Ehrlichs solution (Sassa, 1982) against a 
blank in 1cm path-length semi-microcuvettes after 15 minutes 
and the extinction at 555nm measured. Blanks were prepared 
exactly as for samples except that no cells were present. 
The amount of PBG produced was calculated as described and 
activity was expressed as pmoles PBG produced/hour/10^ 
cells.
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(iv) In vitro studies
In these experiments, the effects of metabolism of 
carbamazepine on ALA-D in vitro were studied. ALA-D 
activity was measured by taking 0.1ml from the reaction 
mixtures described in 2.8 and assaying it exactly as 
described for restored or activated human erythrocytes. 
Activity was expressed as a percentage of the original 
starting activity.
2.2.3 PORPHOBILINOGEN DEAMINASE (EC 4.3.1.8)
Porphobilinogen deaminase (PBG-D) activity is measured by 
fluorometric determination of uroporphyrin I(URO-I). ÜRO-I is formed 
by oxidation of uroporphyrinogen I which in turn is formed by rapid 
non-enzymatic cyclization of hydroxymethylbilane, the end product of 
the sequential head-to-tail condensation of 4 molecules of PBG by 
PBG-D. The enzyme was measured in human erythrocytes, rat liver and 
cultured human lymphocytes. For the assay in human erythrocytes, the 
substrate (PBG) is either added directly or produced in situ from ALA 
by ALA dehydratase (present in the erythrocytes). This latter 
enzymatically coupled method will be referred to as measurement of 
ÜRO-I synthase (URO-I-S) activity to distinguish the two. (This was 
the nomenclature used in the paper frcan which this method was taken). 
UroDorphvrinogen-I Svnthase Assay in Human Erythrocytes
The assay was performed exactly as described by Piepkorn, 
Hamernyik and Labbe (1978). Briefly, blood was haemolysed and 
incubated for 30 minutes with dithiothreitol (DTT) and zinc sulfiiate 
in order to maximise ALA-D activity. ALA was added and the mixture
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Incubated for 1 hour before termination with trichloroacetic acid 
(TCA). UROgen I formed in the assay was converted to ORO-I by 
oxidation catalysed by the added TCA. After centrifugation to remove 
precipitated URO-I protein was quantified in 1cm path length cuvettes 
by fluorimetry (excitation wavelength 396nm» emission wavelength 
594nm; both with a lOnm band pass). Standardisation was achieved 
using a solution of coproporphyrin of known concentration. A 
correction factor was also calculated from a standard curve of 
URO-I fluorescence versus concentration. After making the necessary 
corrections» results were expressed as nmol ÜRO produced/hour/ml/RBCs.
The effects of increasing ALA-D activity on erythrocyte URO-I-S 
activity were investigated by adding purified ALA-D to whole blood. 
50pl of ALA-D, purified as described in section 2.9.2, was diluted to 
5ml with sodium phosphate buffer (0.1M,pH7.4) containing 
dithiothreitol (lOmM) and ZnCl2(1mM), This gave a solution 
containing 1.36 x 10"’^ units of ALA-D activity/ml (1 unit was defined 
as the amount of enzyme which converts 1 ^ mole of ALA to 0.5 ^ mol 
PBG/min). An aliquot of this, usually 5C^ (6.8 x 10”^  units), was 
added to the URO-I-S assay at the start of the preincubation period. 
In order to assess if the purified enzyme itself contained any URO-1-5 
activity, an aliquot was assayed for activity exactly as described 
previously for an aliquot of blood. This revealed that there was 
slight URO-I-S activity present, but only enough to increase the 
average URO-I-S result by 0.6 nmol URO/hour/ml HBC for a 5()pl aliquot 
of added ALA-D. Results were adjusted accordingly.
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forPhobilinogen Deami naap
PBG-D activity was measured in:
(i) human erythrocytes
(ii) rat liver and
(iii) cultured human lymphocytes 
The methods used for all 3 assays were modified frcxn Anderson and 
Desnick (1982). PBG, the substrate for the assay, was prepared as 
described in 2.9 or purchased from Sigma. Both preparations gave 
identical activities althou^ the material synthesized in 2.9 gave 
hi^er blank readings.
(i) Human Erythrocytes
All reagents were equilibrated at 37°C prior to assay. 
0.2ml of whole blood was haemolysed by the addition of 0.8ml 
of haemolysis buffer (sodium phosphate buffer (ImM, fil7.6) 
containing DTT (ImM), magnesium chloride (ImM) and Triton X- 
100 (0.0556 v/v)).
For each sample, three plastic tubes were required, one 
for a blank and two duplicates for assays. 1.8ml of assay 
buffer, (TRIS-HCl 0.1M, pH8.1) containing DTT (0.1mM)), was 
added to all three tubes; 0.1ml of haemolysate was added to 
the two assay tubes.
After preincubation at 37°C for 3 minutes, 0.5ml of 
assay buffer containing PBG (ImM) was added to all tubes and 
the tubes miaœd followed by incubation at 37°C for 1 hour in 
the dark. After termination with 0.35ml of TCA (4056 w/v), 
lOOJpl of haemolysate was added to the blank and all tubes 
exposed to ultra-violet light for 20 minutes to oxidise 
UROgen to URO. Ihe blank was prepared in this way to take
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into account non-enzymatic polymerization of PBG with 
subsequent cyclization. Precipitated protein was removed 
by centrifugation for 15 minutes at 1,500g and the 
concentration of URO determined by fluorimetry in 1cm path- 
length cell (excitation wavelength of 4Q5nm and emission 
wavelength of 595nm, both with a lOnm band pass).
Standardisation was performed with a solution of 
coproporphyrin of known concentration and results calculated 
by applying a correction factor obtained from a standard 
curve of URO fluorescence versus concentration. Results 
were expressed as nmoles URO produced/hour/ml erythrocytes,
(ii) Jteit liver
Liver homogenates were prepared exactly as described in
2.2.2 for rats. After the 10,000g step, 0.5ml of homogenate 
was added to 1ml of haemolysis buffer previously described. 
At this stage samples were stable in the refrigerator for at 
least 2 days. The homogenates were then treated exactly 
the same as blood haemolysates and assayed as described 
previously. Results are expressed as nmoles URO 
produced/hour/g protein.
(iii) Oiltured himian Ivmphocvtes
2-4 X 10^ cells (cultured as described in 2.6) were 
spun down at 500g and lysed by freeze-thawing 3 times in 
0.25ml of sodium phosphate buffer (lOOmM, pH7.6) containing 
PBG (0.2mM), Tubes were then incubated in the dark for 1 
hour at 37°C after which the reaction was terminated by the 
addition of 2.75ml of TCA (10% w/v). A blank was prepared
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by omitting cells from 1 tube. Samples were then treated 
as described for rat and human assays except that a 
different correction factor was required, due to the altered 
fluorescence of URO in high concentrations of TCA. 
Activity was expressed as pmoles of URO produced/hour/10^  
cells.
2.2.4 HBQPQRPHYRINOgEN DECARBOXYLASE B.C. 4.1.1.37
The assay used for determination of uroporphyrinogen 
decarboxylase (URO-D) consisted of several stages. These were (a) 
generation of uroporphyrinogen (URO-gen) substrate (b) incubation for 
determination of URO-D activity, (c) termination of the assay and (d) 
analysis of the reaction products by fluorimetry and HPLC.
The method used was adapted from Brodie fit. fil (1977 (O) which 
was developed from an assay for PBG-D (Frydman and Feinstein, 1974). 
Sane features from Alleman fit. fil. (1982) were also incorporated into 
the method.
URO-D activity was measured in (i) human erythrocytes and (ii) 
rat liver.
(i) Human ervthrocvtes
4-5ml erythrocytes were isolated from fresh heparinised 
blood by centrifugation and washed twice with 5ml ice-cold 
saline. 0.5ml erythrocytes was mixed with 0.5ml assay 
buffer (sodium phosfdiate buffer (83mM, pH7.65) containing
reduced glutathione (3.2mM)) and an aliquot taken from 
determination of packed cell volume prior to haemolysis by 
freeze-thawing 3 times in acetone dry ice. 0.2ml haemolysate 
was added to each of 3 tubes containing 1ml of assay buffer.
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UROgen was synthesized by adding 0.1ml of I.OmM PBG in assay 
buffer to all tubes and incubating at 37°C in the dark for 1 
hour. URO-D activity was then measured by adding 0.2ml 
potassium dihydrogen orthophosphate solution (0.4M) to 
change the pH from one which favours PBG-D activity to the 
optimum assay pH for URO-D. Two of the four tubes were 
removed at this stage and designated zero times. One of 
these was frozen and lOml of 2:1 (v/v) ethyl acetate: acetic 
acid was added to the other. After 1 hour at 37°C, the 
remaining tube was frozen. After centrifugation to remove 
protein (1,500g, 15 minutes) porphyrins were extracted from 
the tube to which ethyl acetate: acetic acid had been added 
by washing with 5% HCl until no fluorescence was detectable 
in the acid extract when viewed under U.V. light (typically 
4 X 5m 1 5% HCl). The amount of porphyrin extracted was 
quantified by spectrof luori me try (excitation 396nm, emission 
594nm, both with lOnm band pass) following calibration of 
the f luori meter with a coproporphyrin solution of known 
concentration. The contents of the other tubes (one zero 
time and one assay) were freeze-dried and the porphyrins 
separated (after preparation of methyl ester derivatives) 
and the relative amounts of each determined by HPLC as 
described in section 2.3.4. (see fig. 9).
Combining the two sets of data - the quantity and 
oomposition of porjAiyrins in the mixture - for the zero time 
and after 1 hour's incubation allowed calculation of the 
number of decarboxylations catalysed by the enzyme over the
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FIG. (9)
HPLC ANALYSIS OF THE SUBSTRATE AND REACTION PRODUCTS 
IN THE URO-D ASSAY IN HUMAN ERYTHROCYTES
Trace A shows substrate generated from PBG in the first stage of the 
assay. The major peak is uroporphyrin.
Trace B shows the reaction products after the second stage of the assay. 
The majority of the uroporphyrin has been converted to copropori^yrin and 
intermediates.
The assay details are given in sub-section 2.2.4.
assay period. The calculation assumed that each of the 
porphyrins had equivalent fluorescence at the settings used. 
Activity was expressed as nmoles decarboxylations/hour/1 
erythrocytes.
(11) Rat Liver
Livers were removed as described in 2.5.2 and 3g 
homogenized in 10ml assay buffer just described. 0.2ml was 
then assayed exactly as for erythrocyte assays and activity 
expressed as yi^ moles decarboxylations/hour/g protein.
/ii:,
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2.3 fOEPHÏRIN PRECURSORS AND PQRPHYRTW5Î
2.3.1 5rAMIN0LAEVULINIC ACID IN URINE
ALA was measured in urine using test kits supplied by Bio-rad 
Laboratories. The procedure followed was exactly as described in 
Bio-rad Laboratories Technical Bulletin No.4208 (1979). The basis of 
the method was that urine from which PBG was removed as described in
2.3.2 was passed throu^ a column of cation-exchange resin on which 
the ALA was retained. ALA was then eluted and condensed with acety- 
lacetone. The pyrrole produced was mixed with para- 
dimet hyl am in obenz aldehyde and the resultant coloured complex 
quantified by spectrophotcmetric measurement. Results are calculated 
from the molar extinction coefficient of the complex at 555nm (imM=52) 
and expressed as nmoles ALA excreted/1 or /24 hours.
2.3.2 PORPHOBILINOGEN IN URINE
PBG was measured in urine using test kits supplied by Bio-rad 
Laboratories. The procedure followed was exactly as described in 
Bio-rad Laboratories Technical Bulletin No.4208 (1979). PBG was
removed from urine by retention on an anion exchange resin. It was
then eluted from the resin, complexed with para-dimethylaminobenzalde- 
hyde and quantified as described for the complex formed in 2.3.1. 
Results are expressed as nmoles PBG excreted/1 or /24 hours.
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2.3.3 TOTffl. PORPHYBTN TU
Total porphyrin in urine was determined using test kits supplied 
by Bio-rad Laboratories. The procedure followed was modified from 
Bio-rad Laboratories Technical Bulletin No.4003 (1981).
Method
Columns from the Bio-rad kit were shaken to resuspend the ion 
exchange resin and allowed to drain. 1 ml of urine was added and 
allowed to run through after which the column was marked with 10ml of 
distilled water. Porphyrins were then eluted into a test-tube 
with 2 X 2ml of 3M HCl and the fluoresence of the sample determined in 
a f luori meter (excitation wavelength 396nm, emission wavelength 594nm; 
both set with a 10 nm band pass. Concentration of porphyrin was 
calculated by reference to a coproporphyrin standard of known 
concentration. Results are expressed as nmoles porphyrin excreted /I 
or /24 hours.
2.3.4 Him PERFORMANCE LIQUID CHROMATOGRAPHIC 
ANALYSIS OF PORPHYRINS
Using HFLC it is possible to individually resolve uroporphyrin, 
hepta-,hexa- and penta-carboxylic porphyrins, coproporphyrin and 
protoporphyrin. Such resolution cannot be achieved using methods 
whereby porphyrins are extracted from mixtures by the use of different 
solvents (e.g. Rimington, 1971).
For HPLC analyses two methods were used:
(a) Tree por^iyrin method"; porphyrin was subjected to HFLC 
after a preliminary extraction step, and
(b) "Porphyrin methyl ester method"; por^iyrin was extracted, 
derivatized by estérification, re-extracted and analysed.
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In both cases, individual porphyrins were expressed as % of 
the total porphyrin content of the sample. To do this, it 
was necessary to apply correction factors to the peak areas. 
These factors were calculated from injection of a sample 
containing known amounts of each of the relevant porphyrins 
(this is necessary because of the different fluorescence 
characteristics of each of the porphyrins).
ÏTQS. POrPhVrin method for pornhvrlns in urine
The method was essentially as described by Jordan (1984). 
Porphyrins were extracted from 1ml of urine as described in
2.3.3, or by retention, washing and elution from C18 Sep-Paks (Waters 
Associates) as described by Muraca and Goosens (1984). 0.1ml of
porphyrin in 10% HCl was then injected onto the HFLC system described 
in 2.1.2 linked to a Waters Bondapak C-18 column (300 x 4mm). A 
linear gradient of acetonitrile in sodium phosphate buffer (lOmM, 
pH7.5) was run over 25 minutes. Acetonitrile was then increased to 
65% for 10 minutes before returning to starting conditions. The flow 
rate was 1 ml/minute and detection was by fluorescence (excitation at 
405nm, emission at 595nm).
This method has the advantage of requiring only a small sample, 
but the drawback of taking a long time to run. This precludes the 
preparation of many samples at once since certain porphyrins 
(particularly uroporphyrin) are unstable in acid. A further 
disadvantage with this method is that if the column is not 
sufficiently re-equilibrated between each analysis, retention times 
and peak resolution are affected. The method used for all HPLC 
analysis was therefore the estérification method now described.
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Porphyrin methyl. ester method
The method used was essentially that of Seubert and Seubert 
(1 9 8 2 ) with modifications depending on the starting material. The 
method will be dealt with in two sections:
(a) extraction, estérification and preparation of HFLC
(b) HPLC analysis of esters
(a) Extraction, estérification and preparation for HPL&
(i) Human urine
200ml of urine from a 24 hour urine collection was 
adjusted to pH5-7 with glacial acetic acid. 2.0g of talc 
were added and the mixture left to stir in the dark for 15 
minutes. The talc with absorbed porphyrins was removed by 
filtration under suction throu^ a sintered glass filter 
funnel and dried at 90°C for 1 hour. Porphyrins were 
. recovered by adding 25ml of methanol/concentrated sulphuric 
acid (95/5, v/v) to the funnel and collecting the filtrate 
in a large tube. Methyl esters of the porphyrins were 
formed by heating this solution and the funnel at 60°C for 1 
hour or by leaving both at room temperature in the dark for 
16 hours. Both esterifioation procedures yielded identical 
results. The talc left in the funnel was washed with 2 x 
8ml of chloroform to remove residual porphyrin ester and the 
washes added to the previously prepared filtrate. 10ml of 
water was added to separate the organic and aqueous phases 
after which the upper aqueous i*ase was removed and 
discarded. The Aloroform left was washed with 15ml of
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water, 15ml of 3% sodium bicarbonate solution and finally 
2 X 15 ml of water. It was then shaken with 0.1 g of 
anhydrous sodium sulphate and filtered before evaporating to 
dryness under air. The residue was dissolved in 0.1ml of 
chloroform to which was added 0.9ml mobile phase (to be 
described). This was filtered through 0.2^ filters 
(Gelman Sciences) and 0.1ml was injected.
(ii) .Bat Urine
Exactly as for human urine except that only 10ml of 
urine mixed with 0.5g of talc was used. Porphyrin esters 
were dissolved in 2()pl of chloroform and then 0.18ml of 
mobile phase was added. Samples were filtered as described
above and 0.1ml was injected.
(iii) iQrphyriPs from cell culture studies
The starting material was porphyrin in acid prepared as
described in 2.6.4. The pH of the solution was adjusted to
between pH5 and 7 with saturated sodium acetate after which
0.1 g of talc was added. The procedure was essentially that
described for human urine except that the volumes of all
reagents were reduced by a factor of 5. Porphyrin esters
were dissolved in 1(^ of chloroform to which was added 9CJpl
of mobile phase - all of this was injected.
(iv) Porohvrins from uroporphvrinogen decarboxylase assays - 
HPLC analysis of Porphvrin composition
HPLC analysis of porphyrins from URO-D assays was 
performed using the same system as for the other p>orphyrins, 
but the estérification procedure was modified from Alleman 
et al (1 9 8 2 ). Freeze-dried samples were dissolved in 1ml
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of chloroform. Estérification was achieved by adding 5m 1 
of methanol/concentrated sulphuric acid, (90/10,v/v), and 
incubating the tube for 1 hour at 40®C. The solution was 
transferred to a larger tube and 9ml of water, then I8ml of 
chloroform were added. The upper aqueous phase and protein 
at the solvent interface were removed by suction and 
discarded. The chloroform was washed with 15ml of water, 
15ml of 5% sodium bicarbonate, 2 x 15ml of water, filtered, 
then evaporated to dryness. The residue was dissolved in 
25pl of chloroform, 25()pl of mobile phase was added and the 
solution filtered throu^ a 0.2pm filter (Cïelman Sciences). 
lOOjpl were injected.
(b) Hifh performance liquid chromatography of porphyrin methyl-es terjs 
Chromatography was performed using the HFLC system described 
in 2.1.1 and an HP 79915 Si Opt. 174 column (200 x 46mm) from 
Hewlett Packard. The solvent used was n-heptane/ethyl 
acetate/chloroform/methanol (60/25/12.5/2.5) at a flow rate of
1.2 ml/min. Detection was by fluorescence at 625 nm, excitation 
wavelength was 405 nm, (both with 10 nm band pass). The 
chromatogram produced following injection of a solution of 
porphyrin methyl ester standards is shown in fig. (10).
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FIG, (10)
HFLC CTROMATOGRAM OF PORPHïSm .STANDARDS
2.4 MBASOREMENT OF DRUG CQNCENTRATTm.q
Many of the experiments undertaken required determination of drug 
concentrations. Samples in which drugs were measured were human 
plasma* rat serum* cell culture media auid in vitro drug metabolism.
Samples were prepared as described in the relevant sections and 
stored at ~18®C for up to 2 months prior to analyses with no effects 
on drug levels. For determination of "total" carbamazepine (CBZ) in 
human plasma and rat serum, and of phenytoin* valproic acid and 
phenobarbitone in human plasma, the EMIT system (Syva) was used, 
following the procedure in the appropriate EMIT instruction booklet. 
Certain experiments necessitated the determination of concentrations 
of both CBZ and its epoxide metabolite (CBZ-E). These were measured 
by an HFLC method modified frcxn Meijer (1981).
Throu^out this thesis, drug concentrations are expressed in mg/1 
rather than in molar units* the reason being that these are the units 
normally used to report drug concentrations in this hospital.
2.4.1 DRPG CONCENTRATION BY EMIT
The equipment used is outlined in 2.1.2 and all necessary 
reagents are supplied in kit form by Syva. The principle of the 
assay is that a sample containing a given drug is mixed with antibody 
to that compound and then a precise quantity of drug labelled with 
glucose—6—phosphate dehydrogenase (G-6-PH1) is added. Labelled and 
unlabelled drug compete for the antibody and the amount of unlabelled 
drug present will determine the extent of inactivation of G-6-PDH. 
The residual activity* as determined by the spectrophotometric 
measurement of the rate of NADH production from NAD+* is directly 
related to the concentration of drug present. Calibration with
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standards is necessary, after which the concentration of unknown 
samples can be calculated from a standard curve of reaction rate 
versus concentration of drug. Results for all drugs measured are 
expressed as mg/1.
2*4.2 CARBAMAZEPINE AND CARBAMAZEPINE 10.11 EPnYTDR RY 
The assay involves 3 steps:
(i) preparation of standards
(ii) extraction of drug and 
( iii ) chromatography
(i) Preparation of standards
CBZ in methanol was added to blank plasma to give 
concentrations of 20» 15» 10 and ^/ml. CBZ-E standards were 
likewise prepared to give final concentrations of 10, 7.5, 5 and
p
2.5^ml. These were then extracted in tandem with the unknown 
samples as described below.
(11) Extraction
CBZ and CBZ-E were extracted with 7m 1 of chloroform from 1 
1 ml of sample to which 5()pl of 0.5mg/ml 5-(-p-methylphenyl)-5- 
hydantoin (Supelco Inc.) in methanol had been added as internal 
standard. After thorough mixing, samples were centrifuged at 
1500g for 10 min and the upper aqueous phase removed by suction. 
The chloroform extract was decanted into clean tubes and 
evaporated to dryness under air.
(ill) CbrnmatQgraphV
Chromatography was performed using the HFLC system described 
in 2.1.2 and a Sfdierlsorb 5 CDS column (250 x 4.6mm) from Phase 
Separations. The solvent used was water/methanol/acetonitrile
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(56/24/20) at a flow rate of 1.0 ml min. Detection was by ÜV 
absorbance at 230 nm. Dried samples were reconstituted in 200 ^  
of mobile phase and 5(^ was injected onto the column. Drug 
concentrations were calculated from the ratio of peak rea of the 
drug to the peak area of the internal standard. Calculations 
were automatically performed after calibration with standards of 
known concentration by the computer terminal linked to the 
system. Results of both CBZ and CBZ-E are expressed as mg/1.
Fig. (11) shows the chromatogram obtained following 
injection of a standard sample onto the column.
2.4.3 DETERMINATION OF FREE CARBAMAZEPINE BY EQUILIBRIUM DIALYSIS
Free CBZ levels were determined by equilibrium dialysis using the 
equipment described in section 2.1.2. Dialysis was performed in 
teflon cells. 0.9ml plasma was injected into one half of the cell 
and 0.9ml potassium phosf^ate buffer (0.13M,pH7.4) into the other 
half. The two halves were separated by a dialysis membrane 
(Spectrapor, mol.wt. cut-off=6000-8000) and the assembly was rotated 
for 24 hours at 37°C. The respective compartments were then emptied 
and the concentration of free and bound CBZ in each fraction 
determined by 01IT as described in section 2.4.1.
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FIG. (11)
ANALYSIS OF CBZ AND CBZ-E BY HFLC
The figure is a chromatogram showing the resolution of CBZ> CBZ-E and 
internal standard (I.S.) obtained by HFLC. The sample shown is a standard 
prepared by adding CBZ» CBZ-E and LS. to blank plasma. The analysis was 
then performed as described in sub-isection 2.4.2.
fsak Retention time
CBZ-E 5.69
CBZ 9.82
I.S. 13.61
2.5 ANIMALS
Animals used in experiments were male Sprague-Dawley rats (150- 
250g). Rats were fed and watered ad libitum with Oxoid 4IB diet and 
tap water.
2.5.1 ACMINISTRATION OF CARBAMAZEPINE TO RATS
CBZ was administered orally twice daily (at 9.00 a.m. and 9.00 
p.m.) as a suspension of ground tablets (Tegretol) in cottonseed oil 
(40 mg CBZ/ml). Control animals were given identical doses of
cottonseed oil containing ground placebo tablets.
2.5.2 SACRIFICE AND REMOVAL OF LIVER AND BLOOD
Rats were fasted for 24 hours prior to sacrifice to minimise 
differences in enzymes which may arise due to differences in the 
nutritional status of the animal. The animals were sacrificed 2 
hours after the last dose by cervical dislocation, the livers excised 
and perfused with ice-cold potassium chloride (0.15M) then stored in 
this solution prior to processing as described in 2.2 for the relevant 
enzyme assays. Blood was collected from the hepatic vein prior to 
removal of livers and allowed to clot before centrifugation at 4°C and 
removal of serum for drug analyses described in 2.4,
2.5.3 COLLECTION OF URINE
Urine was collected from individual rats over 24 hour periods by 
keeping the animals in metabolic cages.
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2.5 ANIMALS
Animals used in e^>eriments were male Sprague-Baw ley rats (150- 
250g). Rats were fed and watered ad libitum with Oxoid 41B diet and 
tap water.
2.5.1 ADMINISTRATION OF CARBAMAZEPINE TO RATS
CBZ was administered orally twice daily (at 9.00 ajm. 9.00
p.m.) as a suspension of ground tablets (Tegretol) in cottonseed oil 
(40 mg CBZ/ml). Control animals were given identical doses of 
œttonseed oil œntaining ground placebo tablets.
2.5.2 SACRIFICE AND RQCVAL OF LIVER AND ELOCB
Rats were fasted for 24 hours prior to sacrifice to minimise 
differences in enzymes which may arise due to differences in the 
mtritional status of the animal. The animals were sacrificed 2 
hours after the last dose by cervical dislocation, the livers excised 
and perfused with ice-cold potassium chloride (0.15M) ttmn stored in 
this solution prior to processing as described in 2.2 for the relevant 
enzyme assays. Blood was collected frtm the hepatic vein prior to 
removal of livers and allowed to clot before caatrifugatian at 4 %  and 
removal of serum for drug analyses described in 2.4.
2.5.3 CCLLBCTId? (F ïïlffliE
Urine was collected from individual rats over 24 hour periods by 
the animals in metabolic cages.
62
2.6 CILL CÜLTDRE STÜDTF.S
The effects of CBZ and CBZ-E on some of the enzymes of haem 
biosynthesis were studied in cell culture. The most convenient 
system for these experiments was mitogen-stimulated human lymphocytes 
the preparation and maintenance of which is now described.
2.6.1 PREPARATION OF LYMPHOCYTES
Lymphocytes were prepared from the buff y coat obtained frcxn 1 
pint of blood. The buffy coat was diluted with 3 volumes of Hanks 
Balanced Salts solution (HBSS). 25ml aliquots were layered onto 10ml 
of Histopaque in 35ml sterile screw-top tubes and centrifuged for 30 
minutes at 400g. The lymphocyte rich interphase frcan each tube was 
removed with a sterile pasteur pipette, resuspended in 20ml of HBSS 
and centrifuged for 10 minutes at 300g. The resultant pellets were 
combined and washed twice more before suspending in RPM1 1640 medium 
with the following supplements: foetal calf serum (10%), sodium 
bicarbonate (0.75mg/ml), L-glutamine (2mM), Penstrep (100 D/ml), 
pokeweed mitogen (2.5 i^g/ml) and phytohaemagluttinin (5yg/ml). Cell 
density was determined using a Hawksley Cristallite improved Newbauer 
Counting Chamber and viability was determined by exclusion of trypan 
blue. Viability was usually in excess of 90%.
2.6.2 COLTDRE CONDITIONS
Typically 10 or 15ml of medium containing 7.5 x 10^  cells/ml was 
placed in a 50ml Lux tissue culture flask and incubated at 37°C in an 
LEEC automatic CO2  incubator model GA2 with an atmosphere of 5% COg in 
air. Chiltures were maintained under these conditions until required 
for assays, but no cultures were kept for more than 5 days.
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2.6.3 ADDITION OF PROGS
Additions to cultures were made by dissolving the material to be 
added in dimethylsulfoxide (DMSO) and adding lOpl of the solution to 
flasks. If less than lOpl was to be added, the difference was made 
up with DMSO. Stock solutions of CBZ, and CBZ-E (30 and 15mg/ml) 
respectively) were prepared and stored at 4°C.
2.6.4 ENZYME ASSAYS AND PORPHYRIN FORMATION
Enzyme assays are described under the relevant headings in 
section 2.2. The formation of porphyrins from ALA was also 
investigated using a method modified from Sassa stâl. (1978).
Method for porphyrin formation
7.5 X 10^  cells, cultured as described for 4 days, were pellet ted 
by centrifugation at 300g for 10 minutes, resuspended in 10ml HBSS and 
recentrifuged. Ihe cells were then suspended in 10ml of the medium 
described in section 2.6.2 but omitting the foetal calf serum and 
mitogens. The medium also contained ALA (0.6mM) and calcium 
magnesium ethylenediam inotetra-acetic acid ( CaMgEDTA) ( 5mM ). CaMgEDTA
was prepared frcxn calcium chloride, magnesium chloride and disodium 
EDTA as described by Sinclair and Granick (1977). After incubation 
for 24 hours at 37°C in an atmosphere of 5% CO2 , the cells were 
collected by centrifugation at 300g for 10 min. Porphyrin was 
extracted from the pelletted cells by agitation with 1ml of 0.5N 
perchloric acid - 50% methanol solution. This was then transferred 
to the flask from which the cells had come to extract porpdiyrin from 
cells ïriiich may remain in the flask. After centrifugation at 1500g 
for 10 minutes to remove precipitated protein, the supernatant was
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diluted to 3m 1 with hydrochloric acid (5%) and the fluorescence 
measured in 1 cm path length cuvettes, (excitation: 396nm,
emission:594nm, band-pass:lOnm). Standardisation Wcis performed using
a solution of coproporphyrin of known concentration. Porphyrin in 
the medium from which cells had been removed was isolated and measured 
as described in section 2.3.3 for urine except that 10ml of medium was 
added to the columns. Results were expressed as ng porphyrin 
produced/24 hours/10^  cells.
For HFLC analysis of porphyrins in these extracts, the solutions 
were adjusted to pH6 with saturated sodium acetate. The subsequent 
steps are described in section 2.3.4.
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2-7 IBRTTO INVESTIGATIONS QN 5-AMXNXAEVULINATE DEHYDRATASE IN MAN
In the course of these studies, it was established that ALA-D 
activity in human erythrocytes was affected by treatment with CBZ. 
This section describes several methods used to further study the 
effect. One such technique has already been covered: the effects of
including dithiothreitol and zinc chloride in the assay to restore 
non-active ALA-D (2.2,2), Other experiments looked at the effects of 
dialysis on activity. Parameters such as apparent Km values of 
erythrocyte ALA-D for its substrate and the optimum assay pH were 
determined. Attempts to reproduce the effect by adding CBZ and some 
metabolites to blood were also made. The methodology for these 
experiments now follows.
2.7.1 DIALYSIS OF ERYTHROCYTES
Red cells were separated from fresh, heparinised blood by 
centrifugation at 1,500g, washed twice with ice-cold isotonic saline 
and 2ml then placed in dialysis tubing (ViskLng size 5-24/32") either 
as they were, after reconstitution with dialysis buffer (50% v/v) or 
after haemolysis by sonication. The samples were dialysed against 2 
litres of sodium phospdiate buffer (0.15M,pH7.0) containing DTT (2mM) 
and ZnCl2  (O.ImM) for 24 hours at 4°C, then assayed as described in 
section 2.2.2. Controls were prepared by separating and treating red 
cells as described above and storing them for 24 hours at 4°C without 
dialysis. Results were expressed as percentages of controls.
2.7.2 DETERMINATION OF APPARENT Kin VALDES FOR ERYTHHOCYTE_ALA-D
The apparent Km of ALA-D for ALA was measured to determine 
Wiether or not the altered enzyme activity was a result of altered 
substrate affinity.
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The assay was performed as described in section 2.2.2 for 
untreated human erythrocytes, but a range of ALA concentrations was 
usedf (0.5» 1.0» 5.0 and lO.OmM). The final pH of each solution was 
6.6. For each concentration of ALA used» ([S]) the assays were 
terminated at 0»5»10»15»20 and 30 minutes (or in cases where activity 
was normal» after 0»4»8»12 and 16 minutes) and the amount of PEG 
formed after this time determined.
Plots of Ag^g versus time for each concentration were made, 
fig.(12). Frcan these the rate of reaction (V) at eadi concentration 
of ALA substrate ([S]) was calculated and expressed as V = A^^^/30
minutes. Plots of 1/V versus 1/[S3 were constructed and apparent Km 
values determined by taking the negative reciprocal of the x-axis 
intercept fig.(13) according to the Michaelis-Menten equation:
1 = m  + 1
V  Vmax.CS] Vmax
2.7.3 OPTIMUM ASSAY dH OF ERYTHROCYTE ALA-D
The optimum assay pH of ALA-D was determined in patients taking 
CBZ to investigate the possibility that the alteration of activity may 
be due in part to an altered jiî activity profile» as is the case with 
lead (Chiba, Tashiro and Kikuchi, 1977; Farant and Wigfield, 1984).
The assay was performed as described in section 2.2.2 for 
untreated erythrocytes except the lÆI of the ALA solution added to the 
blood haemolysate was varied. Buffers of the required pH were 
prepared by mixing appropriate volumes of disodium hydrogen phosphate 
(0.1M) containing ALA (lOmM) and sodium dihydrogen phosphate (0.1M), 
also containing ALA (lOmM). Buffers of pH 5.6» 5.8» 6.0» 6.2» 6.3, 
6.4» 6.5» 6.6 6.7, 6.8, 7.0, 7.2» 7.4, 7.6 and 7.8 were prepared in
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FIG. (12)
THE RATES OF REACTTION AT VARIOUS SUBSTRATE CONCENTRATIONS 
IN TOE ERÏTHROCÏTE ALA-J_ ASSAY
The figure shows the data used for the calculation of the apparent km 
of erythrocyte ALA-D for ALA in fig. (13). This was the method by which the 
apparent Km values presented in table (11)were calculated.
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FIG. (13)
ESTIMATION OF THE APPARENT Km OF HUMAN ERYTOROCÏTE ALA-D FOR ALA
The figure shows the calculation of the apparent Km of the enzyme for 
ALA by plotting the data from fig. (12) on a double reciprocal plot.
this way and these produced final pH values of 6.0, 6.1, 6.25, 6.4,
6.5, 6.6, 6.7, 6.8, 6.9, 6.95, 7.1, 7.3, 7.5, 7.5 and 7.75
respectively when added to blood haemolysates. Results were 
calculated as normal and enzyme activity was plotted against the final 
assay pH (see fig. 14).
2.7.4 ADDITION OF CBZ AND METABœiTES TO BLOOD
CBZ, CBZ-E and HgiCBZ were added to blood in an attempt to 
reproduce the effects of CBZ treatment on erythrocyte ALA-D.
Experiments were performed on fresh heparinised blood in 3 
situations :
(a) untreated (b) sonicated and (c) washed red cells. In
those experiments which involved whole blood (untreated or 
sonicated),CBZ, CBZ-E or H2 CBZ were added in ICjpl acetone
or methanol to 2ml of blood to give concentrations of up to
50mg/l. Appropriate controls to which acetone or methanol 
above had been added were also prepared. The samples were 
incubated for 1 hour at 37°C or for 5 minutes at 60°C. 
ALA-D activity was then determined immediately, after 16 
hours and again after 40 hours. The preparations were 
stored at 4°C between assays. Washed red cells were 
resuspended (50$ v/v) in sodium phosphate buffer 
(0.15M,î^ î7.4) to which drugs had been added as described for 
whole blood to give concentration of up to 50mg/1 and then 
treated as described above.
Similar experiments were performed on the rat liver 
extract in which ALA-D was assayed (see 2.2.2) and on 
purified bovine hepatic ALA-D (see 2.9.1).
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FIG. (14)
nw.CULATION OF OPTIMUM ASSAY pH FOR ALArP
2.8 JQj._yiTRQ DRUG METABQLTSM STUDIES
Attempts to reproduce the effect of CBZ treatment on erytrocyte 
ALA-D by direct addition of CBZ have been described (2.7.4). The 
studies described in this section investigated the possibility that 
the observed effect was linked to metabolism of the drug. Hiis was 
achieved by incubating purified enzyme with CBZ in the presence of 
microsomes containing a cytochrome P-450 dependent mixed function 
oxidase system. The experiments consisted of 3 steps:
(i) preparation of microsomes
(ii) preparation of ALA-D
(iii) incubation of microsomes and OBZ with ALA-D.
2.8.1 PREPARATION OF MICROSOMES
Microsomes were prepared essentially by the method described by 
Hajek, Cook and Novak (1982) fran the livers of untreated rats, rats 
treated with 75mg/Kg CBZ b.d. for 4 days (as described in 2.5.2) and 
rats treated with 0.1% (w/v) phenobarbitone in drinking water for 5 
days. The animals were sacrificed and the livers excised and 
perfused as described in 2.5.3. All subsequent manipulations were 
performed at 4°C using ice-cold solutions. Livers were diced and 
homogenized in 3 volumes of TRIS-acetate buffer (0.1M,pH7.5) 
containing potassium diloride (0.1M) and disodium EDTA (ImM) using a 
Potter-Elvehjam homogenizer. The homogenate was centrifuged at 
2,500g for 15 minutes and the supernatant removed and spun at 8,000g 
for 30 minutes. The resultant supernatant was filtered through glass 
wool and re-centrifuged at 10,000g for 30 minutes. "Die pellet was 
discarded and the supernatant filtered as before then spun at 105,000g
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for 90 minutes. The supernatant from this step was discarded and the 
pellet was resuspended in sodium phosphate buffer (0.1M,pH7.4) 
containing Na2 EDTA(lmM) then repelletted by centrifugation at 144,000g 
for 60 minutes. The resultant pellet which contained the microsomes 
was resuspended in TRIS-acetate buffer (50mM,pH7.4) containing NagEDTA 
(ImM) and 20% glycerol to give 20-50mg protein/ml then stored at 
-80°C. The cytochrome P-450 content was determined as described in 
section 2.11.1.
2.8.2 PURIFICATION OF ALA-D
ALA-D purified for the biosynthetic preparation of 
porphobilinogen was used. The procedure was as detailed in section 
2.9.1.
2.8.3 IN VITRO METABOLISM OF CARBAMAZEPINE
The incubation conditions for the in vitro metabolism of CBZ were 
adapted from Koizumi âtâL (1984) and Fujita âtâL (1984). The total 
incubation volume was 1.5ml and typically contained 0.2ml microsomes 
(5 nmoles cyt P-450), 0.88ml potassium phosfiiate buffer (incubation 
buffer: 100mM,i^ i7.4) containing DTT to give a final DTT concentration 
of 2mM, 0.5 units of ALA-D in 0.1ml of incubation buffer and 20 ^  of 
a lOmg/ml solution of CBZ in acetone. The reaction was started by 
the addition of 0.3ml of incubation buffer containing 5mM NADPH. The 
mixture was incubated at 37°C in 5ml conical flasks with agitation. 
At various time intervals after initiation of the reaction 0.1ml was 
removed and assayed for ALA-D activity as described in 2.2.2 (iv). 
In some experiments, a further 0.05ml was removed and diluted to 1ml 
with incubation buffer for analysis of CBZ and metabolites by the HFLC
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method described in section 2.4,2, At each time point, assays were 
performed in duplicate and two measurements of the Ehrlichs-PBG colour 
salt made for each of these duplicates. Control incubations were 
also performed in which NADPH, CBZ or the microsomes were replaced by 
incubation buffer.
The results were expressed as the percentage of ALA-D activity 
present at the start of the incubation which remained after a given 
time.
&K #>h' of -op': . . ; - . / '
tW- fo# T Xr /" v.' /c.
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2.9 BIOSYNTHESIS OF PORPHOBILINOGEN
Porphobilinogen (PBG) was required for a number of assays (see 
section 2.2.3 and 2.2.4). Due to the hi^ cost of the commercially 
available preparation, it was decided to synthesize PBG frcrn ALA using 
immobilized ALA-D. The procedure consisted of 3 stages:
(i) purification of ALA-D from bovine liver
(ii) biosynthesis of PBG using immobilized ALA-D and
(iii) isolation of synthesized PBG 
The overall synthesis was generally as described by Anderson and 
Desnick, (1982). The purification of ALA-D was taken from Graham 
(1978) and the subsequent steps in the procedure modified from March, 
Parildi and Cuatrecasas (1974) and Gurne and Shemin (1973).
2.9.1 HJRIFICATIQN OF 5-AMINCLAE7ULINIC ACID DEHYDRATASE.
ALA-D was purified from bovine liver obtained fresh from the
slaugbter-house. Unless indicated, all procedures were carried out 
at 4°C. Portions of liver were diced and homogenized in 3 volumes of 
ice cold potassium phosi*iate buffer (0.02M,pH6.8) containing potassium 
chloride (0.15M) and 2 -mercaptoethanol (ImM). The homogenate was 
spun at 2,500g for 4 5  minutes and the resultant supernatant heated in
a water bath to 60°C, held there with constant stirring for 5 minutes
then placed in crushed ice to cool. The extract was centrifuged at
2,500g for 2 0  minutes and the pellet discarded. 24.7g of ammonium
sulphate (NH^  SO4 ) was added per 1 0 0 ml of supernatant with constant 
stirring, and the solution left for 1 hour after total solution of 
NH]jSOi|. The precipitate was removed by spinning at 2,500g and 
discarded. A further 10.6g of NH4 SO4 per 100ml was added as
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previously described and the resultant precipitate containing the 
bulk of the remaining ALA-D activity pelletted at 2,500g and stored 
ovemi^t at -25°C.
Tlie following day» the precipitate was dissolved in the minimum 
amount of potassium phosphate buffer (0.05M,pH6.8) containing 2- 
mercaptoethanol (ImM) to give a protein concentration of 20-30mg/ml). 
The solution was then heated to 72-74°C in a water bath and held there 
for 3 minutes followed by rapid cooling in crushed ice. The 
supernatant obtained following centrifugation of the solution was 
placed in dialysis tubing (Visking Size 5-24,32") and dialysed 
overnight against 2 liters of the buffer in which the pellet was 
dissolved. The next day precipitated protein was removed by 
centrifugation.
The final yield of ALA-D was 7.1% and the specific activity was 
50.7 umol PBG for med/hour/mg protein, a purification factor of 23.8. 
ALA-D was precipitated by adding NHijSG^ j to 40g/100ml, spun down and 
stored at -80°C. Following this treatment, it was necessary to add 
DTT to the enzyme before use to restore activity. This is described 
in the relevant sections.
2.9.2 IMMOBILIZATION OF ALA-D AND BIOSYNTHESIS OF
50ml of cyanogen-bromide Sepharose CL-4B (Sigma) was activated by 
washing with hydrochloric acid (ImM), water, suspending in sodium 
hydrogen carbonate for 3 hours and washing with potassium i^os{*ate 
buffer (0.1M,pH7.0). It was then mixed with 600mg of protein from
2.9.1 dissolved in 20ml of potassium phosphate buffer (0.1M,pH7.0) 
containing DTT (0.3mM). Potassium chloride (KCl) was added to 0.4M
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and the mixture stirred overni^t at 4°C, then washed with 1 litre of 
potassium phosphate buffer (0.1M,pH7.0) containing KCK0.7M). The 
gel-protein complex was resuspended in 500ml of TRIS-HCl buffer 
(0.2M,pH8.0) containing DTT (5mM) and left overnight at 4°C. The 
next day the buffer was decanted off and the complex washed with 500ml 
of potassium phosjiiate buffer (0.1M,pH7.0) containing DTT (2mM) then 
poured into a column (10 x 2.5cm).
PBG was produced by pumping a solution of ALA (2mM) in potassium 
phosphate buffer (20mM,pH6.7) with DTT(O.SmM) at a flow rate of 
I.Oml/minute. The column was wrapped in aluminium foil to protect 
PBG produced from light and was maintained at 25°C, at which 
temperature 80-85% of the ALA was converted to PBG.
2.9.3 ISOLATION OF PORPHOBILINOGBJ
PBG was separated frcxn ALA and DTT by retention on a 1 x 30cm 
c o lu m n  of Dowex anion exchange resin (in the acetate form) placed in 
series with the column described in 2.9.2 and kept at 4°C in the dark. 
When the effluent gave a positive test with Ehrlichs reagent, 
(described in 2.3.1), the column was disconnected, washed with 2 
volumes of ice-cold distilled water and PBG eluted with acetic acid 
(4M). The PBG containing solution was freeze-dried, but in the 
latter stages of the process the frozen solution turned to a brown 
liquid. This should not have occurred and may be a consequence of 
the acidic pH. This material was dissolved in water and the pH 
adjusted to 6.0 with ammonium hydroxide (2M) and the solution 
lyophilized to a pale brown powder.
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3g of material were prepared in this way, but analysis revealed 
that only 30% (by wei^t) was PBG. The nature of the remaining 70% 
was uncertain, but it was not porphyrin (there was less than 0.05% 
uroporphyrin by wei^t). However, use of this PBG (after correcting 
for the fact that only 30% was PBG when preparing solution) in the 
assays described in 2.2.3 and 2.2.4 gave identical results when 
compared with those obtained froà commercially available PBG.
y
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2.10 MEASUREMENT OF GLUTATHTOMF:
Analysis of total glutathione (reduced + oxidized) in human blood 
and rat liver was performed by modifications of the methods of Brehe 
and Burch (1976) and Sunderman et al (1984). The principle of the 
method is that reduced glutathione (GSH) can react with 5,5'-dithiobis 
( 2-nitrobenzoic acid) (DIDB) to release the hi^ly coloured 2-nitro-
5-thiobenzoic acid (NTB). In the presence of glutathione reductase
(GR) and NADPH, a cycle is formed (Tietze, 1969) which can be
schematically illustrated as shown:
DTNB  ^ / 2GSH
NADPH2NTB ^ GSSG
This method has the advantage of being selective for glutathione 
because althou^ DTNB will react with almost any thiol, after the 
initial stage of the assay when the cycle is established, the rate of 
production of NTB is completely dependant on the concentration of 
glutathione present.
2.10.1 dUTATHIONE IN HUMAN BLOOD 
Methsd.
ICjpl of fresh, heparinised, venous blood was hemolysed by adding 
1.99ml of sodium phos#iate buffer (0.01M, pH7.4) containing Na2 EDTA 
(5mM). 0.3ml of this solution was added to two 3ml cuvettes, each
holding 2.7ml of sodium phosphate buffer (0.1M, pH7.4) containing 
NagEDTA (5mM), DTNB (0.25mg/ml) and NADPH (0.1 ImM). Both cuvettes 
were incubated at 30°C in a double beam spectrophotometer for 5 
minutes, after which Kÿil of glutathione reductase (Type III from
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Yeast, Sigma, 220 U/ml) was added to the test cuvette and the rate of 
change in absorbance of the test cuvette with respect to the blank at 
4l2nm was monitored for 5 minutes. The concentration of glutathione 
in the haemolysate was calculated by referring to a standard curve 
prepared by assaying 30C^ of a solution of glutathione in haemolysis 
buffer with concentration ranging from 0-10 After correcting for
dilution, glutathione concentration was expressed as pmoles/ml whole 
blood. I
2.10.1 GLUTATHIONE IN RAT LIVER 
Msthai
Rats were killed auid the livers excised and prepared as described 
in 2,5.2. 2.0g of liver were homogenised in 8ml of ice-cold Tris-HCl 
buffer (0.15M, pH7.4) using 5 strokes of a motor-driven Potter 
Elvehjem homogenizer. 4ml of perchloric acid (3M) containing Na2 EDTA 
(6mM) were added and the hcxnogenate centrifuged at I8,000g at 4°C for 
15 minutes. 0.1ml of the supernatant was diluted to 25ml sodium 
phos#iate buffer (0.1M, pH7.4) containing Na2 EDTA (5mM). 0.3ml of
t-hi« solution was then assayed exactly as described for the blood 
haemolysate. The pellet of denatured protein was dried at 100°C for 
6 hours then weired. After correcting for dilution, glutathione 
concentration was expressed as ^ oles/g of liver.
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2.11 ADDITIONAL METHQRc;
2.11.1 MICROSOMAL CYTOCHROME P-450
Cytochrome P-450 (cyt P450) was measured in purified rat liver 
microsomes.
(I) Preparation of microsomes
Livers were removed from rats and perfused as described 
in 2.5.2. All subsequent procedures were performed at 4°C. 
Typically 4g of liver were homogenized in 10ml ice-cold 
potassium phospdiate buffer (0.15M,pH7.0) using a Polytron 
ultrasonic mechanical hcxnogenizer. After an initial spin 
(1,500g for 15 minutes), to remove major cell debris, the 
sample was centrifuged at 17,500g for 20 minutes to remove 
mitochondria, nuclei, etc. The post-mitochondrial 
supernatant was spun at 105,000g for 1 hour and the 
resultant supernatant discarded. The pellet which 
contained the microsomes, was resuspended in the buffer 
described above to give a protein concentration of around 
âng/ml.
(II) Measurement of cvtochrome P45_0
The cyt P450 content of the microscmes was determined 
by the method of Omura and Sato (1964). Briefly, the 
solution of resuspended microsomes was split between two 1cm 
path length glass cuvettes and carbon monoxide (CO) was 
bubbled throu^ one of the cells (designated the test cell). 
Sodium dithionite was added to both cuvettes and CO once 
pgpin bubbled through the test cell, which was then scanned 
against the reference cell to produce a difference spectrum 
covering the range 400 to 500 nm at 20 C.
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Cyt P450 concentration was calculated from the 
difference spectrum using the extinction coefficient € =9ImM 
for the difference in extinction between 450 and 490nm and 
expressed as nmoles cyt P450/mg microsomal protein.
2.11.2 DETERMINATION OF PROTEIN CONCENTRATION
Protein concentrations in samples were determined by the method 
of Lowry âl. (19851) using crystalline bovine serum albumin as the 
standard.
Briefly» a range of standard solutions was prepared ranging from 
0 to 20()pg protein/ml. Unknown samples were diluted with distilled 
water to lie within this range. Standards and samples were then 
treated in tandem as described in the aforementioned paper and the 
extinction at 750nm measured. A standard curve of protein 
concentration versus Ay^g was prepared and used to determine the 
protein concentration in the unknown samples. A correction factor 
for the initial dilution was applied and results were expressed as 
mg/ml.
2.11.3 DETERMINATION OF BLOOD LEAD CONCENTRATIONS
Blood lead concentrations were determined by flameless atomic 
absoprtion spectrophotometry. Blood was collected in potassium EDTA 
tubes, then lOOul was diluted with 1 ml of 0.1$ Triton X-100. Blood 
lead concentrations were then determined using the standard conditions 
(for the apparatus described in section 2.1.2) listed in Perkin-Elmer 
Analytical Methods for Furnace Atomic Absorption Spectroscopy 
publication No.332-A1.
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2.11.4 DETEHHIHATIOM OF QUINARY 6-p^m)R0XTORTISCL EXCRETKM
Measurements of urinary 6-p-hydroxycortisol were kindly performed 
by Dr. B.K. Park of the Department of Pharmacology and Therapeutics, 
Liverpool University by a direct radio-immunoassay (Park, 1978).
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2.12 STATISTICAL ANALYSES
Groups of associated results were expressed as the mean value ± 1 
standard deviation.
The significance of differences between sets of data were 
assessed using Students t-test.
Linear and curvilinear relaWonships were determined using linear
I
suid curvilinear regression analyses.
All of the above tests and the relevant calculations were 
performed on an Apple He computer using the Biostats III statistics 
package (R.C.Targett, 1982).
Results from all statistical analyses were taken to be 
statistically significant when the probability of an event occurring 
on the basis of a formulated null hypothesis was less than 5$ 
(P<0.05).
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CHAPTER 3
THE EFFECTS OF CHRONIC ANTICONVULSANT THERAPY 
ON HAEM BIOSYNTHESIS IN MAN
3.1 INTRODUCTION
As explained in the final section of Chapter 1, there is some 
controversy over which drugs are safe to use in seizure management in 
epileptic porphyria, patients. This chapter aimed to resolve this 
problem by examining the effects of three anticonvulsant drugs on 
selected aspects of haem biosynthesis in epileptic patients receiving 
long-term anticonvulsant therapy. The three drugs studied were 
carbamazepine (CBZ), sodium valproate (VPA) and phenytoin (DFH). The 
long-term affects of CBZ were of particular interest because as 
described in the final section of Chapter 1, Rapeport £t. aL (1984) 
and Yeung et al (1983) found changes in the haem biosynthetic pathway 
in individuals treated with CBZ which were representative of the 
biochemical features of the latent or remission phase of acute 
intermittent porphyria (AIP). These changes included elevation of 
ALAS activity, depression of PBG-D activity, increased urinary ALA 
excretion (and in one case increased PBG) and an increase in the % URO 
in the urinary porphyrin fraction. These studies examined only 
subjects who had taken the drug for periods of less than three weeks. 
Therefore, a major portion of the investigations described in this 
chapter were devoted to the long-term effects of CBZ on haem 
biosynthesis in man in an attempt to explain these previous findings 
and to evaluate the potential of this treatment as a model for
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studying AIP. Four groups were investigated (see Appendix I for 
details).
(1) a group of epileptic patients on CBZ monotherapy
(2) a group of epileptic patients on sodium valproate (VPA) 
monotherapy
(3) a group of epileptic patients on phenytoin (DPH) monotherapy
(4) a group of healthy control subjects age and sex matched to 
each of the above groups
In addition to this, some analyses were carried out on samples from a 
few epileptic patients taking phenobarbitone. Only a selection of 
the analyses applied to the other groups were performed and the 
numbers involved were not large enough for accurate statistical 
analysis. These figures therefore are not presented in the tables of 
results but will be referred to in the text where appropriate.
In the li^t of the earlier studies of Rapeport £t. âL (1984) and 
Yeung jat âL (1983) it was decided that it was not necessary to assay 
all of the enzymes in the haem biosynthetic pathway. COPRO-0, PROTO-0 
and FERRO-C were omitted because they are not relevant to the 
potential porphyrogenicity of CBZ, VPA or DPH and also because they 
did not appear to be involved in the syndrome described by Rapeport 
et al and Yeung êîl aL for example (a) the two enzymes affected by CBZ 
are in the first part of the pathway (b) they have no bearing on the 
increased ALA excretion and (c) the increase in the URO fraction of 
the urinary porphyrins could have occurred in one of two ways, neither 
of which involve COPRO-0, PROTO-0 or FERRO-C. The first of these is 
throu^ a depression of PBG-D activity as is found in AIP, leading to 
a build up of PBG which would undergo non-enzymatic condensation and
83
cyclization to produce URO-genl. This would be excreted in the urine 
as URO-I, (the oxidized product of URO-genl), because it is a poor 
substrate for URO-D compared with the enzymatically produced UROgenlll 
(see section 1.2.4). The second way in which the URO fraction could 
be increased is through a reduction in URO-D activity as occurs in POT 
(see 1.2.10) leading to accumulation of UROgenlll which would 
subsequently be excreted in the urine as URO-III. In any case, a 
change in the activities of these enzymes would be reflected in the 
porphyrin excretion pattern.
The chapter is divided into five sections, this introduction 
being the first. The second section discusses the effects of chronic 
anticonvulsant therapy on the activities of the enzymes in the pathway 
and the third looks at the effects of the same on the urinary 
excretion of porphyrins and precursors. The fourth section examines 
the effects of chronic treatment on 6p-hydroxycortisol excretion (an 
index of mixed function oxidase activity) and the fifth summarises the 
chapter.
Plasma drug levels were also measured where applicable. Not all 
of the patients studied were able to provide both blood samples and 24 
hour urine collections, nor was it always possible to assay all of the 
required enzymes in a given blood sample. For these reasons the 
number of results for different analyses may vary within a group.
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3*2 IHE EFFECTS OF CHRONIC ANTICONVULSANT THERAPY ON THE ENZYMES 
OF HAEM BIOSYNTHESIS IN RLOQD CELLS
As stated in the introduction to this chapter, the activities of
some of the enzymes of haem biosynthesis were measured in epileptic
patients undergoing long-term anticonvulsant therapy. The following
enzyme analyses were performed:
Blood enzyme analvses
5-aminolaevulinic acid synthase (ALA-8)
5-aminolaevulinic acid dehydrase (ALA-D)
porphobilinogen deaminase (PBG-D)
uroporphyrinogen decarboxylase (URO-D)
The results of these analyses are presented in table (2). Each
enzyme will be discussed in turn with reference to this table.
3.2.1 THE EFFECTS OF CHRONIC ANTICONVULSANT THERAPY ON ALA-S ACTIVITY
The mean activities of ALA-S in both CBZ and VPA treated patients 
were raised significantly with respect to controls (P<0.001 for both 
groups), but there was no significant difference in those patients on 
chronic DPH therapy. Possible explanations for the lack of effect 
with DPH will be discussed later in this sub-section. In none of the 
groups studied was there any correlation between plasma drug levels 
and ALA-S activity. Why is ALA-S derepressed in CBZ and VPA treated 
patients? There are three possible mechanisms by which this could 
occur. These are (a) throu# an increased haem requirement (b) 
through a blockage at a specific enzyme site in the pathway with 
consequent reduction in haem out-put and (c) through direct 
derepression of ALA-S. The mechanisms whereby these situations may 
arise and cause an increase in ALA-S activity are discussed in detail 
in the introductory chapter (see 1.2.9), but it is likely that in the
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TABLE (2)
amARY OF THE RESULTS OF BLOOD ENZTME ANALYSES IN 
■CONTROLS AND IN ANTICONVULSANT TREATED PATIENTS
ALA-S^ ALA-D^ PBG-D° URO-D®
CONTROLS 154 + 57 1224 ± 216 30.8 ± 4.7 17.9 ± 2.4
(85 - 303) 
n=26
(684 - 1602) 
n=36
(21.9 - 39.6) 
n=31
(13.2 - 21.8) 
n=12
CBZ 336 ± 273* 747 ± 384* 25.4 + 6.6* 17.3 ± 3.8
(61 - 934) 
n=23
(78 - 1752) 
n=50
(9.7 - 39.7) 
n=43
(8.1 - 23.5) 
n=25
VPA 475 ± 188* 1299 ± 312 30.4 ± 4.9 17.6 ± 2.4
(88 - 619) 
n=8
(768 - 1647)
n=12
(23.9 - 38.5 
n=12
(13.8 - 21.7) 
n=8
DPH . 162 ± 105 1185 ± 366 32.6 ± 8.2 17.8 ± 3.1
(43 - 360)
n=8
(561 - 1689) 
n=11
(23.5 - 38.6) 
n=8
(12.6 - 22.7) 
n=8
* p<0.001 as compared to controls 
Values presented are mean ± 1 S.D.
Figures in brackets represent ranges 
a units are pmoles ALA produced/h/mg protein
b units are moles PBG produoed/h/ml erythrocytes
o units are moles OBO produoed/h/ml erythrocytes
d units are moles decarboxylations/h/ml erythrocytes
case of bo th  CBZ and VPA, d e re p re ss io n  o ccu rred  th ro ug h  an inc rea se d  
haem requirement. CBZ is metabolized by the hepatic mixed function 
oxidase (m.f.o) system (Frigerio, Cavo-Briones and Belvedere, 1976) 
and is also a potent inducer of this system in man (Eichelbaum al; 
1985). As cyt P450, the functional component of the hepatic m.f.o. 
system, requires haem as a prosthetic goup, then it follows that 
increased levels of haem will be required to meet the demand generated 
by increased cytochrome P450 apoprotein synthesis. In the case of 
CBZ, it is also possible that derepression of ALA-S occurred through 
mechanism (b) since as will be shown, CBZ causes a reduction in ALA-D 
activity. Derepression of ALA-S due to a deficiency of ALA-D 
activity occurs in lead poisoning and plumboporphyria (see 1.2.10). 
Although, as will be discussed later in this chapter, this may play 
some part in the derepression of ALA-S in some of the CBZ treated 
patients, this is not likely to be the principal means by which this 
was accomplished in the majority of patients. How could VPA cause an 
increased haem requirement? VPA is not primarily metabolized by the 
hepatic m.f.o. system, but the system must have some potential for 
metabolizing the drug since drugs which do induce hepatic m.f.o. 
activity accelerate VPA metabolism and clearance (Mihaly jgt ai, 1979; 
Reunanen at. ai, 1980). VPA has also been shown to have inhibitory 
effects on the hepatic m.f.o. system (Kapetanovic at aL 1980) and it 
is possible that in this way it reduces the amount of functional cyt 
P450 and thus increases the demand for haem, leading to derepression 
of ALA-S. As part of a separate study, the short term effects of 
VPA treatment on leucocyte ALA-S activity were investigated. 8 
healthy male volunteer subjects ingested either VPA (SOOmg t.d.s.) or
86
a placebo for a period of 7 days. ALA-S activities were measured 
after 1, 3 and 5 days. The results, show n in table ( 3 ) ,  r e v e a l  a 
hi^ly significant mean increased in ALA-S activity of 128$ (P<0.001) 
after 3 days treatment with VP A. The mechanism whereby this occurs
is probably as just discussed. Further discussion of the reasons why 
ALA-S should be derepressed in VPA and CBZ treated patients is 
presented in section 3.4.
The reasons why CBZ and VPA should have caused chronic elevation 
of ALA-S activity but DPH did not is uncertain. DPH has been shown 
to increase ALA-S activity during short-term treatment (McColl âl» 
1980) in the same way as CBZ (Rapeport 1983). However CBZ-
treatment resulted in sustained elevation of activity (albeit at lower 
levels than in the initial stages of treatment) and it would appear 
that DPH did not. Measurement of the plasma DPH concentrations in 
the 8 patients whose ALA-S activities were measured revealed that in 
four of these patients, plasma drug concentrations were almost 
undetectable and were very low in another two of the patients. In 
view of the doses supposedly taken by the patients, this is suspicious 
of non-compliance. This non-compliance renders any significant 
deviations from the control group inconclusive in the case of DPH.
3,2.2 THE EFFECTS OF CHRONIC ANTICONVULSANT THERAPY ON ALA-D ACTIVITY
Carbamazepine was the only drug to affect ALA-D activity: the
mean ALA-D activity of the CBZ-treated group was 61$ of the mean 
activity of the control group (P<0.001). In the 23 patients for which 
ALA-S data was also available the mean activity was 71$ that of the 
control group. It is possible that this reduction in ALA-D activity 
is partly responsible for the increased ALA-S activity in some
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table (3)
I^-EFFECTS OF .SHORT T^M VPA TREATMENT ON 
LEUCOCYTE ALA^ ACTIVITY IN MAN
DAYS OF 
TREATMENT
ALA-S ACTIVITY^
PLACEBO VPA
1 153.4 + 40.9 164.1 ± 65.9
3 157.5 ±41.1 373.5 ± 115.6*
5 161.5 ± 32.3 335.5 ± 140.8*
» P<0.001 as compared to placebo 0iase.
8 healthy males ingested VPA (500tag,tds) or a placebo.
Leucocyte ALA-S activities were determined after treatment for 1, 3 and 
5 days.
^ units are pmoles ALA produced/h/mg/protein
patients because Meredith al (1978) showed that below ALA-D 
activities of550mnol PBG/h/ml erythroctes, (48$ of the mean control 
value in this study) haem biosynthesis was impaired to such an extent 
that ALA-S was derepressed. 19 of the patients studied fell into 
this category. However, the findings of Meredith et al are not 
completely applicable to this situation since that study was concerned 
with the effects of lead on the pathway. Lead affects enzymes other
than ALA-D (see 1.3.10). Therefore in the majority of CBZ treated 
patients in this study, ALA-S was not derepressed as a consequence of 
the reductions in the levels of ALA-D activity. In support of this, 
no correlation was found between ALA-D and ALA-S activities. A 
correlation did exist however, between total plasma CBZ and ALA-D 
activity. For 47 patients in which both these parameters were 
measured there was a negative linear correlation between the 
two (r=-0.45,P<0.01), fig.(15). Interestingly, as regards fig.(15), 
extrapolation to zero concentration of CBZ gives an ALA-D activity of 
1167 nmolPBG/h/ml erythrocytes. This can pares well with the mean 
ALA-D activity found in controls (1124 ± 216 nmolPBG/h/ml 
erythrocytes, n = 36). There are three possible explanations as to 
why ALA-D activity is depressed:
(a) CBZ or a metabolite directly reduces enzyme activity
(b) CBZ or a metabolite indirectly reduces enzyme activity
(c) the derepression of ALA-D activity is somehow related to the
increase in ALAiS activity
At this stage only option (c) can be eliminated since no correlation
was found between the two and many cases of increased ALA-S activity
have been reported without any depression of ALA-D. Further
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FIG. (15)
ERYTHROCYTE ALA-D AND PBG-D ACTIVITIES: RELATIONSHIPS WITH PLASMA CBZ
Statistically significant relationships were established between 
erythrocyte ALA-D and PBG-D activities and plasma CBZ concentrations in 
samples from epileptic patients on CBZ monotherapy.
Enzvme n Linear Reeression Correlation IkKfficient
ALA-D 47 - 0.45 , p<0.01
PBG-D 42 - 0.48 , p<0.01
investigations into the nature of the effect are described in 
Chapter 4.
ALA-D activity was also determined in 3 subjects on 
phenobarbitone monotherapy, but was not significantly different from 
controls (mean activity = 1128 ± 150 nmolPBG/h/ml erythrocytes).
3.2.3 m s  EFFECTS OF CHRONIC ANTICONVULSANT THERAPY ON PBG-D ACTIVITY
PBG-D activity was determined using the method designated the 
ÜR0-1-S assay (see 2.3.2). The results show that CBZ, but neither 
VPA nor DPH, significantly reduced PBG-D activity. The mean PBG-D 
activity of the CBZ treated group was 82% of the mean control value 
(P<0.002). This reduction in PBG-D activity is in agreement with the 
findings of Yeung et al, (1983) and Rapeport ^  al? (1984) but does not 
match the findings of Rideout £i. âi.* (1983) or Doss and Schafer 
(1984), both of whom reported normal PBG-D activities during CBZ 
treatment. Reasons for this difference will be discussed presently. 
A negative linear correlation was found between total plasma CBZ and 
erythrocyte PBG-D in 42 patients (r = -0.48, P<0.01), fig.( 15 ). 
Using the data frcan these patients in fig. (15), extrapolation to a 
theoretical zero concentration of CBZ gives a PBG-D activity of 32.5 
nmolesURO/h/ml erythrocytes, which compares very well with the mean 
value of 30.8 nmolesURO/h/ml erythrocytes found in 31 controls. This 
suggests that CBZ does indeed cause a depression of PBG-D activity. 
If this were the case then the mechanisms whereby this could occur 
would be as for ALA-D. The fact remains, however, that other 
workers could not repeat these results. The answer to these 
discrepancies may lie in the methodologies used by the different 
groups. The assay from which these results were obtained utilized
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ALA as a substrate and was dependent on ALA-D activity to generate 
PBG, the true substrate for the assay. The same assay was used by 
Yeung Êtâl*(1983) and Rapeport &L (1984) for their findings. 
The assays adopted by the other groups used PBG as a substrate. As 
ALA-D activity is reduced in patients undergoing CBZ therapy (see 
previous sub-section), a fact also noted by Rideout and Doss, it is 
possible that there is insufficient active enzyme to generate 
saturating quantities of PBG. The rate of PBG synthesis from ALA may 
be reduced to such an extent that the rate of UROgenI production is 
not dependent on the levels of PBG-D activity but on the rate of PBG 
production by ALA-D. This possibility is fully explored in later 
chapters.
PBG-D activity was also determined in 3 subjects on 
phenobarbitone monotherapy, but was not significantly different from 
controls (mean activity 32.8 + 6.1 nmolURO/h/ml erythrocytes).
3.2.4 THE EFFECTS OF CHRONIC ANTICONVULSANT THERAPY ON ÜRO-D ACTIVITY
No changes were found in URO-D activity in any of the groups 
studied with respect to controls. This enzyme is not, as far as is 
known, inducible or repressible. Given that a transient effect of CBZ 
on the enzyme is improbable, then it is unlikely that URO-D activity 
would be reduced in individuals undergoing short-term treatment. This 
refutes the suggestion made earlier in this chapter that a reduced 
URO-D activity may be the reason for the increase in the % URO in the 
porphyrin fraction of urine observed by Rapeport sL (1984).
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3.3 IHE EFFËCT3 OF CHRONIC ANTICONVULSANT THERAPY ON THE URINARY 
EXCRETION OF PORPHYRINS AND PRECURSORS IN MAN
As stated in the introduction to this chapter, the urinary 
excretion of porphyrins and precursors were measured in epileptic 
patients undergoing long term anticonvulsant therapy. The following 
urinary analyses were performed:
24 hour 5-aminolaevulinic acid excretion 
24 hour porphobilinogen excretion 
24 hour total porphyrin excretion 
HFLC analysis of porphyrin ccanposition 
The results of these analyses are presented in table (4). Each of 
these analyses will now be discussed with reference to this table.
3.3.1 THE EFFECTS OF CHRONIC ANTICONVULSANT THERAPY ON 
URINARY ALA EXCRETION
None of the drugs studied produced mean 24 hour urinary ALA 
excretion values which differed significantly from the control group, 
though both CBZ and VPA treated groups did display slight increases. 
This indicates, at least in the 22 patients studied for which ALA-S 
data was also available, that CBZ does not inhibit ALA-D to such an 
extent that the flow of intermediates throi# the pathway is disturbed 
in vivo, as this would produce an accumulation of ALA. This 
reinforces the statement made earlier in this chapter that ALA-S in 
these patients was not elevated as a consequence of a blockage in the
pathway.
No correlation was found between 24 hour ALA excretion and ALA-S 
or ALA-D activities for any of the groups studied.
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3*3.2 IËE_EFFECTS OF CHRONIC ANTICONVULSANT THERAPY ON 
URINARY PBG EXCRETTOM
The VPA treated group was the only one to exhibit significantly 
different excretion values for PBG as compared to controls» though 
both CBZ and DPH treated subjects showed sli^t increases. For 8 
subjects on VPA, the mean PBG excretion over 24 hours was 539% that of 
controls (P<0.01). The increased PBG excretion during VPA treatment 
may have been due to the elevated ALA-S activity. The same may not 
have occurred in the case of CBZ because (a) in the patients whose 
urines were studied, ALA-S was not derepressed to the same extent as 
in those patients on VPA or (b) because less PBG was produced due to 
reduced ALA-D activity. This latter suggestion would imply that a 
reduced level of PBG synthesis did not have adverse effects on haem 
biosynthesis because a greater percentage of the PBG produced would be 
utilized i.e. there would be less wastage. There was no correlation 
between PBG excretion and ALA-S, ALA-D or PBG-D activities in any of 
the groups studied. Interestingly, a relationship was found between 
urinary ALA and PBG excretion in all groups with the exception of the 
CBZ-treated group. Combining the data from the control, DPH and VPA 
groups revealed a positive linear correlation between these two 
parameters, (n=29,r=0.57,P<0.01). No such relationship was found in 
the CBZ treated group (n=22,r=0.041, P>0.1) table (4). This disparity 
between the two sets of data is probably due to the reduction in ALA-D 
activity (caused by CBZ treatment), leading to subtle differences in 
the ALA/PBG ratio.
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3-3.3 ,1HE EFFECTS OF CHRONIC ANTICONVULSANT THERAPY OM 
URINARY TOTAL PORPHYRIN EXCRETTOM
No significant differences were found between the CBZ and DPH 
treated groups and the control group, although in the case of CBZ 
there was a trend towards higher values. Patients treated with VPA 
showed a significant mean increase of 232% over controls which is, as 
for PBG, a reflection of the increased ALA-S activity. The reasons 
why a hi^er level of porphyrin excretion was not observed in CBZ- 
treated patients are probably the same as just discussed in the case 
of PBG excretion, namely ALA-S activities were not as hi^ and also 
because the reduced ALA-D activity may mask the effect to some extent. 
No correlations were found between total urinary porphyrin and ALA-S, 
ALA-D, PBG-D or URO-D activities nor was there any correlation with 
the values for 24 hour ALA or PBG excretion.
3.3.4 THE EFFECTS OF CHRONIC ANTICONVULSANT THERAPY ON 
URINARY PORPHYRIN COMPOSITION
Analysis by the HFLC method described in sub-section 2.3.4 of the 
percentage composition in urine of each of the porphyrins produced in 
the transformation of URO to COPRO revealed little change with respect 
to controls. The mean excretory pattern obtained with CBZ was 
virtually identical to that observed in controls. This contrasts 
with the findings of Yeung fit âl (1983) and Rapeport fit al (1984), 
both of whom reported large increases in the URO fraction. The 
reasons for this difference are uncertain, but the most likely 
explanation is that the level of ALA^ activity plays an important 
role. Rapeport fit (1983, 1984) demonstrated that treatment with 
CBZ over a period of two weeks produced peak increases in ALA-nS of
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657% and 1145% of controls (figures are for 400mg CBZ/day and 600mg 
CBZ/day respectively), during which time the % fraction of URO in 
urine was also elevated. This was followed by a decline in ALA-S 
levels. The results presented here show that, although ALA-S 
activity does not remain at the very high levels observed in the 
initial stages of treatment, it does not return to normal levels and 
remains slightly derepressed. Moreover, at these moderately 
increased levels of ALA-S activity, no abnormality was found in the 
urinary porphyrin excretion pattern, implying that the transiently 
very hi^ activities produced in the initial stages of treatment are 
the cause of the altered porphyrin profile. This could occur as 
follows. In the initial stages of treatment when ALA-S activities 
are very high, so much PBG is produced that PBG-D activity is 
saturated, and the excess PBG will be excreted in the urine. This is 
possible because after ALA-S, PBG-D has the lowest endogenous 
activity in the haem biosynthetic pathway (Elder, 1982). Thus the 
situation is analogous to that described in AIP (see 1.2.10): urinary 
PEG will accumulate and will cause an elevation of the urinary URO 
fraction through non-enzymatic polymerisation and cyclization. In 
support of this theory, a slight but not statistically significant 
increase in PBG excretion was found by Rapeport fit âl^ ( 1984). When 
ALA-S activity falls, PBG-D can cope because there is not such 
excessive production of PBG. The fact that ALA-D activity is 
depressed may also have a role to play at this stage since in the 
previous section it was shown that ALA-D activity was sufficiently 
reduced to alter the ALA : PBG ratio. An additional factor which may 
have some bearing on these results is that the method used here
94
c o n ta in s  c e r ta in  re fin e m e n ts  w hich  g re a t ly  im proved th e  r e s o lu t io n  o f  
the individual porphyrins. For example, Rapeport fit âL (1984) found 
that COPRO accounted for almost 100% of the urinary porphyrin in 
subjects with only slight traces of the other porphyrins. In the 
results presented in this chapter, COPRO accounted for around 76% of 
the total urinary porphyrin excretion in controls and URO, 7-COOH, 6- 
COOH and 5-COOH accounted for around 12, 5, 2 and 5% respectively. 
This is in good agreement with the findings of Ostrowski fit. fil (1984) 
who reported COPRO values of 58-87% and URO values of 13-31%, and also 
agrees well with Doss (1978).
VPA had some significant effects on the urinary porphyrin 
profile, predominantly an increase in the COPRO fraction with 
consequent reduction in each of the other fractions. The mechanism 
whereby this occured is uncertain, but it was not due to increased 
activity of URO-D (see 3.2.1). It could have arisen through a 
slight inhibition of COPRO-0, though this was not further 
investigated. A more likely explanation is that the increased flow 
throu^ the pathway as a result of derepression of ALA-S provides more 
substrate for URO-D and allows an increased rate of COPRO formation 
which may lead to a greater excretion of COPRO. This proposal 
assumes that there is an endogenously higher level of URO-D activity 
than COPRO-0 activity, which is the case in rat liver (Bishop and 
Desnick, 1982). In human liver, however, the activities of the two 
enzymes are almost equivalent (Elder, Lee and Tovey, 1978), thou^ the 
above proposed is still valid because URO-D has a hi^er km value and 
could therefore cope with more substrate (Elder, 1982).
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DPH also affected the urinary porphyrin excretion profile, with a 
significant reduction in the COPRO fraction and corresponding 
increases in the remaining fractions. However, for the reasons 
stated earlier in this chapter, the results obtained from the studies 
described here must be treated with caution due to the low drug 
concentrations found in this group of patients. An additional 
complicating factor may be the small number of urines studied from 
this group (n=5). For conclusive results, a larger number of urine 
samples would be required from patients complying with their 
therapeutic drug regime.
T.L
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3.4 EFFECTS OF CHRONIC ANTIC0NVIII.5^ ANT THERAPY ON
ILRINARY 6-P-HYDROXYCORTISQL EXCRETION
6^-hydroxycortisol (5p-0HC) is a minor metabolite of cortisol 
formed primarily in the endoplasmic reticulum of hepatocytes by the 
mixed function oxidase (m.f.oj system. It is excreted in the urine 
without conjugation and has been used as an jji vivo index of m.f.o.
activity. (Park, 1981). Measurement of the levels of this ccmpound
in the urine of epileptic patients receiving chronic anticonvulsant 
therapy therefore allows assessment of the state of m.f.o. activity in 
these patients as compared to age and sex-matched controls. The 
analyses were performed on 24 hour urine collections from the 
following groups:
(i) a group of epileptic patients receiving CBZ monotherapy
(ii) a group of epileptic patients receiving VPA monotherapy
(iii) a group of controls, age and sex matched with the above 
The results are presented in table (5) and show that chronic 
treatment with either CBZ or VPA produced a highly significant 
increase in 6p-0HC excretion. Increases of 147% (P<0.005) and 104% 
(P<0.05) compared to the control group were found for CBZ and VPA 
treated groups respectively. This result was not unexpected in the 
case of CBZ since this compound is a well-known inducer of m.f.o. 
activity and has previously been reported to cause increased 6p-0HC 
excretion (Roots, Ley and Hildebrandt, 1977). This provides support 
for the proposal that ALA-S is chronically derepressed in these 
patients to produce sufficient haem for increased cyt P450 synthesis. 
The result with VPA, however was unexpected. Since VPA is not 
primarily metabolized by this system, it would not be expected to 
induce it. There may be increased m.f.o. activity in order to
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TABLE (5)
THE EFFECTS OF CHRONIC CBZ AND VPA MCMOTHERAPÏ 
ON DBINAJ1Ï ep-HTDBOXÏCORTISCL EXCRETION IN EPILEPTIC PATIENTS
TREATMENT
6P-0HC
EXCRETION
Control
(n=l6) 291 + 102
CBZ
(n=19) 720 ± 526**
VPA
(n=8) 595 + 552*
• P<0.05. •• P<0.005
6P-0HC was measured In 24 urine collections by radioimmunoassay. The 
units used are ug 6BŒIC excreted/24 hours.
compensate for the inhibitory effects of VPA on the system 
(Kapetanovic fit aJL, 1980). However, regardless of the mechanism by 
which m.f.o. activity is increased (as evidenced by the rise in 6^-OHC 
excretion), the increase is the likely cause of the chronic 
derepression of ALA-S found in these patients.
There was no correlation between 6JB-0HC excretion and ALA-S 
activity or total porphyrin excretion in any of the groups studied. 
ConcIuslQug Qt Section 3,4 >
CBZ and VPA produced increases in 6^-OHC excretion in patients 
treated chronically with either drug. These increases reflect a rise 
in hepatic m.f.o. activity, which is probably the underlying cause of 
the derepression of ALA-S vrtiich is found in these patients.
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3.5 SUMMARY OF CHAPTER 3
The conclusions from each of the groups studied are summarised 
separately.
3.5.1 THE EFFECTS OF CHRONIC CARBAMAZEPINE TREATMENT ON 
HAEM BIOSYNTHESIS
The long term effects of CBZ on the enzymes studied were a 
sustained increase in ALA-S activity (which did not correlate with 
plasma drug concentration) and a depression of both ALA-D and PBG-D 
activities (both of which correlated with plasma drug concentration). 
ALA-S was probably derepressed as a result of an increase in hepatic 
cytochrome P450 synthesis. This was supported by the finding of an 
increased 6B-0HC excretion in these patients. The mechanism of the 
depression of ALA-D and PBG-D activities is uncertain. URO-D 
activity was unaffected by CBZ. Urinary ALA, PBG and total porphyrin 
excretions were sli^tly elevated in comparison to controls, but not 
to a statistically significant extent and there was no correlation 
between any of these parameters and plasma CBZ concentration. The 
depression of ALA-D activity, however, produced a change in the 
relationship of urinary ALA to PBG. The results of the analyses of 
urinary porphyrin excretion profiles during prolonged CBZ therapy were 
no different from controls. This finding is in conflict with 
Rapeport fit. aL (1984) but the difference is probably attributable to 
the very hi^ levels of ALA-S activity produced in the initial stages 
of CBZ treatment in that study.
3 . 5 . 2  THE EFFECTS OF CHRCTJIC VALPROIC ACID TREATMENT ON HAEM BIOSYNTHESIS
The only enzyme shown to be affected by VPA was ALA^ This was 
most probably derepressed as a result of increased hepatic cytochrome
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P450 synthesis, required to maintain the high levels of m.f.o. 
activity found in these patients. This increase in m.f.o. activity 
is probably the result of over compensating for the inhibitory effect 
of VPA on the system. There was no correlation between plasma drug 
concentration and ALA-S activity. VPA also produced an increase in 
the urinary excretion of ALA, PBG and total porphyrin, though only the 
latter two were affected to a statistically significant degree. 
These increases were probably due to the increased ALA-S activity. 
Again, there was no correlation between any of these parameters and 
plasma VPA concentration. There was also a significant change in the 
urinary porphyrin excretion profile, which may be attributed to 
increased availability of pathway intermediates.
3.5.3 THE EFFECTS OF CHRONIC PHENYTOIN TREATMENT ON HAEM BIOSYNTHESIS
In the patients studied, DPH did not affect any of the enzymes or 
the urinary excretion of ALA, PBG and total porphyrin. Tiese results 
cannot be considered to be conclusive, primarily because of the very 
low plasma drug concentrations in the patients studied.
3.5.4 FURTHER EXPERIMENTS
On the basis of these results, it was decided to further 
investigate the effects of CBZ on haem biosynthesis with particular 
reference to ALA-D, PBG-D and the urinary excretion of porphyrins and 
precursors. These investigations constitute the remainder of this 
thesis.
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CHAPTER 4
4. C^ARBAMAZEPINE AND HAEM BIOSYNTHESIS IN MAN
This chapter investigates in greater detail the effects of CBZ on 
certain aspects of haem biosynthesis in man. It is divided into four 
sections. The first of these is concerned with ALA-D, the second 
with PBG-D and the third with the urinary porphyrin excretion 
profiles. The fourth summarises the results of this chapter. At 
this point it is appropriate to recall two aspects of CBZ therapy 
which may have scane bearing on the effects which will be discussed. 
The first of these is carbamazepine-10,11-epoxide (CBZ-E), the 
principal metabolite of CBZ. This accounts for 10-20% of the total 
circulating levels of the drug in man. (Brodie, Forrest and Rapeport, 
1983). There is a relationship between plasma CBZ-E (as determined 
by HPLC) and total plasma CBZ (as determined by EMIT). This is 
demonstrated in fig, (16) using data from 47 epileptic patients on 
CBZ monotherapy. The curvature of the line at high plasma CBZ 
concentrations means that the % CBZ-E increases with increasing drug 
levels. This is due to auto-induction: CBZ stimulates its own
metabolism (Eichelbaum fit aL 1975). The second aspect of CBZ which 
is of interest is free CBZ. CBZ is normally about 80% bound to serum 
proteins. The remaining percentage is termed "free CBZ". Free CBZ 
is in equilibrium with CBZ inside cells and is therefore considered to 
be the fraction with pharmacological activity. Free CBZ is also 
related to total CBZ (as determined by Q4IT). This is illustrated in 
fig (17) using data from 33 epileptic patients on CBZ monotherapy. 
Both CBZ-E and free CBZ are discussed in more detail in the 
introductory chapter (1.2.3).
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FIG. (16)
TSE RELATIONSHIP BETWEEN TOTAL CBZ AND CBZ-E IN HOMAN PLASMA
Samples were taken from 43 epileptic patients on chronic CBZ 
monotherapy.
"Total CBZ" refers to CBZ and all metabolites thereof as determined by 
the EMIT system (see sub-section 2.4.1). CBZ-E was determined by the HFLC 
method described in sub-section 2.4.2.
Linear Regression Correlation Coefficient = 0.93» p<0.001
Curvilinear Regression Correlation Coefficient = 0.94, P<0.001
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FIG. (17)
THE RELATIONSHIP BETWEEN TOTAL CBZ AND FREE CBZ IN HUMAN PLASMA
Samples were taken from 33 epileptic patients on chronic CBZ 
monotherapy.
"Total CBZ" refers to CBZ and all metabolites thereof as determined by 
the EMIT system (see sub-section 2.4.1). Free CBZ was determined by 
equilibrium dialysis as described in sub-section 2.4.3
Linear Regression Correlation Coefficient = 0.92, p<0.001.
All of the analyses described in this chapter were performed on 
fresh blood or urine samples as described in the appropriate methods 
section.
4.1 CARBAMAZEPINE AND 5-AMINOLAEVULINIC ACID DEHYDRATASE
Results in the previous chapter revealed that treatment with CBZ 
caused a reduction in the activity of erythrocyte ALA-D in man, the 
extent of which was related to the total plasma levels of CBZ. This 
section examines the nature of the relationship between CBZ and ALA-D 
in greater detail. There are several ways in which the reduction in 
ALA-D activity observed could have occurred, each of which could be 
due to a direct or indirect effect of CBZ. These are (a) a reduced 
rate of synthesis of the enzyme (b) partial inactivation (or 
modification) of all molecules of enzyme or (c) total inactivation 
of a percentage of the enzyme. Option (a) is not very likely because 
ALA-S is the only enzyme in the pathway so far shown to be inducible 
or repressible. The remaining possibilities are more probable and 
are also easier to test. Each of the sub-sections which now follow 
discusses various aspects of the relationship between CBZ and ALA-D 
with possibilities (b) and (c) in mind.
4.1.1 ATTB4PTS TO REVERSE THE CBZ-MEDIATED REDUCTION IN ALA-D ACTIVITY
One of the first steps in understanding the nature of any enzyme 
inhibition is to establish if it is reversible or not. Therefore the 
experiments described in this sub-section were designed to resolve 
hhia question. Two different techniques were used in an attempt to 
restore ALA-D activity. The first attempted to achieve this through 
treatment with activators and the second by dialysis. Each of these 
is discussed separately.
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(i) Ireatment of ALA-d with activators
ALA-D from all tissues is very susceptible to loss of 
activity through oxidation of essential thiol groups or 
removal of essential zinc ions. Reduction of these oxidised 
thiols with sulphydryl reagents such as dithiothreitol 
(DTT), cysteine or mercaptoethanol, and the addition of zinc 
ions generally restores enzyme activity to what it was 
previously. These compounds are therefore referred to as 
activators of the enzyme. Even in fresh blood from healthy 
subjects, not all of the ALA-D present in the erythrocytes 
is catalytically active. Treatment with these activators 
however, realises the full potential activity and will be 
referred to as "restored activity" whereas activity in 
untreated blood will be termed "circulating activity". A 
good example of the effectiveness of these activators is in 
reversing the effects of lead - a potent inhibitor of ALA-D 
(Mauras and Allain, 1982). This experiment investigated 
if the reduction in erythrocyte ALA-D activity which 
occurs during CBZ therapy was reversible by treatment with 
DTT and Znf* using the methodology described in section 
2.2.2.
The analyses were performed on blood from the same 
groups of patients as described in Chapter 3. DPH and VPA 
treated patients were also included for completeness. For 
each subject studied a value was obtained for circulating 
activity and restored activity. The results are presented 
in graphic form in fig (18). Table (6) summarises the
data.
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FIG. (18)
CIRCULATING AND RESTORED ERYTHROCYTE ALA-D ACTIVITIES IN CONTROL SUBJECTS 
AND IN EPILEPTIC PATIENTS RECEIVING ANTICONVULSANT MONOTHERAPIES
In each compartment» A = circulating activities and B = restored 
activities. Only CBZ treated subjects were significantly different from 
controls on the basis of students t-test. (p<0.001 for both A and B).
The data is presented in tabular form in table (6).
TAH.E (6)
CIRCOLATmG AND RESTORED M.A-D IN COMTRCLS AMD 
m  CBZ.VPA AMD DPH TREATED PATIENTS
Circulating ALA-D 
activity
Restored ALA-D 
activity
CONTROL
CBZ
VPA
DPH
1224 ± 216 ,n=36 
747 ± 384* ,n=50 
1299 ± 312 ,n=12 
1185 ± 366 ,n=11
1902 ± 264 , n=29 
1050 ± 393* , n=50 
1881 ± 291 , n=12 
1728 ± 333 , n=11
» P<0.001 as oanpared to controls 
Values presented are mean + 1 S.D.
Units are nmoles PEG produoed/h/ml erythrocytes
The circulating activities in all 4 groups were 
increased following treatment with activators. The 
activity in CBZ-treated samples, although showing an 
increase, did not return to normal levels of activity. 
This contrasts with the effect of these activators on ALA-D 
which has been inactivated by binding lead. In the process 
of restoring activity, the mean ALA-D activity of the CBZ- 
treated group fell from 61% of the mean circulating 
activity of the controls to 55% of the mean restored 
activity, suggesting that less activation occurs in CBZ- 
treated erythrocytes. This was confirmed by calculating 
the meem % increase in activity for each patient. Control 
ALA-D activities were increased by a mean value of 56.8 + 
28.6% (n=29) whereas CBZ treated activities increased by a 
mean value of 41.2 ± 32.7% (n=44; P<0.02). This latter 
figure excludes values where the circulating ALA-D activity 
was less than 300nmol/PBG/h/ml erythrocytes since on 
activation these produced an artificially high percentage 
increase. This observation can be interpretated as showing 
that in CBZ-treated patients a greater percentage of the 
enzyme is present in the catalytically active state. No 
correlation was found between the percentage activation and 
plasma CBZ concentration. As expected VPA and DHi behaved 
exactly as the controls, being activated by mean values of
51.6 ± 40.5% (n=12) and 54.3 ± 33.7% (n=11) respectively.
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(11) Dialysis of ALA-D
If activity was lost through the action of a non- 
covalently bound inhibitor, it should be possible to remove 
this inhibitor by dialysis, thus restoring activity. This 
experiment investigated if depressed ALA-D activity could be 
restored in this way and was performed as described in 
section 2.7.1.
ALA-D activity was assayed in washed erythrocytes and 
sonicated erythrocytes, both before and after dialysis as 
described in section 2.7.1, in 6 CBZ-treated individuals 
with reduced ALA-D activities and in 6 age and sex matched 
controls. The results are presented in table (7).
From the results, it is clear that dialysis did not 
restore activity in either washed or sonicated cells. 
Conclusions about the reversibility of CBZ-mediated
inhibition of ALA-D
In contrast to lead-mediated inhibition of ALA-D, treatment of 
the enzyme frcxn individuals with reduced ALA-D activity due to CBZ 
treatment with the activators DTT and Zn^+ did not restore activity. 
This suggests that the inhibition does not occur through interaction 
of the drug with essential thiol groups. Further evidence for this 
will be presented in section 4.1.5. CBZ treated patients also had a 
greater percentage of the ALA-D present in erythrocytes in the active 
state. There are two possible explanations for this. The first is 
that inactive and active ALA-D are in equilibrium and CBZ treatment 
can only affect the inactive enzyme, reducing the ratio between the 
two species. However, as a consequence of the equilibrium, activity 
would also be reduced in the active fraction. The second possibility
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is that CBZ treatment affects all of the enzyme molecules equally but 
the cell increases its reserve of zinc ions and reduced glutathione (a 
tripeptide responsible for maintaining protein cysteine residues in 
the reduced state), thus leading to a reduced total activity but with 
a higher percentage of enzyme in the active state. The inhibition 
may be a covalent interaction between the inhibitor species and ALA-D, 
as it was not reversible by dialysis. The nature of this interaction 
is open to speculation.
4.1.2 TIME COURSE OF THE CBZ-MEDIATED REDUCTION IN ALA-D ACTIVITY
Knowledge of the time course of the reduction in erythrocyte
ALA-D activity caused (either directly or indirectly) by CBZ would be
useful in the consideration of the nature of the effect. Numbers of
patients in this section are limited because it was only infrequently
that new epileptic patients were started on long-term CBZ monotherapy.
However, ALA-D activities were determined in 4 such individuals before
starting on CBZ and then after 1 week and after 4 weeks of treatment.
The effects of a single large dose of CBZ on ALA-D activity in 9
volunteers over a period of 42 hours were also measured. These
results are presented first.
(i) The effects of a single dose of CBZ on erythrocyte 
ALA-D activity
ALA-D activities were measured in 9 healthy adults (5 
females, 4 males) after administration of a single dose of 
CBZ equivalent to lOmg/Kg body weight. Activities were 
determined 10,14,18,34 and 42 hours after ingestion of the 
drug, and in the same subjects at the same time intervals 
after taking a placebo. The results are presented in
table (8).
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The r e s u l t s  show t h a t  e ven  i n  th e  p re s e n c e  o f  h ig h  
plasma CBZ levels (9mg/l) there was no effect on ALA-D 
activity. Furthermore, there was no significant change in 
either circulating or restored activities with respect to 
control values at any time point in the experiment and both 
activities remained essentially constant in both the control 
and drug-tested phases.
(ii) Ihe-fiffects of CBZ-treatment on ervthrocvte 
ALA-D activity over four weeks
4 epileptic patients, over a period of a year, were 
initiated onto a regime of 200mg CBZ twice daily. Table (9) 
shows ALA-D activities both before and after taking the 
drug. The results are expressed as percentages of control 
values. No results are presented after 4 weeks because in 
three of the subjects the dosage was increased after this 
time preventing further analysis of the time course of the 
reduction.
The table shows that there was a reduction in the mean
activity of both circulating and restored ALA-D after 1 week
(13.5% and 20.3% respectively). Further reductions of 20%
and 17.5% respectively occurred after a further 3 weeks
treatment with CBZ.
Conclusions about the time course of CBZ-medlated reduotion in 
ALA-D activity
The reduction of ALA-D activity by CBZ is a slow process: 
mairimai depression of enzyme activity does not occur after 1 week of 
exposure to the drug as further reductions were observed after a 
another 3 weeks. However it is not certain if these effects were
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maximal for the dosage of CBZ used. Most activity was lost from the 
inactive pool of ALA-D confirming the observation made in section
4.1.1 namely that CBZ-treated patients have a greater percentage of 
their potential ALA-D activity realised. Exposure of untreated 
subjects to levels of CBZ which were shown to cause reduction in ALA-D 
activity during prolonged treatment (see figs. (15) and (19)) for 
almost two days produced no changes in enzyme activity.
There are a number of possible explanations as to why CBZ 
treatment takes so long to produce the observed depression of ALA-D 
activity. If the reduction in activity is the result of a direct 
action of CBZ or CBZ-E on the enzyme then either the reaction is slow 
or the drugs take a long time to penetrate the erythrocyte. This 
latter proposal is improbable as both compounds are highly lipid 
soluble and should easily pass through cell membranes. 
Alternatively, if ALA-D activity is indirectly reduced by CBZ 
treatment, it may be that it takes time for CBZ and CBZ-E to reduce 
the levels of scxne compound or protein essential for the maintenance 
of ALA-D activity. One possible example of this, glutathione, is 
investigated in 4.1.5. A further possibility is that some other 
metabolite of CBZ, present only at very low concentrations, or 
unstable, is the species responsible for the observed effect. If 
this was the case it would be very difficult to prove.
4.1.3 THE RELATIONSHIP BETWEEN CBZ AND ALA-D ACTIVITY
This section examines in greater detail the relationship 
established in section 3.1 between plasma CBZ concentration and ALA-D 
activity. There are several variables to be examined. In the case 
of CBZ these are total plasma levels of the drug, free plasma levels
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of the drug (i.e. drug which is not protein bound) and the 
concentration of CBZ-E, the principle metabolite (there are many other 
metabolites but these are present in such small amounts it was not 
possible to detect them in the samples studied). These variables 
were plotted against circulating ALA-D and restored ALA-D activity and 
a correlation sought using linear regression analysis. The samples 
were obtained from epileptic patients receiving CBZ monotherapy. 
Free drug was determined using equilibrium dialysis (section 2.4.3) 
CBZ and CBZ-E were measured by an HFLC method (section 2.4.2).
The results consist of 3 sections (i) total CBZ (ii) free CBZ 
and (iii) CBZ-E. The numbers for each section varied and therefore 
to correctly evaluate if consideration of a particular variable 
improved the correlation coefficient obtained between total CBZ and 
ALA-D activity it was necessary to determine a correlation coefficient 
for the relationship between total CBZ levels and ALA-D activity for 
each group. All results are presented in table (10). When 
considering these results it is important to remember that a 
correlation between two variables does not always mean they are 
directly related: there may be some intermediary factor.
(i) Total CBZ and ALA-D activity
As was stated in section 3.1, a negative linear 
correlation was found to exist between total plasma CBZ and 
circulating ALA-D activity. When total CBZ was plotted 
against restored ALA-D activity for the same samples, the 
correlation coefficient improved from -0.45 to -0.51 
(n=47»P<0.001). This is shown in fig. (19). As will be 
seen, better correlations were found when restored levels of 
ALA-D activity were considered in all groups studied.
109
TAH.E (10)
CORBH.ATIOM COEFFICIENTS FOR ILOTS OF TOTAL CBZ. FREE CBZ AND 
CBZ-E AGAmSI CIRCDLATmG Alfo RESTORED ALA-D ACTIVITY
Circulating 
ALA-D activity
Restored 
ALA-D activity
Number 
of points
Total CBZ - 0.4** - 0.51*** 47
Total CBZ - 0.33 - 0.41 * 33
Free CBZ — 0.26 - 0.29 33
Total CBZ - 0.42** - 0.50*** 40
CBZ alone - 0.51*** - 0.57*** 40
CBZ-E alone - 0.43** - 0.52*** 40
# p<0.05 •• P<0.01 P<0.001
restored ALA-D ACTIVITY 
(nmoles PBG/h/mi RBC)
2500
2000-
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0 5 10 15
TOTAL PLASMA CBZ (mg/l)
FIG. (19)
TOE RELATIONSHIP H ' RESTORED ERYTOROCYTE ALA-D ACTIVITIES 
AND H.ASMA CBZ
The figure shows a significant relationship between restored erythrocyte 
ALA-D and plasma CBZ in samples from 47 epileptic patients receiving chronic 
CBZ monotherapy.
Linear regression correlation coefficient = —0.51 » p<0.001
Curvilinear regression correlation coefficient = —0.60» p<0.001
(ii) Znee CBZ and ALA-D activity
Free CBZ concentrations were determined because it is 
the free fraction of the drug which is available for binding 
to receptors, diffusing into cells and producing its 
pharmacological effects as opposed to the remainder of the 
drug which is bound to serum proteins and is therefore 
unable to enter cells, A good correlation might be 
expected between free CBZ and ALA-D activity, but none was 
found. These results, however, are not conclusive because, 
in contrast to the other groups, there was not a significant 
correlation between total CBZ levels and circulating ALA-D 
activity and although there was a statistically significant 
correlation between total CBZ and restored activity, this 
was much weaker than that obtained in other groups (P<0.05 
as opposed to P<0.001). The results therefore do not 
. necessarily imply that there is not a correlation because 
the controls, which should have displayed significance, 
either failed to do so, or did not do so to the same extent 
that they ou^t. The reason that these results were not as 
significant as those obtained earlier is due to the fact 
that fewer data points were available and the scatter was 
greater, thus weakening the correlation coefficients. 
However, in the cases of both circulating and restored 
activity, consideration of the free fraction weakened the 
correlation coefficient obtained from total drug levels and 
therefore the free fraction is probably not of significance 
in the relationship between CBZ and ALA-D.
110
(iii) CBZ-E and ALA-D activity
This sub-section investigated the relationship between 
CBZ-E and ALA-D activity. This would be a likely candidate 
for the effects observed because most epoxides are 
chemically active. The original results were confirmed by 
the finding of a significant correlation between total CBZ 
values and both circulating and restored ALA-D activities
i
(the correlation in the case of restored activity being the 
stronger) in the 40 subjects studied in this section. When 
total CBZ values were broken down into CBZ and CBZ-E 
concentrations (See final section of table (10)), 
significant negative linear correlations were found between 
both of these parameters and ALA-D activity in the 
circulating and restored states, fO.43 and-0.52 respectively 
for CBZ-E, P<0.001). For both CBZ and CBZ-E, the 
correlation was strongest when considering restored 
activities. This would be expected in the case of CBZ 
because it accounts for up to 90$ of the total drug and in 
the case of CBZ-E because there is a very strong 
relationship between the concentrations this compound and 
total CBZ levels (see fig.l6). However, in considering 
CBZ alone, there was a large increase in the correlation 
coefficient in both ALA-D states whereas the increase found 
with the epoxide was sli^t. 
liai nna about the relatiOR^blp between CBZ and ALA-D actlvitY.
There was a negative linear relationship between plasma CBZ and 
both circulating and restored ALA-D activity. In each of the
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situations studied the correlation was best when considering restored 
rather than circulating activity. The concentration of free drug is 
probably not of importance although this is uncertain for the reasons 
stated. Individually, CBZ and CBZ-E both appeared to be related to 
ALA-D activity, although CBZ seemed to be of greater importance. 
However, this is only to be expected because there was so much more 
CBZ present. The correlation found with the epoxide is of uncertain 
significance as it may merely be a result of the fact that epoxide 
concentrations are directly related to the total drug levels. 
Lastly, all of the correlations described are weakened by several 
factors the most important of which are (a) the large fluctuations in 
drug levels which occur throu^out the day eind (b) the large inter­
individual variations in ALA-D activity. The principle point made in 
this sub-section is that a relationship does exist between the plasma 
concentration of CBZ and the activity of ALA-D in the erythrocytes.
4.1.4 THE EFFECTS OF CBZ TREATMENT ON THE APPARENT Kin AND OPTIMOM 
ASSAY PH OF ERYTHROCYTE ALA-D
In the introduction of section 4.1, it was stated that there were 
two possible explanations for the mean reduction of approximately 40$ 
in ALA-D activity: (a) total inactivation of 40$ of the enzyme
present (i.e. a reduced amount of normal enzyme is present) or 
(b) modification of all enzyme present such that the catalytic 
activity of each molecule is reduced by 40$. If (a) was the case 
then the Km and the optimum of the enzyme would be unaltered as 
activity present would come from unaffected enzyme. If however (b) 
was the case then the Km of the enzyme for its substrate would be 
altered and there is a possibility that the optimum assay pH of the
1 1 2
enzyme would also be changed (Chiba, Tashiro and Kikuchi, 1977; 
Wigfield and Far ant, 1979; Farant and Wigfield, 1984). Measurement of 
these two parameters, therefore, should allow a distinction to be made 
between the two possibilities outlined above.
The results from each of these experiments are now presented.
(i) %  of.,.ALA-D in control and CBZ-treated ervthrocvtes
True Km values were not determined as this would have 
involved lengthy purifications of ALA-D frcxn large volumes 
of blood from each of the individuals studied. Instead 
apparent Km values for ALA-D in whole blood were calculated 
by measuring the rate of reaction in the presence of 
different concentrations of substrate as described in 
section 2.7.2. Two groups were studied: (a) a group of 7
CBZ treated patients (4 males and 3 females; mean 
circulating ALA-D activity = 729 + 369 nmol PBG/h/ml 
erythrocytes and (b) a group of 7 age and sex matched 
controls (mean circulating ALA-D activity = 1296 ± 372 nmol 
PBG/h/ml erythrocytes). The results are 
presented in table (11).
This method of determining Km values in whole blood is 
not as precise as a similar experiment using purified enzyme 
would be, hence the spread of results (control; 0.257- 
0.310mM: CBZ; 0.233-0.334mM). There was however no 
significant difference between the two groups, the mean 
values being absolutely identical. The mean Km value of 
0.273mM obtained from this experiment compares excellently 
with the figure of 0.270mM reported by Anderson and Desnick 
(1979) for purified erythrocyte ALA-D.
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TMLE (11)
iPPABBTO Bn VÆDES FOB B mHUOCrTE ALA-D IN
comnas m d  cbz-trraied patients
Sample No. Control CBZ-treated
1 0.257 0.272
2 0.318 0.300
3 0.238 0.310
4 0.252 0.287
5 0.281 0.257
6 0.334 0.285
7 0.233 0.203
Mean ± 1 S.D. 0.273 ± 0.039 0.273 ± 0.036
The values In the table are iLA oonoentrations in moles/l
pH optimum of AT,A-D in cnntrol and CBZ-hr,>ahA^  
_ervthronvt.f>a
A range of buffers of varying pH was prepared as 
described in section 2.7.3 and ALA-D activity was determined 
in the usual way. Two groups were studied: (a) a group of 6 
CBZ treated patients (mean circulating ALA-D activity = 
669 ± 225 nmol PBG/h/ml erythrocytes) and (b) a group of 6 
age and sex-matched controls (mean circulating ALA-D 
activity = 1251 ± 243 nmol PBG/h/ml erythrocytes). Fig (14) 
in sub-section 2.7.3 shows a typical pH activity profile and 
the manner in which the optimum assay pH was determined. 
The results are presented in table (12). Note that the pH 
values quoted are the final pH values in the assay, not the 
pH of the buffer solutions used.
A spread of values was found in each case, but there
was no statistically significant difference in the optimum
assay pH between the two groups. The mean figure of pH6.5
compares excellently with the results of Farant and
Wigfield, (1984).
Conclusions about the effects__of .CBZ .treatment on the Km 
and .QDtimm agsay pH of er.ytto.sYt.e-JL.M)
The mean Km and optimum assay pH of ALA-D in CBZ-treated
subjects showed no differences with respect to controls and the
mean values calculated for each of these parameters was in good
agreement with the literature. This suggests that option (a) as
discussed in the introduction to this sub-section is the most
valid, namely that ALA-D activity is depressed because there is a
reduced amount of normal enzyme present.
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TAB.E (12)
OPTIMDM ASSAY PH VALUES FOR E R n H R O C m  ALA-D ACTIVITY M  
aWTRCLS AND IN CBZ4TREATED PATIENTS
Sample No. CONTROL CBZ
1 6.54 6.42
2 6.44 6.58
3 6.53 6.42
4 6.54 6.51
.5 6.46 6.55
6 6.51 6.35
Mean + 1 S.D. 6.50 ± 0.04 6.43 ± 0.09
Bie difference in the mean optimum assay pH In the two groups Is not 
signifleant.
4-1 "5 THE SFFSÇTS OF CBZ TREATMENT ON ERYTHROCYTE GLUTATHIONE
In the preceding sub-sections it has been established that ALA-D 
activity is irreversibly reduced during CBZ treatment and that the 
depression of activity is related to the plasma concentration of the 
drug. As was stated in the introductory chapter, ALA-D contains a 
number of reduced thiol groups, the oxidation of which results in a 
loss of enzyme activity. These groups are normally maintained, at 
least in a large percentage of ALA-D molecules, in a reduced state by 
reduced glutathione (GSH), a tripeptide found in large quantities in 
erythrocytes responsible for maintaining the cysteine residues in 
cellular proteins in a reduced state. The amino acid sequence of GSH 
is shown below
N-glutamylcysteinylglycine 
GSH itself contains a thiol group and can become oxidized resulting in 
the union of two GSH molecules throu^ a disulphide bond to produce 
the oxidized form, GSSG. This can be converted back to GSH by the 
action of glutathione reductase (GR). If CBZ or one of its 
metabolites caused a loss of ALA-D activity throu^ indiscriminate 
reaction with essential thiol groups, it should also reduce the 
erythrocyte concentration of GSH and consequently the concentration of 
GSSG. CBZ-E is a likely candidate for such a reaction due to the 
reactive nature of the epoxide moiety. This sub-section examines 
therefore the effect of CBZ on total erythrocyte glutathione (i.e. 
GSH + GSSG).
Total glutathione levels were determined in blood samples 
from the four groups of subjects shown:
(i) a group of 10 CBZ—treated patients
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(ii) a group of 10 control subjects, age and sex attached 
with the above
(iii) a group of 9 VPA treated patients
(iv) a group of 10 DPH treated patients 
Interest was primarily directed at the first two groups to find out if 
glutathione levels were affected by CBZ. The VPA and DPH treated 
groups were included for completeness. The method used to measure 
glutathione was as described in section 2.10.1. The results of the 
study are presented in table (13). The mean ALA-D activities for 
each group are also shown.
No significant differences were found between the CBZ-treated 
group and controls, even althou^ ALA-D activities varied almost two­
fold, nor was there any correlation between CBZ levels and blood 
glutathione concentrations. Thus CBZ treatment does not affect the 
intracellular GSH concentration. This implies two things: (a) 
neither CBZ nor any of its metabolites react indiscriminately with 
thiol groups and (b) ALA-D activity is not reduced due to a deficiency 
of intracellular GSH. These results however presume that GSH-CBZ or 
GSH-CBZ metabolite complexes (the proposed products of reaction of CBZ 
or a metabolite with GSH in the hypothesis put forward at the start of 
t-hj R section) are not substrates for GR. The assumption is probably 
valid because such a structure is quite different to that of GSSG, 
glutathione being small and highly polar whereas CBZ is bulky and 
hydrophobic. These differences would adversely affect binding to the 
reductase. Also other adducts of GSH and drugs e.g. acetaminophen, 
are not metabolized by GR and do not interfere with the assay (Adams, 
Lauterburg and Mitchell, 1983).
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table (13)
ERYTHROCYTE ALA-D A(TriVITIES AND BLOOD GLUTATHimE CONCENTRATIONS 
IN CONTROLS AND IN CBZ, VPA AND DPH-TREATED PATIENTS
BLOOD
(LUTATHIONE&
ERYTHROCYTE 
ALA-D ACTIVITY^
CmTROLS 1.15 + 0.21 1248 ± 198
n=10
CBZ 1.10 ± 0.12 762 ± 402*
n=10
VPA 1.11 ± 0.11 1260 ± 354
n=9
DPH 1.12 ± 0.19 1236 ± 363
n=10
* p<0.001 as compared to controls 
Values presented are mean ± 1 S.D. 
g uni ta are nmoles glutathione/1 blood
b units are nmoles FBG produced/h/ml erythrocytes
As expected no significant changes with respect to controls were 
found with the VPA and DPH treated groups» nor was there any 
correlation between drug levels and blood gluthatione concentrations.
4.1.6 BLOOD LEAD CONCENTRATIONS IN CBZ-TREATED PATIENTS
Erythrocyte ALA-D is susceptible to inhibition by lead in the 
blood. Due to the number of lead water pipes in the Glasgow area, 
many individuals have sufficiently high blood levels to significantly 
reduce the activity of ALA-D. Since all of the patients studied live 
in this area, it was therefore necessary to check their blood lead 
levels to affirm that the observed depression of ALA-D activity was 
due to CBZ treatment and not to a hi^er blood lead concentration than 
the other groups studied. Blood lead concentrations were therefore 
determined in 24 controls and 28 CBZ treated patients by the method 
described in section 2.11.3. ALA-D activities for the two groups 
were also measured. TOe results are summarised in table (14).
The results show that mean lead concentrations were not hi^er in 
the CBZ treated group than they were in control group, even althou^ 
ALA-D activities in the former were greatly reduced. Indeed the mean 
blood lead concentration of the CBZ treated group was actually lower 
t-han the mean control value. Thus the observed reduction of ALA-D 
activity in these patients is not due to lead inhibition of the
enzyme.
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TAH.E dip
ERYIHROCm: ALA-D ACTIVITIES AND ELOOD LEAD LEVB.S 
m  COMTRCLS AMD IN CBZ-TREATED PATIENTS
CONTROL CBZ-TREATED
n=24 n=28
ALA-D^ 1230 + 231 618 ± 276*
Blood lead^ 0.45 ± 0.21 0.38 ± 0.25
» P<0,001
Values presented are mean ± 1 S.D. 
a units are moles PBG produced/h/ml erythrocytes
b units are pioles/1
NUMMARY AND GENERAL DISCUSSION OF SECTION 4.1
This section has investigated several aspects of the depression 
of ALA-D activity which occurs during treatment with CBZ. A summary 
and a discussion on the implications of the results now follows.
Chapter 3 established that CBZ, or a metabolite thereof, reduced 
ALA-D activity. In contrast to lead inhibition, activity could not 
be restored by treating the enzyme with activators nor was the loss of 
activity reversed by dialysis. Thus the effect is irreversible and 
possibly due to a covalent interaction between the inhibitory 
substance and the enzyme. The depression in activity tsikes some time 
to become manifest: no changes were observed after two days treatment, 
but effects were detected after treatment for 1 week. This indicates 
one of three things: (a) the proposed inhibitory substance reacts
slowly with ALA-D; (b) it takes time for the proposed inhibitor to 
accumulate to levels which significantly affect ALA-D; (c) it takes 
time for some compound essential for the maintenance of ALA-D activity 
to be depleted to an extent at which activity would be adversely 
affected. In the case of the latter suggestion, glutathione, a 
likely candidate, was not affected. A negative linear correlation 
was found between total CBZ (as determined by EMIT) and both 
circulating and restored ALA-D activities. This correlation was not 
improved by consideration of the concentration of free CBZ, but both 
CBZ alone and CBZ-E showed an improved correlation with ALA-D activity 
with respect to those obtained using total CBZ levels. In all cases 
considered, the correlation of drug concentration with restored ALA-D 
activity was much better than that obtained with values for 
circulating activities. No changes were found in the apparent Km or
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pH optimum of ALA-D from subjects with greatly reduced activities 
indicating that the low activity observed was due to a reduced amount 
of normal enzyme rather than a normal level of modified enzyme» i.e. 
the effect is all or nothing. The reduction of ALA-D activity in 
this group was not due to a hi^er than normal blood lead level.
Throu^out this section it has been assumed that ALA-D activity 
was reduced due to enzyme inhibition, modification or destruction. 
However, none of the experiments described exclude the possibility of 
activity being depressed as a consequence of a reduction in the rate 
of enzyme synthesis. Indeed this could explain several aspects of 
the effect, for example, why it takes so long to occur. The 
synthesis of ALA-D could only be affected in actively transcribing 
cells, in this case, the erythroid cells. It would take some time 
before the affected cells matured and made up a significant part of 
the erythrocyte population. However, as was stated in the 
introductory section, ALA-D synthesis has not been shown to be 
inducible or repressible. Furthermore, results presented later in 
t-hi a thesis confirm that the assumptions made here, namely, that CBZ
or a metabolite are the causative factors of the reduction in ALA-D
activity and that the effect was not due to a reduction in synthesis, 
are valid. The results from this section do not confirm if activity 
was depressed as a consequence of a direct or indirect effect of CBZ 
treatment. This is explored further in later sections.
In the majority of patients, ALA-D activity was not depressed to
an extent where it presented a serious threat to the flow of
intermediates through the pathway, although it did cause some 
perturbations of the ALA/PBG relationship (see 3.3.2). Although the
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mean activity of the CBZ treated group was 61% of that of controls, 
26% of these individuals had activities less them 30% of mean control 
values and 3 subjects had activities less than 15% of mean control 
activities. If ALA-D activity was already impaired by, for example, 
a high blood lead concentration or high alcohol intake, further 
depression of ALA-D activity by treatment with CBZ of the magnitude 
observed in these individuals may produce a significant impairment in 
the flow of intermediates throu^ the pathway. This would lead to 
further derepression of ALA-8 with consequent over production of ALA 
and the potential clinical problems associated with this. This is 
discussed further at the end of this chapter.
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4.2 CAHBAMAZEPINE AND PORPHOBILINOGEN DEAMINASE
In chapter 3 it was shown that long-term treatment with CBZ 
resulted in a depression of PBG-D activity, the extent of which was 
related to CBZ concentration (see fig. (15)). This confirmed the 
findings of both Rapeport &L aL (1984) and Yeung at. aL (1983), but 
was in conflict with those of Doss and Schafer, (1984) and Rideout 
fit aL (1983). Both of these groups obtained their results with an 
assay which utilized PBG as a substrate whereas the results from this 
study and those of Raoeport et al. (1984) and Yeung et al. (1983) used 
ALA as substrate and depended on ALA-D to act as a coupling enzyme, 
converting ALA to PBG. In support of the data presented in the 
previous section, both Doss and Schafer, (1984) and Rideout et al.
(1983) noted that ALA-D activity was depressed by CBZ. Both 
suggested that since the assay used by Yeung et al, (1983) depended on 
ALA-D to produce PBG, reduced activity of this enzyme would mean 
insufficient substrate was produced for the PBG-D assay and 
consequently an artificially low result would be obtained. This 
would therefore also apply to the results of Rapeport sL aL (1984) 
and those presented in Chapter 3. This may seem unlikely when the 
relative activities of these two enzymes in peripheral blood are 
considered (frcxn the controls in chapter 3, mean ALA-D activity was 
1224 nmolPBG/h/ml erythrocytes and the mean PBG-D activity was 39.8 
nmolURO/h/ml erythrocytes). Even in the case of CBZ treated patients 
there is still an apparent excess of ALA-D activity. However when 
activities are expressed in ALA equivalents, the relative activities 
of ALA-D and PBG-D become 2448 nmoles ALA/h/ml erythrocytes (in the 
case of CBZ, 1494 nmoles ALA/h/ml erythrocytes) and 31#-!^  nmoles
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ALA/h/ml erythrocytes respectively. A further point to consider when 
comparing relative activities of the two enzymes is that the 
aforementioned ALA-D values were measured at an assay pH of 6.95, but 
the coupled assay system for determination of PBG-D activity operated 
at pH 7.5. Using the results from the study described in section 
4.1.4, it was calculated that ALA-D activity at this was reduced by 
a mean value of 34.0 + 2.9% with respect to activity at pH 6.95. 
TsücLng this into account further reduces the mesin relative activities 
of ALA-D and PBG-D to 1616 nmoles ALA/h/ml erythrocytes (984 nmoles 
ALA/h/ml erythrocytes in the case of CBZ) and 318 ). nmoles ALA/h/ml 
erythrocytes respectively. Thus there may not be as large an excess 
of ALA-D as appears at first si^t. In support of the proposal 
put forward by Doss and Shafer, (1984) and Rideout &L (1983), 
plotting PBG-D results from preceding chapters (determined by 
the ÜR0-1-S assay) against ALA-D activities in the same subjects (24 
controls, 40 CBZ, 12 VPA and 8 DPH) demonstrates that the two 
parameters are, in fact related, fig. (20).
The objective of this section was to ascertain whether or not CBZ 
affects PBG-D activity and if so, why. Two methods of determining 
activity were used: (a) utilizing ALA as substrate and (b) utilizing 
PBG as substrate. To differentiate between the two methods, results 
from the first will be termed UR0-1-S activity whereas those from the 
second will be referred to as PBG-D activity. The methodologies are 
described in section 2.2.3.
122
URO-I-S ACTIVITY 
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FIG. (20)
THE RELATIONSHIP BETVEEN ALA-D AND PBG-D (AS DETERMINED BY 
THE URO-I^ METHOD) ACTIVITIES IN HOMAN ERYTHROCYTES
The graph shows a significant relationship between circulating levels of 
erythrocyte ALA-D and PBG-D activity (determined by the ÜR0-1-S method) in 84 
subjects when analysed using either linear or curvilinear regression. This 
relationship may exist because the ÜR0-1-S assay relies on ALA-D present in 
the erythrocytes to act as a coupling enzyme to generate PBG - the substrate 
for the assay
Linear regression correleation coefficient = 0.56, P<0.001
Curvilinear regression correlation coefficient = 0.68, P<0.001
'••2.1 .ME EFFECTS OF CBZ TBEATHEMT ON ERYTHROCYTE 0R0-1-S JiMD 
PBG-D ACTIVITIES
As stated in the foregoing introduction PBG-D activity was 
measured by two methods, one using ALA as substrate (ÜR0-1-5 assay) 
and the other utilizing PBG as substrate (PBG-D assay). Enzyme 
activity was determined by both methods in the 4 groups of subjects 
listed below:
(i) a group of 43 CBZ treated patients
(ii) a group of 23 controls age and sex-matched with (i)
(iii) a group of 12 VPA treated patients
(iv) a group of 8 DHi treated patients
The results are presented in table (15).
The results show that, as expected, when the ÜR0-1-S method was
used, mean CBZ activities were 84$ of mean control activities, but VPA
and DPH treated subjects did not differ significantly from controls.
However, when PBG-D activities were determined (using PBG as
substrate), none of the groups studied, including CBZ, showed any
significant differences with respect to controls. The mean
activities for each group were all very close. Mean PBG-D activities
were 90.1$, 90.1$ and 91.0$ of mean DR0-1-S activities for the
control, VPA treated and DPH treated groups respectively, but were
117.4$ for the CBZ treated group. This indicates that the
relationship between these two activities was upset by CBZ treatment.
Conclusions on the effects of CBZ-treatment on erythrocyte .PRO-I-S 
and PBG-D Activities
CBZ treatment caused a reduction in 0R0-1-S activity with respect 
to controls, but did not affect PBG-D activity. Whether or not this 
difference is attributable to the effect of CBZ treatment on ALA-D is 
investi^ted in the following sub-sections.
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TMLE (15)
COHPAKESON OF TOO METOODS. ORO-1^ AND PBG-D. FOR THE 
DETEBMINATION OF ERÏTHKOCÏTE PBG-D ACTIVITY IN CONTRCLS AMD IN 
CBZ. VPA AMD DPH TREATED PATIENTS
ÜRO-1-nS
ACTIVITY^
PBG-D
ACTIVITY^
PBG-D ACTIVITY AS 
% OF URO-1-6 ACTIVITY
CONTROL
n=23
30.2 + 5.0 27.3 ± 3.2 90.1 ± 9.8
CBZ
n=43
25.4 ± 6.6* 28.8 ± 5.5 117.4 ± 41.8*
VPA
n=12
30.4 + 4.9 27.2 ± 3.6 90.1 ± 7.1
DPH
n=8
32.6 + 8.2 29.3 ± 5.8 91.0 ± 7.5
# p<0.002 as ocmpared to controls
Values presented are mean ± 1 8.D.
a units are nmoles DEO produoed/h/ml erythrocytes
•^2.2 THE RELATIONSHIP BETWEEN APPARENT URO-I-S AND ALA-D ACTIVITIES 
PORING CBZ TREATMENT
The preceding sub-section established that URO-I-S activity 
appeared to be reduced during CBZ treatment whereas PBG-D was 
unaffected. This sub-section investigates the possibility of a 
relationship between URO-I-S activity and reduced ALA-D activity. 
When considering this relationship, values for restored ALA-D activity 
(whole blood treated with ZnClp and DTT as described in section
2.2.2.) were used. This was because when ALA-D was used as a 
coupling enzyme in the ORO-l-S assay, it was activated prior to assay 
by pre-incubation with zinc sulphate and DTT.
For each of the samples in table (15), the ratio of URO-I-S 
activity to PBG-D activity was plotted against ALA-D activity (n=75, 
as restored activities were not available for all samples). The 
resultant graph is shown in fig. (21), and demonstrates that the two 
parameters are in fact related. As restored ALA-D activity increases 
the ratio of URO-I-S activity to PBG-D activity approaches a constant 
value. The mean ratio of URO-I-S activity to PBG-D activity was
1.10 ± 0.13 (n=23), 1.11 ± 0.09 (n=12) and 1.10 ± 0.09 (n=8) for
control, VPA treated and DPH treated groups respectively but 
0.90 ± 0.22 (n=43) for CBZ (not all of these are plotted for reasons
just described). Control, VPA and DPH values fall in the upper
horizontal part of the graph, where the ratio of URO-I-S to PBG is 
independent of restored ALA-D activity. CBZ values fall in the 
lower, left hand side of the graph where the ratio appears to be 
dependent on restored ALA-D activity. The cut-off point appears to 
be a restored ALA-D activity of 1500 nmol PBG/h/ml erythrocytes.
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FIG. (21)
THE RELATIONSHIP BETIVEEN RESTORED ERYTHROCYTE ALA-D ACTIVITY AND 
PBG-D ACTIVITY DETERMINED BY TWO DIFFERAT METHODS
PBG-D activities were determined by two different methods: utilizing
PBG as substrate (PBG-D assay) or using ALA as pre-substrate (URO-I-S assay). 
The ratio of these measurements was then plotted against the restored ALA-D 
activities of the samples. This ratio was independent of restored ALA-D 
activities in controls, sodium valproate (VPA) and phenytoin (DPH) treated 
patients. However, below restored ALA-D activities of 1500 nmoles PBG/h/ml 
RBC (which includes most CBZ treated patients), the ratio of PBG-D to URO-I-S 
was related to restored ALA-D activity. This proves that in the majority of 
CBZ treated patients, determination of PBG-D activities by the URO-I-S method 
does not give reliable results.
Below this level of activity» ÜR0-1-S results seemed to be lower than 
they actually were as evidenced by the departure from the mean 
control ratio of UR0-1-S/PBG-D activity of 1.10. Thus if there is 
not a minimum restored ALA-D activity of 1500 nmolPBG/h/ml 
erythrocytes, an artificially low ÜR0-1-S activity will result. This 
is not a problem for normal patients as 96.5$ of all controls studied 
had restored ALA-D activities in excess of this. In contrast, only 
10$ of the CBZ treated patients studied had restored activities 
greater than 1500 nmolPBG/h/ml erythrocytes. This means that for the 
CBZ treated group, 90$ were giving a falsely low URO-I-S result, the 
extent of the deviation from the true activity being dependent on the 
extent of reduction in ALA-D activity.
Conclusions on the relationship between apparent URO-I-S and 
restored ALA-D activities
The activity of URO-I-S was dependent on the level of restored 
ALA-D activity up to 1500 nmol PBG/h/ml erythrocytes above which it 
became independent. This was shown by examining the ratio of URO-I-S 
and PBG-D activity, the latter being entirely independent of ALA-D 
activity. Almost all control subjects studied had restored ALA-D 
activities exceeding this minimum value and therefore the assay would 
normally give true results. This is so even for lead-poisoned 
individuals because although the circulating ALA-D activities are low 
in these subjects, treatment with activators results in a hi^er than 
normal level of restored activity. In the case of CBZ however, 
almost all of the patients studied had a falsely low URO-I-S activity, 
apparently due to the irreversibly reduced levels of restored ALA-D
activity.
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This sub-section has shown that URO-I-S activity is, up to a 
point, related to restored ALA-D activity. The results, however, do 
not prove that the apparent reduction in URO-I-S activity is a direct 
result of a low restored ALA-D activity in the sample. This is 
investigated in the following sub-section.
^•2.3 IHg W tfÇTS OF SUPPLEMENTARY ALA-D ACTIVITY ON ERYTHROCYTE UR0-1.mS 
ACTIVITY
If, as suggested, URO-I-S activities in CBZ treated patients are
low as a direct consequence of reduced ALA-D activity, increasing the
ALA-D activity in these samples should produce an increase in URO-I-S
activity. This was done by adding purified ALA-D to blood samples
from both CBZ-treated patients and controls as described in section
2.2.3. Two experiments were performed:
(i) investigated the effects of adding a sigle, measured amount
of ALA-D to a set of controls and CBZ-treated patients with
a wide range of ALA-D activities
(ii) investigated the effects of adding increasing amounts of
purified ALA-D to a single control blood sample and a single
CBZ treated blood sample.
(i) The effects of adding a constant amount of ALA-D activity on 
ervthroGVte URO-I-S activities
11 CBZ-treated patients and 7 controls were studied.
ÜR0-1-S, PBG-D, circulating and restored ALA-D activities, and
ÜR0-1-S activity supplemented with 6.8 x 10“^  units of ALA-D (as
described in section 2.2.3) were measured in each of the
subjects. The results are summarised in table (16).
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There was, as expected, a significant difference in URO-I-S 
activity between the controls and CBZ-treated patients but no 
difference in PBG-D activities between the two groups. Mean 
ALA-D activities of the CBZ group were 44.4? and 49.5? of the 
mean circulating and restored control activities respectively. 
When ALA-D activity was supplemented by the addition of purified 
enzyme, URO-I-S activities increased in both groups, but the 
increase was greater in the case of the CBZ treated group, the 
mean increase in activity being 10.1 nmol/hr/ml erythrocytes as 
opposed to 5.3 nmol/hr/ml erythrocytes. This was reflected by 
mean CBZ-treated URO-I-S activities rising from 75.9? of control 
URO-I-S activités to 91.9? of control values following addition 
of ALA-D. There was a relationship between the initial level of 
ALA-D activity and the increase in URO-I-S activity, fig. (22). 
The lower the initial activity of ALA-D, the greater was the 
increase following addition of purified ALA-D. However, the 
increase in URO-I-S activity became constant above an initial 
restored ALA-D activity of 1500 nmolPBG/h/ml erythrocytes. 
This finding confirmed the results found in the previous sub­
section: addition of supplementary ALA-D only affected activity 
to a greater extent than controls if the initial level of 
restored activity was less than 1500 nmolPBG/h/ml erythrocytes. 
The reasons for the increase in URO-I-S activity in controls 
following addition of ALA-D will be discussed in the second part 
of this subsection.
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FIG. (22)
THE EFFECTS OF SDPFLEMENTARY ALA-D ON ERYTHROCYTE ÜRO-1-^ ACTIVITY: 
RELATIONSHIP TO INITIAL RESTORED ERYTHROCYTE ALA-D ACTIVITY
The figure shows that the extent of the increase in URO-I-S activity 
following the addition of a fixed quantity of ALA-D to the assay was related 
to the initial restored ALA-D activity up to a level of 1500 nmoles PBG/h/ml 
RBC. Thereafter the increase was rapidly becoming independent of ALA-D and 
attributable to contaminating PBG-D in the purified ALA-D as shown in fig. 
(23). This proves that URO-I-S activities appear low due to a deficiency of 
ALA-D.
Geometric regression correlation coefficient = 0.88, P<0.001,(n=l8)
(11) The effects of adding increasing amounts of ALA-J) activity on 
erythrocyte DR0-1-S activity
Increasing amounts of purified ALA-D were added to a series 
of URO-I-S assays in blood frcxn 1 control subject (circulating 
n^d restored ALA-D activities were 1290 and I605nmol PBG/h/ml 
erythrocytes respectively) and from 1 CBZ treated subject 
(circulating and restored ALA-D activities were 33 and 516 
nmolPBG/h/ml erythrocytes respectively). The number of units 
added and the effects of each addition on erythrocyte URO-I-S 
activity are shown in table (17). Fig. (23) presents these 
results in graphic form by plotting the magnitude of the increase 
over the initial activity against the number of units added. 
This reveals that in the control, there is a linear relationship 
between the increase in URO-I-S activity and the number of units 
added i.e. for each unit added there is a constant increase in 
ÜR0-1-S activity. This was not the case with the CBZ treated 
subject. In this patient the initial additions produced very 
large increases in URO-I-S activity. These increments became 
smaller as ALA-D activity was increased and from the figure, 
would appear to approximate the rate of increase in URO-I-S 
activity observed with the control after 6.8 x 10”^  units were 
added, at which time the restored ALA-D activity of the sample 
would have been 1236 nmolPBG/h/ml erythrocytes. This is not too 
far removed from the figure of 1500 nmolPBG/h/ml erythrocytes 
calculated as the minimal ALA-D activity required for URO-I-S 
activity to be independent of ALA-D activity. It is clear from 
the graph that this occurs because the slope approximates the 
slope of the control curve which is independent of ALA-D
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TAH.E (17)
ÎHE EFFECTS OF ADDING INCREASING m)ONTS OF ALA-D TO PRO-I-S 
ACTIVITY IN WHCLE ILOOD FROM A CONTROL SDBJECT 
AMD FRCM A CBZ TREATED PATIENT
UNITS OF 
ALA-D ADDED
URO-I-S
ACTIVITY^
INCREASE IN 
ACTIVITY^
CONTROL
1 0 27.8 0
2 1.4 X 10“^ 28.6 0.8
3 3.4 X 10“^ 29.7 1.9
4 6.8 X 10“^ 31.6 3.8
5 10.2 X 10"4 34.1 6.3
6 13.6 X 10"^ 35.3 7.5
CBZ
1 0 17.3 0
2 1.4 X 10"^ 23.1 5.8
3 3.4 X 10-^ 27.1 9.8
4 6.8 X 10“^ 31.0 13.7
5 10.2 X 10"4 32.9 15.6
6 13.6 X 10-^ 34.6 17.3 1
units are nmoles OBO produoed/h/ml erythrocytes
INCREASE in 
URCH-S ACTIVITY 
(n moles URO/h/rrt RBC)
•  CBZ 
A CONTROL
15-
10-
UNTTS of ALA-0 ADDED x 10^
FIG. (23)
THE EFFECTS OF SgPHEMENTARY ALA-D ON ERYTHROCYTE URO-1^ ACTIVITY 
IN A (X)NTRCL SUBJECT AND IN A CBZ TREATED PATIENT
The figure shows the effects of supplementary purified ALA-D on 
erythrocyte URO-I-S activity in a control and in a CBZ treated patient. In 
the control subject, supplementary ALA-D caused a linear increase in URO-I-S 
activity per unit added. Hiis was due to the presence of some contaminating 
PBG-D in the preparation- In the CBZ treated subject the initial increases 
were much greater, but after 6.8 x 10 units had been added, the rate of 
increase became the same as in the control, i.e. ALA-D had ceased to be rate- 
limiting. At this point, the total ALA-D activity in the assay was 
equivalent to 1236 nmoles PBG/h/ml RBC, which compares excellently with the 
results from figs. (19) and (22).
activity, having a restored ALA-D activity of 1605 nmolPBG/h/ml 
erythrocytes. After the largest addition of ALA-D, the URO-I-S 
activity in the CBZ sample was 98$ of the URO-I-S activity in the 
control sample compared to 62$ of the activity in the control 
sample before any additions had been made. It seems therefore 
that the addition of supplementary ALA-D corrects falsely reduced 
URO-I-S activities implying that URO-I-S activity was indeed low 
as a direct consequence of a low ALA-D activity.
The reason for the increase in control URO-I-S activity 
following the addition of purified ALA_D observed both here and 
in the first part of this subsection is uncertain, but the fact 
that it is constant for each unit of ALA-D added and does not 
appear to reach a plateau suggests that the purified ALA-D used 
contains some URO-I-S activity. However as described in section
2.2.3, purified ALA-D was checked for URO-I-S activity and 
although some activity was found, the levels were very low. 
According to the figures obtained, the largest amount of ALA-D 
added would only have increased the average URO-I-S activity by
1.2 nmol/h/ml erythrocytes. This could alternatively be 
expressed as an increase of 882 nmol/h/ml erythrocytes per unit 
of ALA-D activity added. This falls far short of the mean 
increase of 5750 nmol/h/ml erythrocytes per unit of ALA-D 
activity added which was found in the controls. One possible 
explanation for this discrepancy is that the URO-I-S activity 
determined in the purified ALA-D was reduced because the enzyme 
was unstable in the very dilute protein solution in which URO-1-^ 
activity was measured. The activity would not be affected in
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this way in assays of whole blood since this contains sufficient
protein to stabilize the enzyme.
Conclusions on the effects of supplementary ALA-D activity on 
ervthroGVte UR0-1-S activity
These experiments have shown that PBG-D activity (when measured
by the method designated URO-I-S) is reduced in patients taking CBZ as
a direct consequence of the low levels of ALA-D activity produced by
this drug. This was proven by showing that addition of supplementary
ALA-D activity produced increases in PBG-D activity determined by the
URO-I-S method which were inversely related to the initial restored
ALA-D activity i.e. the lower ALA-D activity was, the greater was the
increase in URO-I-S activity following addition of ALA-D.
Furthermore, subsequent additions of ALA-D caused CBZ treated URO-I-^ S
activities to approach the values obtained in control samples. Thus
the apparent reduction in PBG-D activity was reversed by addition of
ALA-D and was therefore due to the low ALA-D activities found in these
patients.
4.2.4 smMARY AND GENERAL DISCUSSION OF SECTION 4,2
In this section, PBG-D activity was determined by two different 
methods in a series of blood samples from control and CBZ-treated 
subjects to investigate if the reduction in PBG-D activity which was 
found during CBZ treatment was a consequence of the reduction in ALA-D 
activity produced by CBZ in these patients. The two different 
methods used (a) ALA as substrate (URO-I-S assay) and (b) PBG as 
substrate (PBG-D assay). Using method (a), significant reductions in 
activity were found in CBZ treated patients compared to controls, but 
when method (b) was used to determine activity in the same samples, 
the results from the two groups were not significantly different.
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Examination of the results demonstrated that there was a relationship 
between restored ALA-D activity and PBG-D activity as determined by 
the ORO-l-S assay. Subsequent experiments revealed that this was 
directly attributable to the CBZ mediated depression of activity anri 
that the effect could be reversed by the addition of supplementary 
purified ALA-D. In the case of CBZ treated patients, therefore, the 
rate of PBG synthesis was the factor governing the rate of ÜRO 
production rather than the amount of PBG-D present, and consequently 
the activity measured did not reflect the true activity of this enzyme 
but the activity of restored ALA-D. This limitation only became 
effective at restored ALA-D activities of less than 1500 nmolPBG/h/ml 
erythrocytes and therefore would not affect the determination of PBG-D 
activity by the URO-I-S method in normal blood samples.
These results indicate that there is in fact no effect of CBZ on 
PBG-D activity during long-term treatment and also that the reductions 
in activity found by Rapeport fit al, (1984) and Yeung fit aL (1983) 
were artefacts. This shows that a misdiagnosis of AIP because of a 
reduced PBG-D activity is possible if this assay is used without first 
checking the restored level of ALA-D activity. It would be advisable 
when using this assay to screen for latent AIP to determine the 
restored levels of ALA-D whenever a positive result is obtained to 
check that ALA-D activity was sufficiently high to guarantee a 
satisfactory supply of PBG.
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^•3 gA^MAZEPINE AND URINARY PORPHYRIN EXCRETION
This section is concerned with the effects of CBZ treatment on 
the urinary porphyrin excretion profile. This profile defines the 
relative proportions of each of the 5 porphyrins, from URO throu^ to 
COPRO, in a 24 hour urine collection as described in 2.3.4. The 
reason for investigating the effects of CBZ on this profile was that 
Rapeport fit. at (1984) reported that the profile was altered by CBZ 
treatment yet it was shown in sub-section 3.3.4 of this thesis that 
chronic CBZ therapy had no effect. This disparity was investigated 
in the first part of this section. In the second part the urinary 
porphyrin excretion profiles from a number of porphyric patients with 
acute intermittent porphyria (AIP) or porphyria cutanea tarda (PCT) 
were determined. Both of these corxiitions (described in detail in 
1.3.10) produce characteristic profiles which differ greatly from 
normals. These were investigated to see if a statistically 
significant comparison could be made between either of these 
conditions and the changes reported by Rapeport fitfil (1984) following 
administration of CBZ.
Since this section is primarily devoted to explaining the 
finding of Rapeport fil aL (1984), the methods used for determining 
the profile were exactly as described in that paper. Althou^ this 
method ^ve poorer resolution of the individual porphyrins than the 
procedure outlined in 2.3.4, this was the only way in which the 
questions raised could be answered.
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't.3.1 JHE.SFFECTS OF CBZ ON DRINABÏ PORPHYRIN EXCRETION
Rapeport fit aL (1984) reported large increases in the % ÜRO in 
the urinary porphyrin excretion profiles of volunteer subjects who 
took CBZ, but it was shown in sub-section 3.3.4 of this thesis that in 
epileptic patients receiving chronic CBZ monotherapy, there was no 
change in the profile compared to controls. Slightly different 
methods were used. This raised the question: was the difference in
the findings a consequence of the different methodologies or was there 
a temporary change in the urinary porphyrin excretion profile in the 
initial stages of CBZ treatment? To answer this question, urinary 
porphyrin excretion profiles were examined in four epileptic patients 
prior to starting CBZ therapy and at intervals thereafter. All of 
the patients began treatment on a dosage of 200mg CBZ b.d. This 
dosage was maintained in each of the patients except patient No.1, 
whose dose was increased to 200mg t.d. after six weeks. The results 
for all 4 patients are shown in table (18). Before starting on CBZ, 
the profile in each patient was identical to that found in controls 
(see table (19) for the mean results of 10 control urines) and 
consisted of 96$ or more ooproporphyrin (COPRO) with traces of the 
others. Of these remaining porphyrins, URO was the most significant, 
accounting for 1-4$ of the total. After starting to take CBZ, there 
were changes in the profile. The $ COPRO fell and the relative 
proportions of the other fractions, principally URO, increased. 
However, the extent and the timing of the maximal change from the 
baseline profile varied from patient to patient. Following this, 3 
of the patients showed a return towards a normal excretion pattern. 
The return to normal in patient No.1 was slower, possibly due to his
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increased dose. Thus CBZ treatment does cause a change in the 
profile, but the change is not permanent. An explanation for this 
would be that in the initial stages of treatment, very hi^ levels of 
ALA-S activity were attained due to derepression of the enzyme. When 
ALA-S activities are so high, much more ALA than normal would be 
produced. This would be converted to PBG quite easily since ALA-D is 
present in excess. However PBG-D could not cope with the sudden
increase in PBG and the excess would be excreted in the urine. This 
is likely because after ALA-S, PBG-D has the lowest endogenous 
activity in the pathway (Elder, 1982). The excess PBG in the urine 
could undergo non-enzymatic polymerisation and cyclization. When 
ALA-S activity falls, less PBG will be produced, PBG-D will be able to 
cope and consequently less PBG will be excreted in the urine. This 
would lead to a decrease in the quantities of URO detectable in the 
urine. Unfortunately urinary PBG estimations were not performed in 
these patients, and so the theory outlined has not been proven. 
There are however a number of facts to support it. The first of 
these is that in AIP, even in the latent fdiase, an almormal urinary 
porphyrin profile is found, characterized by a large increase in the % 
URO (see 4.3.2). This change is brou^t about by a 50$ decrease in 
PBG-D activity, even though ALA-S may only be sli^tly elevated. The 
situation here, where PBG-D is constant but ALA-5 activity is greatly 
increased, should produce a similar result. A further fact 
supportive of these arguments is that in the paper of Rapeport fil al
(1984) as regards the effects of CBZ on haem biosynthesis, a slight 
(but not statistically significant) increase in PBG excretion was 
detected. Bearing these facts in mind, the proposed explanation 
seems quite valid.
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OflQCl^ glQng. Qn the effects of CBZ on urinary Dorphvrin excretion
Treatment of individuals with CBZ produced changes in the 
urinary porphyrin excretion profile. In particular the % URO was 
increased. These changes however were not permanent and, despite 
continued treatment, the profile gradually returned to normal. There 
was no consistency in the extent or the timing of the dianges. It 
seemed likely that the changes found in the profile were linked to the 
derepression of ALA-S.
4.3.2 CBZ AND URINARY PORPHYRIN EXCRETION: COMPARISONS WITH THE 
URINARY PORPHYRIN EXCRETION PROFILES IN PORPHYRIA
The aim of this section was to determine if the changes in the 
urinary porphyrin excretion profiles produced by CBZ treatment could 
be matched with the distinctive altered profiles found in the 
porphyrias. The only porphyric patients available in sufficient 
numbers to investigate this were 20 patients with acute intermittent 
porphyria (AIP) and 10 patients with porphyria cutanea tarda (PCT). 
All of these patients had previously been classified by thorough 
enzymatic investigation in the Porphyria Research Laboratory, (Jardiner 
Institute, Western Infirmary, Glasgow. Those patients with AIP were 
divided into patients experiencing an acute attack of the disease 
(n=10) and those who were either latent or in remission. 10 control 
subjects were also studied. The results are presented in table (19). 
Unfortunately, as the results in the preceding sub-section show, the 
changes in the urinary porphyrin profile following CBZ treatment 
cannot be said to be representative of any of the conditions shown 
because the changes produced by CBZ were not consistent. However it 
could be argued that at certain time points after the initiation of
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treatment in some individuals the profile could be confused with that 
found in AIP, but never with that found in PCT. This is important 
because of recent interest in screening for porj^ ayria by the analysis 
of urinary porphyrin composition. The relevance of this is discussed 
in 4.3.3.
Conclusions
No real comparison can be made between the changes in the profile 
produced by CBZ treatment and those changes found in AIP and PCT. 
However at times the profile produced by CBZ in some individuals did 
resemble that found in AIP.
4.3.3 SUMMARY OF SECTION 4.3
This section investigated the effects of CBZ treatment on the 
urinary porphyrin excretion profile. Shortly after commencing 
treatment there was a major change in the profile, characterized by a 
large increase in the JtURO. The extent of this change varied from 
individual to individual and in the time at which the maximal 
departure frcxn normal was observed. The altered profile gradually 
returned to normal. These findings suggested that the changes in the 
excretion profile were a consequence of the very hi^ levels of ALA-S 
activity found in the initial stages of treatment. This is of 
interest because it implies that any drug which causes derepression of 
ALA-S to the same degree as CBZ does, would result in an altered 
urinary porphyrin excretion profile. At times this altered profile 
may resemble the characteristic profiles of AIP and presumably those 
of other porphyrias (with the exception of PCT). This is of great 
importance, particularly in the light of recent attempts to screen for 
porphyria by HPLC analysis of urinary porphyrins (Doss, 1978;
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Schreiber, Raisys and Labbe, 1983; Ostrowski 1984; Francis and
Smith, 1 9 8 5 ), as it could result in a misdiagnosis of porphyria if 
comprehensive enzymatic screening tests were not performed. 
Therefore before attempting to screen for porphyria in this way it 
must be affirmed that the subject has not taken any drugs known to 
cause derepression of ALA-S.
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4.4 SUMMARY OF CHAPTER 4
The studies described in this chapter were prompted by the 
findings of Chapter 3 and were devoted to investigating the effects of 
CBZ on erythrocyte ALA-D, erythrocyte PBG-D and the urinary porphyrin 
excretion profile.
As regards the reduction in the levels of ALA-D activity during 
CBZ treatment, a number of findings were made. These were that the 
effect on enzyme activity was irreversible, was not immediately 
apparent, was related to plasma "total" CBZ and CBZ-E concentrations, 
and was not due to an altered Km or a shift in the optimum assay pH. 
Thus it seems that the low activity in CBZ treated subjects arises 
throu^ a reduced amount of normal enzyme. It was also ascertained 
that activity was not lost as a result of reduced erythrocyte 
glutathione levels or hi^er than normal blood lead concentrations. 
However, the results did not confirm if the effect occurs throu^ a 
direct or indirect action of CBZ or a metabolite thereof.
This effect of CBZ on ALA-D was the underlying cause of the 
apparent loss of erythrocyte PBG-D activity in the subjects studied in 
Chapter 3, where the assay relied on ALA-D to act as a coupling 
enzyme. This chapter demonstrated that CBZ treatment does not affect 
PBG-D activity. This was shown by adopting a PBG-D assay which used 
PBG itself as a substrate, obviating the need for a coupling enzyme. 
Further experiments proved that the apparent reduction of PBG-D 
activity observed in Chapter 3 was due to a deficiency of ALA-D 
coupling enzyme. The minimum ALA-D activity required for it not to 
be rate-limiting was also calculated.
CBZ was shown to produce temporary disturbances in the urinary 
porphyrin excretion profile which were characterized by large
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increases in the %URO. These changes were maximal shortly after 
commencing treatment and then gradually returned to normal. The 
changes in the profile were probably related to derepression of ALA-S. 
These results explain why Rapeport jst. sL (1984) found dianges in the 
urinary porphyrin excretion profiles of volunteer subjects taking CBZ 
for a short period of time but no changes were found in epileptic 
subjects on chronic CBZ therapy.
This chapter has answered jsome of the questions raised by the 
results of Chapter 3. The remainder of this thesis investigates the 
effects of CBZ on haem biosynthesis in other systems and is 
particularly concerned with elucidating the mechanism whereby ALA-D 
activity is reduced.
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CHAPTER 5
ÇARBAMAZEPINE and H ABM BIOSYNTHESIS IN THE RAT 
In Chapters 3 and 4, the effects of CBZ on the first part of the 
haem biosynthetic pathway in man were investigated. These studies, 
considered in conjunction with those of Yeung At âl (1983) and 
Rapeport At âL (1984), revealed that in the early stages of treatment 
CBZ caused derepression of ALA-S, resulting in very hi^ levels of 
activity. Althou^ activity fell from these initially higi values, 
it did not return to baseline but remained significantly hi^er than 
controls. It was suggested that this derepression of ALA-S was a 
consequence of increased cytochrome P450 requirement. ALA-D activity 
was chronically depressed during CBZ treatment, and there was a 
significant correlation between ALA-D activity and plasma CBZ 
concentration. The reduction in the levels of ALA-D activity 
produced by CBZ is a slow process, suggesting that it may not be the 
result of a direct effect of CBZ on the enzyme. PBG-D and ÜRO-D 
activities were unaffected by CBZ treatment. There was also no 
effect of CBZ on the remaining three enzymes of the pathway as judged 
by quantitative and qualitative analysis of porphyrins excreted in the 
urine. However, the urinary porphyrin excretion profile was 
perturbed in the initial stages of CBZ treatment. This effect was 
transient and probably produced by the very high levels of ALA-S 
activity found during this period. CBZ also altered the relative 
amounts of the porphyrin precursors ALA and PBG excreted in the urine. 
In t-.bis chapter, studies of the effects of CBZ on haem biosynthesis in 
the rat are described. The aim of these studies was to determine if 
the rat would provide a suitable model for further investigation into
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the effects of CBZ described above page. The use of rats for such 
studies has obvious advantages over the use of human subjects, not the 
least of which is that hepatic enzyme activities can be directly 
measured. There are also several draw-backs, the principle ones being 
the difficulty of obtaining sufficient quantities of unclotted blood 
frcaa whidi to prepare plasma for the various drug analyses, and the 
small amounts of urine produced which limits the number of urinary 
analyses which can be performed. Owing to the difficulties in 
obtaining uncoagulated blood, drug concentrations were determined in 
serum rather than plasma. For most analyses, "total" CBZ 
concentrations were determined using the EMIT system but where 
sufficient volumes were available, HPLC analysis of CBZ-E was also 
performed. No measurements of free CBZ concentration were made. 
This chapter also investigates the effects of CBZ treatment on hepatic 
cytochrome P450, the terminal ccxnponent of the mixed function oxidase 
system and the proposed intermediary in the derepression of ALA-S 
shown to occur in man. To ccxnplement the studies performed in man, 
the effect of CBZ on hepatic glutathione concentrations was 
investigated.
This chapter is therefore composed of 6 sections which are as 
follows :
(1) the metabolism of CBZ in the rat
(2) the effects of CBZ on the enzymes of haem biosynthesis
(3) the effects of CBZ on the urinary excretion of porphyrins
and precursors
(4) the effects of CBZ on hepatic cytochrome P450
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(5) the effects of CBZ treatment on hepatic glutathione 
concentrations
(6) sunmary
In all of the experiments, the animals used were male Sprague- 
Dawley rats, weiring between 150-200g at the start of each study. 
As described in the methods section, CBZ was administered orally as a 
suspension in cottonseed oil. Cottonseed oil alone was given to 
controls. Doses were typically administered twice daily (b.d.) at 
8.30 a.m. and 8.30 p.m. Animals were starved for 24 hours prior to 
sacrifice, which was performed 2 hours after the last dose. All 
animals taking part in the experiments were weired each day. Animals 
in which treatment caused a loss of appetite with subsequent loss of 
weight or failure to gain weight at the same rate as controls were 
excluded.
- a; : . ' ''
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5.1 THE METABOLISM OF CBZ IN THE RAT
This section examines the metabolism of CBZ in the rat. These 
experiments were performed to determine if metabolism of CBZ in the 
rat was comparable to metabolism in man and to investigate what doses 
could be tolerated. Doses in excess of lOOmg CBZ/kg body wei^t b.d. 
were found to produce a loss of appetite followed by wei^t loss and 
general poor health and appearance. Consequently, the doses employed 
in these experiments did not exceed this. Also, the doses used were 
relatively larger than those used in man, (a typical starting dose in 
man would be about 6mg/kg). This was necessary because of the faster 
rate of drug metabolism and excretion found in the rat.
The section is divided into two sub-sections, the first of which 
examines serum concentrations of CBZ and the second of which 
investigates which metabolites of CBZ exist in rat serum.
5.1.1 SERUM CONCENTRATIONS OF CBZ IN THE RAT
All CBZ determinations in this subsection were made using the 
EMIT system (see 2.4.1). CBZ concentrations were measured in serum 
samples from groups of 6 rats 1.5, 2, 3, 4, 5.5, 7, 9 and 11 hours 
after a single dose of CBZ of 50mg CBZ/kg body weight. The rats were 
starved for 24 hours before administration of the drug. Hie results 
are presented in fig. (24). In the first 1.5 hours after dosage 
there was a rapid increase in serum CBZ. This was followed by a slow 
decline in drug levels. After 4 hours this decrease was interrupted 
by a secondary, slower rise in serum CBZ concentration which again 
started to fall after 7 hours. The entire experiment was repeated 
and gave the same pattern: a rapid rise in serum drug levels followed
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SERUM CBZ
(tng/l)
TIME (hours)
FIG. (24)
(XMCaTTRATICWS OF CBZ IH RAT SERUM FOLLOWING ORAL «KENISTHATIOM
OF TOE DRUG
48 male Sprague-Dawley rats were starved for 24 hours then given a 
single dose of 50mg CBZ per kg body weight. At the time indicated, groups 
of 6 rats were sacrificed and blood was collected for determination of serum 
CBZ concentrations by EMIT. The figure shows the mean ± 1 S.D. 
concentrations at these times. The secondary rise in serum CBZ levels is 
probably due to reabsorption of drug and metabolites excreted in bile.
by a slower decrease which was interrupted by a secondary increase in 
serum CBZ. This secondary peak in serum CBZ was probably due to 
reabsorbtion of CBZ which had been excreted into bile. This 
enterohepatic cycling of CBZ in rats has been noted by Morselli 
(1975).
The serum concentration of CBZ falls much more rapidly in the rat 
than in man. Bearing in mind that the results just discussed were 
from un-induced rats (that is rats which had not been exposed to drugs 
which may have caused an increase in the activity of the hepatic mixed 
function oxidase system), the half-life of CBZ ranged from 2-4 hours. 
This compares with a half-life of 26 hours for a non-induced human and 
12 hours for an induced human (Eichelbaum ^  aL 1985). This greatly 
accelerated rate of clearance may partly explain why rats can tolerate 
such hi^ doses of CBZ con pared to man. As is the case with man, the 
mixed function oxidase system can become induced, resulting in a more 
rapid elimination of CBZ. Table (20) shows the effect of regular 
treatment with CBZ (60mg CBZ/kg body weight b.d.) on serum 
concentrations of the drug. Two hours after the last of ten doses, (5 
days treatment), the mean total CBZ concentration in serum was only 
27% of the mean concentration 2 hours after the second dose. The rate 
of clearance is probably maximal at this time as evidenced by the 
results of a separate experiment in which one group of 6 rats was 
treated with 75mg CBZ/kg body weight b.d. for 5 days and a second 
group treated with the same dose for 12 days, (see table (21)). 
The mean serum concentrations of CBZ, (2 hours after the last dose in 
both groups), were 5.3 ± 0.7 mg/1 after 5 days and 5.3 ± 1.0 mg/1 
after 12 days. This shows that CBZ is not cleared any faster after
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TABLE (20) 
gEBOH (az CTOCENTRATIfflIS m  THE RAT 
PORING CBZ TREATMENT
Duration of 
Treatment (h)
Serum [CBZ] 
(mg/1)
14 13.2 ±4.9
38 8.1 ± 3.9
62 4.0 ± 2.3
86 -
110 3.6 ± 0.2
Each result represents the mean ± 1 S.D. for 4 animals.
6Qmg/Kg CBZ was administered at time 0 and thereafter at 12 hourly 
intervals.
Animals were starved for 24 hours prior to sacrifice, 2 hours after 
the last dose of drug.
12 days treatment than it is after 5 days treatment. This is 
probably related to induction of cytodirome P450» whidi is covered in 
Section 5.4.
5.1.2 MTABCtlTES OF CBZ IN THE RAT
As in man, the major metabolite of CBZ in the rat was found tp be 
carbamazepine-10-11-epoxide (CBZ-E). In this sub-section CBZ-E 
concentrations in rat serum were determined by the HPLC method 
described in sub-section 2.4.2. Analysis of the amounts of epoxide 
present in serum saimples frcm 24 rats treated with CBZ revealed that 
the relative proportions of CBZ-E and the parent drug were greatly 
different from those in man. In these 24 rats, CBZ-E accounted for 
87.8 + 5.6% of "total" serum CBZ as determined by EMIT. In man, for 
39 individual subjects, CBZ-E accounted for only 9.2 + 4.6% of total 
plasma CBZ. The figures for CBZ-E levels in the rat are analysed in 
greater detail in table (21). This shows that the percentage of 
epoxide in the rat was remarkably constant and independent of both 
dose and time. This much higher percentage of CBZ-E in the rat is a 
reflection of the greater metabolizing capacity of rat liver and may 
explain (a) why rats can tolerate greater doses of CBZ and (b) why 
the drug has a shorter half-life in rats. This second suggestion is 
based on the fact that CBZ-E is cleared faster than CBZ (Patel, Levy 
and Trager, 1978).
145
TAH.E (21)
SEROM CBZ AMD CBZ-E CONCENTRATIONS IN THE BAT DOSIllG 
CAHBAHAZEPINE TREADOIT
DOSE DURATION n
MEAN 
TOTAL CBZ^
MEAN 
% CBZ-E
75mg/kg b.d. 5 days 6 5.3 ± 0.7 85.3 ± 4.8
75mg/kg b.d. 12 days 6 5.3 ± 1.0 87.8 ± 5.6
lOQmg/kg b.d. 7 days 6 8.1 ± 1.9 89.6 ± 5.8
5Ctag/kg b.d. 7 days 6 4.9 ± 1.0 88.6 + 6.0
Overall. (®Z-E oonoentrations were 87.8 ± 5.6% of total CBZ oonoentrations 
(n=24).
^ serum conoeiitration determined by 0UT. Units are mg/I.
5.1.3 SUMMARY OF SECTION 5.1
Metabolism of CBZ in the rat differs from metabolism of the drug 
in man. Althou^ the principle metabolite was CBZ-E in both cases, 
the epoxide accounted for a much greater percentage of total CBZ in 
the rat than in man. This is a consequence of the greater activity 
of the hepatic mixed function oxidase system in rat. This also 
accounts for the fact that CBZ has a much shorter half-life in the 
rat, since the more rapid and extensive the metabolism of CBZ to the 
epoxide, the more quickly will the levels of the drug be reduced. 
This section also demonstrated that there was a secondary peak in the 
plot of serum CBZ concentration following a single dose versus time. 
This was probably due to enterohepatic cycling of CBZ. As is the 
case in man, the rate of clearance of CBZ increased after several days 
treatment and was maximal after 5 days. This was probably due to 
induction of drug metabolizing systems and is more fully investigated 
in later sections.
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5.2 ANP THE ENZYMES OF HAEM BIOSYNTHESIS IN RAT LTVRR
The experiments described in this section examined the effects of 
CBZ treatment on ALA-S, ALA-D, PBG-D and ÜRO-D activities in rat 
liver. These were the same enzymes that were studied in peripheral 
blood cells of man. The activities of these enzymes in rat liver 
during CBZ treatment were measured to evaluate how useful the rat 
would be as a model for further investigating the effects of the drug 
documented in Chapters 3 smd 4. : All enzyme activities were measured 
in liver using the methods described in the relevant sub-sections of 
section 2.2. Both dose response and time course studies of the 
effects of CBZ on the enzymes mentioned above were performed. The 
results of these studies are presented in the following sub-sections, 
each of which describes the effects of the drug on a particular 
enzyme. Enzyme results are presented in the order in which the 
enzymes occur in the pathway.
5.2.1 THE EFFECTS OF CBZ TREATMENT ON RAT LIVER ALA-S ACTIVITY
In Section 5.1, it was shown that CBZ-E is the major metabolite 
of CBZ in the rat. This compound is produced by the action of the 
hepatic mixed function oxidase system. The fact that CBZ is 
metabolized in this way in the rat would suggest that ALA-S activity 
may beccxne derepressed during CBZ treatment throu^ the mechanisms 
described in sub-section 1.3.9. The results of measuring ALA-S 
activity over 5 days treatment with 60mg CBZ/kg body wei^t b.d. are 
presented in table (22). These show that ALA-S activity was indeed 
derepressed in rats treated with CBZ, but at no time did ALA-S 
activity correlate with serum CBZ concentration. This was probably 
because concentrations were all very similar due to all animals being
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given the same dose. However, further experiments demonstrated that 
the extent of derepression was dependent on the dose of CBZ given (see 
table (23)). Returning to the results in table (22), the observed 
increase in activity was h i ^ y  significant (P<0.001) and was maximal 
after 3 days treatment, at which time the mean CBZ-treated ALA-S 
activity was 480% of the mean control activity. Whereas the increase 
in activity was rapid (even after 2 days treatment mean treated 
activities were 174% of mean control activities), when the levels of 
activity began to fall, (after 3 days), the rate of fall was 
relatively slow. This pattern of a rapid increase in activity 
followed by a slower decrease is the classical picture of derepression 
of ALA-S in rat liver linked to induction of cytochrome P450 synthesis 
(De Matteis and Gibbs, 1972; Rajamanickam at. âl» 1975). The 
relationship between cytochrome P450 and ALA-S will be discussed in 
Section 5.4. Further experiments revealed that, in contrast with the 
results frcm human subjects, described in Chapter 3, ALA-S activity 
in the rat does not remain elevated during prolonged CBZ therapy. 
Table (24) shows that after treatment with a bi^er dosage of CBZ 
(75mg/kg b.d.), ALA-S activities were increased with respect to 
controls after 5 days, but after a further 7 days treatment had 
returned to control levels (in fact activities were significantly 
lower t-ban controls, P<0.05). Studies on the effects of chronic CBZ 
therapy in man described in Chapter 3 revealed that leucocyte ALA-S 
activities (which are believed to mirror hepatic ALA-S activities) 
were elevated, the mean activity of treated patients being 218% of the 
mean activity of age and sex matched controls. Table (25) shows 
that, in the rat, treatment with even greater doses of CBZ does not
148
m s  (23)
THE EFFECTS OF THREE DIFFERENT DOSES OF CBZ
ON RAT i i m  pay? treaimbü
TREATMENT ALA-S ACTIVITY*
CONTROL 67.4 ± 7.9
CBZ 25ng/Kg b.d. 103.2 ± 32.6*
CBZ 5Qng/Kg b.d. 180.5 ± 90.4**
CBZ 75ng/Kg b.d. 279.5 ± 120.1***
* p<0.02, •* P<0.01, *** P<0.001 compared to controls.
Each result represents the mean ± 1 S.D. for 6 animals. 
Animals were starved for 24 hours prior to sacrifice.
a units are nmoles ALA produced/h/g protein.
lA&E (24)
THE EFFECTS OF CBZ ON HEPATIC HAEM ENZYMES 
AFTER TREATMENT FOR 5 AND 12 DAYS
CONTROL GROOP 1 GROOP 2
ALA-S* 88.4 ± 3.0 311.1 ± 177.2*** 74.4 + 18.2*
ALA-D^ 10.5 ± 1.4 7.3 ± 1.8** 7.0 ± 1.6**
PBG-D* 60.1 ± 12.2 62.6 ± 7.3 63.1 ± 8.6
DRO-D^ 4.9+ 2.1 4.6 + 0.9 4.8 ± 1.2
SEROM
[CBZ]® - 5.3 + 0.7 5.3 ± 1.0
• P<0.05» P<0.005, **• P<0.001 as compared to controls.
Each result presented in the table is the mean ± 1 SJ). for 6 animals. Group 
1 was given 75mg/kg CBZ b.d. for 5 days - Group 2 was given the same dosage 
for 12 days.
a units are nmoles ALA produced/h/g protein
b units are pnoles PBG produced/h/g protein
c units are nmoles ÜRO produced/h/g protein
d units are pmoles decarboxylations/h/g protein
e units are mg/1
TABLE (25)
THE ■S OF THREE DIFFERENT DOSES OF (BZ ON HEPATIC HAEM ENZYMES 
AFTER TREATMENT FOR 14 DAIS
CONTRCL GROUP 1 GROUP 2 GROUP 3
ALA-S* 52.0 ± 7.2 54.3 ± 8.1 55.2 ± 9.6 55.6 ± 12.3
ALA-D^ 7.8 ± 0.9 7.1 ± 0.3 6.4 ± 0.5* 5.4 ± 0.4**
PBG-D* 63.5 ± 8.9 62.9 ± 12.9 65.8 + 5.1 61.7 ± 13.2
ÜRO-D^ 6.8 ± 2.1 6.9 ± 3.0 7.1 ± 2.3 6.8 ± 1.8
SER0MECBZ3® - 3.7 ± 0.5 5.3 ± 0.6 8.1 ± 1.9
* P<0.005, •* P<0.001 as compared to controls.
Each result presented in the table is the mean ± 1 SJ). for results frcMn 6 
animls. All treated animals were given 75mg/kg CBZ b.d. for 7 days. The 
following doses were then administered for the next 7 days: Group 1, 50
mg/kg; Group 2, 75mg/kg b.d., Group 3, 150mg/kg b.d. Animals were starved 
for 24 hours prior to sacrifice.
a units are moles ALA produced/h/g protein
b units are ^ oles PBG produced/h/g protein
c units are nmoles ÜRO produced/h/g protein
d units are pnoles decarboxylations/h/g protein
e units are mg/1.
result in sustained derepression. In this case, after a fortnight’s 
treatment with 3 different doses of CBZ, there was no depression of 
activity as was found above, indicating that the seemingly significant 
decrease in activity noted in table (24) was probably an artefact 
caused by the small numbers of rats used in the experiment. Possible 
explanations for the difference in the response of ALA-S to CBZ 
treatment in man and rat will be discussed in sub-section 5.2,5 which 
concludes this section.
goaclugiong on the effects_of CBZ treatment on rat liver ALA-S
As was the case in man, CBZ caused a derepression of ALA-S in rat 
liver. The derepression of activity was probably linked to 
cytochrome P450 and this will be considered in Section 5.4. The 
extent of derepression was related to the dose of CBZ given. However, 
in contrast to man, the elevation of ALA-S activity was not sustained 
but had returned to baseline after treatment for 12 days. This will 
also be further discussed in Section 5.4.
5.2.2 THE EFFECTS OF CBZ TREATMENT ON RAT LIVER ALA-D ACTIVITY
The effects of CBZ treatment on ALA-D activity in the rat were 
investigated. The results of measuring ALA-D activity over 5 days 
treatment with 60mg CBZ/kg body wei^t b.d. are presented in Table 
(22). The results show that there was a significant reduction of 
ALA-D activity in the liver after 4 and 5 days of treatment with the 
drug, (P<0.01 and 0.005 respectively). At this time, there was no 
correlation between activity and serum CBZ concentration. This was 
probably because there were few points to correlate and all of the 
animals had similar CBZ concentrations. The relationship between 
ALA-D activity and serum CBZ will be discussed later in this sub-
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section. Activity was not immediately affected, the first changes 
onlu becoming apparent after 4 days treatment. This is ccxnparable to 
the situation found in man where it was demonstrated that ALA-D 
activity was not affected up to two days after a single dose but was 
reduced after treatment for 1 week. In order to verify that the 
reduction in activity observed was not produced simply by the use of 
small numbers of animals, a further experiment was conducted with a 
group of 8 control rats and a group of 8 rats treated with lOOmg 
CBZ/kg body wei^t b.d. The drug was administered for 6 days, after 
which the mean hepatic ALA-D activity of the CBZ treated group was 80% 
of the mean activity of the control group, a highly significant 
difference (P<0.001). The results of this experiment are shown in 
fig. (25). As a further control, PBG-D activities were measured in 
the same animals and showed no change. As part of the same 
experiment activities of both these enzymes were measured 2 hours 
after a single dose and were no different fran controls.
In all of the preceding investigations into the effects of CBZ 
treatment on ALA-D activity, the enzyme was assayed in the presence of 
dithiothreitol (DTT) and ZnClg. This shows that, as was the case in 
man, the reduction in levels of enzyme cannot be reversed by treatment 
with these activators. To investigate if perhaps ALA-D activity was 
affected at an earlier stage than was shown in table (22), but the 
effect was masked by the inclusion of activators in the assay, a 
further study, identical to the first described in this sub-section, 
was performed. In this study ALA-D activity was determined with and 
without added activators. In the presence of DTT and ZnClg, the same 
pattern as was shown in this previous study was found, namely reduced 
ALA-D activity after 4 and 5 days treatment. However no
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ALA-D ACTMTY 
(Mmol ALA/h/o protein)
p<0.001
CONTROL CBZ TREATED
(n-8) (n-8)
FIG. (25)
THE EFFECTS OF CARBAMAZEPINE TREATMENT ON ALA-D ACTIVITY
IN RAT LIVER
8 male Sprague-Dawley rats were treated with lOOmg CBZ in 
cottonseed oil per kg body weight b.d. for 6 days then sacrificed and 
hepatic ALA-D activities measured. 8 control rats were treated as 
above except that cottonseed oil alone was given. The results show 
that CBZ caused a 20% reduction in the mean ALA-D activity in rat 
liver# P<0.001.
satisfactory results were obtained in the absence of the activators 
because activities were very variable (activities ranged from zero to 
805t of the activities found in the presence of activators).
The effects of CBZ on ALA-D activity after 5 and 12 days 
treatment were also determined. The results of this study are 
presented in table (24) and reveal that ALA-D activity was maximally 
depressed after 5 days treatment» as treatment for a further 7 days 
produced no further depression of activity. This contrasts with the 
effects of CBZ treatment on ALA-D activity in human erythrocytes. In 
that system, as shown in sub-section 4.1.2, activity was not maximally 
reduced after treatment for 1 week. Why should activity remain 
unaffected for 3 days then over the next 2 days suddenly fall and 
remain at a constantly reduced level? It may be that in the study 
from which the results in table (22) were obtained, the effect was 
gradual, but in the earlier stages of treatment was too slight to 
detect: the maximum extent of the reduction in activity as compared
to controls was only 21%. An additional complicating factor was the 
small numbers used in this study. Regardless of this, however, 
subsequent studies with larger numbers of animals have shown that the 
effect is maximal after 5 days treatment. Why should this be the 
case in rat liver and not in human erythrocytes? There are several 
reasons, the most relevant being (a) rats are metabolically more 
active, (b) rats are receiving larger doses of drug, (c) there is a 
greater rate of drug turn-over in the rat, and (d) there is a greater 
rate of protein turn-over in the rat. These points could explain the 
faster attainment of reduced activities in the following ways. If 
the epoxide is the compound responsible for the diminuition of ALA-D 
activity, the higher concentrations produced in the rat would cause
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the levels of enzyme activity to be more rapidly affected. 
Alternatively if the effect was caused by some other metabolite of CBZ 
produced only in small amounts, the faster turn-over of the drug in 
the rat would mean that greater quantities of this compound were 
produced and would exert their effects more rapidly on ALA-D. 
Additionally, ALA-D was measured in the liver of rats, but in the 
erythrocytes in man and due to the proximity of the ALA-D in liver to 
the drug metabolizing systems, there would be higher total 
concentrations of all metabolites of CBZ. If CBZ or a metabolite was 
acting at the level of ALA-D synthesis then the effect would be more 
rapidly manifest than in man owing to the greater rate of protein 
turn-over found in rat liver.
The depression of ALA-D activity in rat liver produced by CBZ 
treatment also exhibited dose dependency. The results of a study in 
which rats were given 3 different doses of CBZ over a two week period 
are shown in table (25). This reveals that ALA-D activity (during 
treatment) was related to serum CBZ concentrations, mean CBZ treated 
ALA-D activities were 91%, 82% and 69% of mean control values for mean 
serum CBZ concentrations of 3.7, 5.3 and 8.1 mg/1 respectively. Note 
that this does not mean that CBZ is directly responsible for the 
actual reduction in the levels of ALA-D activity.
Conclusions on the effects of CBZ treatment on rat J.iver ALA-D
CBZ treatment irreversibly reduced the levels of ALA-D activity 
in rat liver, presumably by the same mechanism by whidi it did so in 
man. As was found in man, the extent of the reduction in enzyme 
activity was related to the plasma CBZ concentration. A further 
parallel between the depression of ALA-D activity in rat liver and the 
depression of erythrocyte ALA-D in man was that the effect took some
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time to manifest itself. However, in the rat, the maxi mal reduction 
in activity was attained much more quickly than in man.
5.2.3 .THE EFFECTS OF CBZ TREATMENT Œ  RAT LIVER PBG-D ACTIVITY
The effects of CBZ treatment on rat liver PBG-D activity were 
investigated. The results of these investigations, which constituted 
dose response, effects of CBZ on enzyme activity over 5 days treatment 
and the effects of 12 days treatment, are presented in tables (22) 
(24) and (25). These show that CBZ had no effect on PBG-D activity, 
confirming the findings of Chapter 4.
5.2.4 THE EFFECTS OF CBZ TREATMENT m  RAT LIVER ÜRO-D ACTIVITY
The effects of CBZ treatment on rat liver ÜRO-D activity were 
investigated. The results of measurements of ÜRO-D activity after 5 
days and 12 days treatment with CBZ and after 2 weeks of different 
doses of CBZ are presented in tables (24) and (25). Unfortunately 
activities of this enzyme over the first 5 days of drug treatment were 
not measured. However, given that no effects were found after this 
time and that a transient effect of CBZ on the enzyme is improbable, 
it is likely that the activity of URO-D in rat liver was not affected 
by CBZ. This confirms the findings made in human erythrocytes in 
Chapter 3.
5.2.5 SUMMARY AND GENERAL DISCUSSION OF SECTION 5^.2
In general, the effects of CBZ on the enzymes of haem 
biosynthesis were the same in rat liver as in human peripheral blood 
cells. Of the enzymes studied, ALA-8 and ALA-D were the only ones 
affected by treatment and although the general effects on these 
enzymes were the same as in man, there were some differences.
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In the initial stages of treatment» as was the case in man, there 
was a rapid dose-related derepression of ALA-8 followed by a slower 
decline in the levels of activity. This suggested that it occurred 
as a consequence of induction of the hepatic mixed function oxidase 
system, in particular, the cytP450 canponent. This proposal was 
confirmed as will be shown in section 5.4. However unlike man, in 
whom ALA-8 r«nained derepressed (see 8ection 3.1), activities in rat 
liver returned to normal. This was perhaps due to the overall 
greater metabolic rate which exists in rats as regards protein turn­
over and drug metabolism. The best explanation would be that ALA-8 
aside, the remaining enzymes of the pathway have endogenously greater 
activities than the corresponding enzymes in man. This would mean 
that the increased haem requirement could be met more readily. In 
addition to this, rats have higher initial levels of mixed function 
oxidase activity and consequently less adaptation of the rate of flux 
throu^ the pathway is necessary. In man however, basal levels of 
mixed function oxidase activity are low as compared to the rat. 
(k>nsequently, greater induction has to occur and, since the enzymes of 
the pathway are also present in reduced amounts, the pathway has to 
have many more intermediates fed into it at the level of ALA than in 
the rat.
ALA-D activity in rat liver was reduced by CBZ treatment with 
features similar to the reduction of activity in human erythrocytes. 
There was a relationship between the dose of CBZ administered and the 
extent of the depression. The reduction in activity could not be 
reversed by treatment with activators. Although the effect on 
activity was not immediate, it occurred more rapidly than in man.
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This was probably a consequence of the greater rate of drug turn-over 
in the rat. As was the case in man, it was not possible to define 
the mechanism whereby CBZ treatment caused reduction of ALA-D 
activity. PBG-D and URO-D were unaffected by treatment with CBZ.
Whether or not the effects of CBZ treatment on ALA-8 and ALA-D 
activities have any influence on the urinary excretion of porphyrins
i
and precursors is examined in the following section.
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5,3 THE EFFECTS OF CBZ TREATMENT ON THE EXCRETION OF P0RFHÏR218..JND 
PRECURSORS IN RAT URINE
This section consists of quantitative and qualitative 
investigations into the effects of CBZ treatment on the excretion of 
por^iyrins and the porphyrin precursors, ALA and PBG, in rat urine. 
The purpose of these investigations was to determine if the effects of 
CBZ treatment on ALA-S and ALA-D activity described in the previous 
section would influence the urinary excretion of porphyrins and 
precursors in rats in the same way as in man (see sections 3.3 and 
4.3). The section is divided into three sub-sections. The first of 
these deals with quantitative aspects and the second with qualitative 
aspects of porphyrin and porphyrin precursor excretion. The third 
summarises this section.
5 .3 . 1  OrTflWTTTATIVE ANALYSIS OF THE EFFECTS OF CBZ TREATMENT (Xf IBE.
EXCRETION OF PORPHYRINS AND PRECURSORS IN RAT URINE
As has been described for human urine, 3 quantitative analyses
were performed on rat urine:
(i) 24 hour ALA excretion
(ii) 24 hour PBG excretion
(iii) 24 hour total porphyrin excretion
The results of urine analysis from rats treated with 75mg CBZ/kg 
body wei^t b.d. for 7 days and then 150mg CBZ/kg body wei^t for a 
further 7 days are shown in table (26). These results are from the 
rats whose enzyme activities following sacrifice were presented as 
group 3 in table (25). Urine samples were stored in the freezer 
at -80°C for 1 month without additives. This was not ideal, as 
neither ALA nor PBG are particularly stable and some deterioration may 
have occurred. However control samples were stored under identical
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TMLE (26)
aBANTlTAIIVE MALÎSIS OF POBmmiHS AWT) PREOmSOHS IN THE DKDIE
OF CBZ TREATED RATS
ALA^ PBG^ TOTAL PORPHYRIN®
(n=12) 110 + 87 21il8 2.19 ± 2.0
5 days 
(n=6)
iSZ
12 days 
(n=6)
47 + 93 
561 + 226***
63 ± 71* 
13 ± 17
5.11 + 2.19** 
12.25 ± 8.98***
• P<0,05» *• P<0.01, •** P<0.001 as compared to controls.
Each result presented in the table is the mean + 1 S.D. for the group. 
CBZ treated animals were given 75mg/Kg CBZ b.d. for 7 days then 150mg/Kg 
b.d. for a further 7 days after which they were sacrificed. Urine 
collections were made at the times indicated in the table.
a units are pmoles ALA excreted/24 hours
b units are pmoles PBG excreted/24 hours
0 units are nmoles porphyrin excreted/24 hours
conditions and therefore the results, thou^ not absolute, should be 
valid. Two urine collections were obtained from each of the six 
control rats. CBZ treated animals were can pared against the combined 
data from these two sets of results. The results presented in table 
(26) are now discussed.
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There was no increase in ALA excretion after 5 days (in fact 
there appeared to be a decrease) but there was a hi^ily significant 
increase after 12 days, CBZ treated rats having an ALA excretion 510% 
that of controls (P<0.001). It is surprising that ALA excretion was 
increased after 12 days and not after 5 days. The increased 
excretion observed at day 12 can only be due to reduced ALA-D activity 
since at this stage of treatment ALA-S activities had returned to 
baseline (see table 24). Therefore an increased ALA excretion would 
also be expected after 5 days treatment since in addition to ALA-D 
activity being reduced (albeit not to the same degree as at day 12) 
ALA-S activity was increased to 352% of control values. The reasons 
for this apparent anomaly are not known.
m .
PBG excretion was significantly increased to 300% of control 
values after 5 days treatment, (P<0.05) but not after 12 days 
treatment. This would suggest that it may be linked to ALA-S
activity as this was shown to be increased after 5 days but to have 
returned to baseline after 12 days (table 24). This could occur as 
follows. After 5 days treatment, ALA-D would be only slightly 
affected, but ALA-S activity would be greatly increased. Since there 
was no increase in urinary ALA excretion at this time, it must be 
presumed that ALA-D could cope with the extra ALA, converting it to
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PBG, However, next to ALA-S, PBG-D has the lowest endogenous 
activity of all the enzymes in the pathway and consequently would be 
unable to cope with the extra substrate, some of which would be 
excreted. After 12 days, ALA-tS activity had returned to baseline but 
ALA-D activities were depressed to 69% of control activities, leading 
to decreased PBG synthesis. This could explain why PBG excretion was 
reduced after 12 days treatment, though not to a significant extent. 
iQtal Porphyrin
Total porphyrin excretion was significantly increased after 5 
days of CBZ treatment (P<0.01) and even more so after 12 days 
treatment (P<0.001), mean values being 233% and 559% of mean control 
values respectively. Since an increase in porphyrin excreted could 
only occur through increased porphyrin synthesis and since ALA-S is 
the rate limiting enzyme of the pathway, it follows that it should 
only be possible to increase total porphyrin excretion as observed 
here by an increase in the levels of ALA-S activity. However vrtiereas 
this may be the case after 5 days treatment, it is not for 12 days 
treatment. Indeed table (24) shows that ALA-S activity at this time 
had returned to control values. How then can total porphyrin 
excretion be increased? One possible explanation is that CBZ 
metabolites in urine interfere with the quantitative measurement of 
porphyrins by fluorescence. If this were so it could explain why 
total porphyrin excretion seemed to be raised in the second week, 
during which the CBZ dosage was increased from 75mg/kg b.d. to 
150mg/kg b.d. To investigate if this was so, solutions of CBZ and 
CBZ-E in HCl were prepared and a scan of the fluorescence emmission 
spectrum was run using an excitation wavelength of 396nm, the
158
wavelength used for quantifying porphyrins by fluoresence. This 
revealed that CBZ-E, but not CBZ, was hi^ily fluorescent under the 
conditions used. Although the maximum emmission wavelength was airound 
450nm, there was still considerable fluoresence at 594nm which lay in 
the tail end of this peak. This is the wavelength at which the 
fluorescence of porphyrin is measured. Therefore the presence of 
CBZ-E, and presumably other metabolites of CBZ, can produce increased 
fluorescence readings at the wavelengths used for porphyrin 
measurements, resulting in over-estimation of the amount of porphyrin 
present. To investigate if this was in fact the case, an attempt was 
made to see if the quantities of CBZ and metabolites in urine could be 
related to the apparent total porphyrin concentration. This was not 
possible using the HFLC method described in sub-section 2.4.3 because 
urine from control animals contained peaks which interfered with 
determination of CBZ and CBZ-E and also because urine from CBZ treated 
rats contained many peaks, presumably metabolites of CBZ, which could 
not be quantified due to the lack of suitable standards. No other 
means of quantifying CBZ and metabolites in urine was available, (the 
EMIT system used for other analyses in this thesis was suitable only 
for plasma drug measurement). Therefore it was not possible at this 
stage to say conclusively that the apparently increased porphyrin 
content of these urine samples was attributable to the presence of 
CBZ-E or other fluorescent metabolites of CBZ. However the following 
experiment shows that this is probably true. Epoxide was added 
directly to rat urine, (adjusted to pH 6.7 as described in sub-section 
2.3.3) to investigate if CBZ-E would be retained on the Dowex ion 
exchange resin used in the assay. After adding the urine to the
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column, washing and eluting, the sample spiked with CBZ-E gave an 
increased fluoresence reading indicating that CBZ-E is not separated 
from porphyrin using Dowex resin at this pH.
In a separate study in which rats were treated with 75mgCBZ/kg 
b.d. for 12 days, urinary total porphyrins were measured without 
adjusting the pH. The results of these analyses are shown in 
table (27). Urinary total porphyrin excretion was measured at 
different intervals after starting treatment and at no time was there 
a significant difference between treated and control animals. This 
indicates that in this case CBZ-E and other metabolites responsible 
for the increase in fluorescence observed in the results shown in 
table (26) are separated from porphyrin by loading onto the ion- 
exchanger at a hi^er pH (rat urine is about pH 9.0).
To summarise, the effects of CBZ treatment on urinary total
porphyrin excretion are not clear. In one experiment where there
appeared to be an increase, it was shown that this was very probably
due to the presence of CBZ-E and/or other metabolites. In the second
experiment, CBZ-E at least and presumably some other similar compounds
which may interfere with fluorescence were removed and no change in
urinary porphyrin excretion was found. However even this is
uncertain as the pH varied between samples and this may cause
differences in the extraction of porphyrins from different samples.
Conclusions on quantitative analvsis of the effects of CBZ treatment 
on the excretion of porphvrins and precursors in rat urine
Treatment with CBZ appeared to cause an increase in urinary ALA 
excretion after 12 days treatment which may be due in part to a 
reduction in ALA-D activity. CBZ treatment also produced an increase
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in the urinary excretion of PBG after 5 days and a decrease in the 
same after 12 days, thou^ the latter was not significant. These 
changes could be explained in terms of the relative activities of 
ILkS and ALA-D. Frcxn table (27) (presented in the following sub­
section), there appeared to be no effect of CBZ treatment on urinary 
total porphyrin excretion. This was in direct contrast to the 
results obtained in table (26). The former is probably the case as 
it was shown that under the conditions used in the determination of 
porphyrin content in the latter, the presence of CBZ-E could have 
resulted in an over-estimation of porphyrin content of the sample.
5.3.2 QUALITATIVE ANALYSIS OF THE EFFECTS OF CBZ TREATMENT ON 
PORPHYRINS IN RAT URINE
This sub-section made a qualitative analysis of urinary 
porphyrins in both CBZ-treated and control rats, to investigate if the 
increase in the % uroporphyrin (URO) found after initiating treatment 
with CBZ in man (see Section 4.3) occurred in the rat. Rats were 
given 75mg CBZ/kg body weight b.d. for a period of 12 days during 
which time urine was collected over 24 hour periods and a qualitative 
analysis of the porphyrins present was made as described in sub­
section 2.3.4. The results are presented in table (27), and are 
taken from the rats whose enzyme activities in the course of this 
particular study were presented in table (24). Two urine collections 
were obtained from each of the 6 control rats. CBZ treated animals 
were compared against the combined data from these two sets of 
results.
The results show that treatment with CBZ produced some 
significant changes with respect to controls, but these were very
161
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generally small, with the exception of the results after 12 days. 
The only effect of interest in relation to man was a sli^t increase 
in the % URO after 2 days treatment with CBZ (p<0.05). The pattern 
found in the remaining analyses was confusing but the general trend 
seemed to be an increase in the % protoporphyrin, up to day 7 of 
treatment, with corresponding decreases in the other fractions. 
These results cannot be satisfactorily explained with the data at 
hand, but are of limited interest because they show that the 
qualitative effects of CBZ treatment on the porphyrin canposition of 
rat urine is not the same as in man.
5.3.3 SUMMARY AND GENERAL DISCUSSION OF SECTION 5.3
This section described quantitative and qualitative investiga­
tions of the effects of CBZ treatment on urinary porphyrin and 
porphyrin precursor excretion in the rat. Quantitatively it was 
shown that CBZ treatment caused an increase in urinary ALA excretion 
at day 12. The reasons for this are not clear, as the depression of 
ALA-D activity was not sufficient to account for the enormous increase 
in excretion. Also at this time ALA-S activities had returned to 
baseline. Therefore there should have been an even larger increase 
earlier when ALA-S activities were increased after 5 days treatment. 
One possible explanation for this is that the urines were stored 
without adjustment of the pH. Rat urine is basic and ALA is not 
stable in basic solutions.
PBG excretion was shown to be increased after 5 days of CBZ 
treatment, probably due to derepression of ALA-S. After 12 days 
there was a non-significant drop in PBG excretion which could have 
been due to the loss of ALA-D activity caused by CBZ treatment.
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The situation as regards quantitative excretion of porphyrins was 
uncertain but it would seem that total porphyrin excreted in urine was 
not increased by CBZ treatment» despite derepression of ALA-S. The 
reasons why derepression of ALA-S activity produces an increase in 
total urinary porphyrin in man but not in the rat is unclear, but may 
be due to differences in the relative levels of different enzyme 
activities. It was shown that if CBZ-E and presumably therefore 
other metabolites of CBZ were present in samples in which a 
quantitative measurement of porphyrin was to be made, then an over­
estimation of the porphyrin content of the sample would result. The 
significance of this latter observation in determining total porphyrin 
concentration in 24 hour urine collections from human patients taking 
CBZ is not as great as in rats because there is less drug present per 
given volume of urine although porphyrin concentrations are 
equivalent.
Qualitatively, the changes in the porphyrin composition of rat 
urine samples were small and did not show the main effect found in the 
initial stages of treatment in man, i.e. large increases in the % URO. 
As was stated in sub-section 3.2.4 it was thou^t that this increase 
in % URO arose fron non-enzymatic polymerization and cyclization of 
PBG molecules in the urine, present in excessive amounts due to 
derepression of ALA-S. It was shown in table (26) that increases in 
PBG excretion did occur, providing scope for sudi a reaction, with 
consequent increase in urinary URO. The fact that this did not occur 
may be because of two things: (i) rat urine is more basic than human
urine which may slow the PBG URO reaction and (ii) samples were 
frozen immediately after collection unlike human samples which may
163
have been left at room temperature for up to 24 hours before either 
freezing or analysis.
Overall» the results of this section parallel the findings made 
in man in some respects (ALA and PBG) but not in others (total 
porphyrin and qualitative analysis of total porphyrin), and so are of 
limited value in understanding the nature of the effects of CBZ 
treatment on the excretion of jirinary porphyrins and precursors in 
man.
' ' ' ' '
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5.4 OBZ AND CYTOCHROME P450
Cytochrome P450 (cytP450) is the name given to the family of 
inducible haemoproteins which are the terminal components of the 
hepatic microsonal mixed function oxidase system responsible for the 
oxidative metabolism of endogenous and exogenous substsinces. The
latter category includes a great many drugs of which CBZ is one. The 
primary product of CBZ metabolism by this system is the epoxide. 
Many of the drugs which are metabolized by the hepatic mixed function 
oxidase system induce de novo synthesis of cytP450 which
subsequently causes derepression of ALA-S in the liver. The
experiments described in this section studied the effects of CBZ 
treatment on the levels of cytP450 in microsomal preparations from 
the livers of treated rats as described in methods 2.11.1.
5.4.1 THE EFFECTS OF CBZ TREATMENT ON CYTOCHROME P450 IN RAT .LIVER
Initial experiments established that CBZ did induce cytP450. 
The absorption peak of the induced, carbon-monoxide treated protein 
was 450nm, indicating that the induced protein belonged to the same 
family of cytP450s as that induced by {iienobarbitone and not to the 
P448 type family of cytochromes induced by 3-methylcholanthrene.
The results of 3 studies are summarised in table (28). The
figures show that in all 3 cases cytP450 levels were significantly 
increased during CBZ treatment and reached maximal levels of induction 
3 to 4 days after initiation of treatment with CBZ. In studies (B) 
and (C), it can be seen that the increase in cytP450 levels was 
preceded by a rise in hepatic ALA-S activity. The relationship 
between ALA-S and cytP450 levels is shown in fig. (26) using the
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FIG. (26)
THE RELATIONSHIPS BETWEEN DEREPRESSION OF ALA-S, INDUCTION OF 
OF CYTOCHROME P450 AND SERUM CBZ CCTJCEHTRATION IN CBZ-TREATED RATS
The figure shows the effects of CBZ treatment (60 mg/kg b.d.) on 
serum CBZ concentration, hepatic ALA-S activity and microsomal cytP450 
concentration. As treatment progresses, ALA-S is derepressed in order 
to produce supplementary haem to satisfy the increased requirement. 
This haem is used in the synthesis of microsomal cytP450 , leading to 
increased concentrations of this protein. As cytP450 is induced in 
this way» serum CBZ concentrations fall.
Each point on the figure is the mean result of measurements from 
i| animals. The arrows on the baseline indicate the times at which CBZ 
was administered.
results from study C. Mean serum CBZ concentrations are also plotted. 
Peak levels of cytP450 were preceded by the peak levels of ALA-S 
activity. This pattern occurs because metabolism of drug may 
initiate de novo synthesis of cytP450 apoprotein (as discussed in 
1.3.9. The newly synthesized apoprotein binds haem from the 
proposed "free haem pool" in the cell. This is limited, and the fall 
in the intracellular free haem levels causes derepression of ALA-S, 
which in turn leads to increased synthesis of haem. This newly 
synthesized haem binds cytP450 apoprotein to form functional P450 
leading to the peak levels of the complex as detected at day 4. How 
does treatment with CBZ induce cytP450? One possible mechanism of 
induction is destruction of cytP450 in the course of metabolism. 
Many olefinic substances are metabolized by cytP450 to form an epoxide 
group from a carbon-carbon double bond, such as occurs with CBZ. The 
majority of olefins metabolized in this way cause alkylation of the 
prostethic haem group of the cytochrome, rendering the enzyme 
inactive. CBZ however does not act in this way (Ortiz de Montellano 
âL 1981; Ortiz de Montellano and Correia, 1983). CBZ-E also does 
not have any effect on cytP450 concentrations (Jung, Bentley and 
Oesch, 1980). It is interesting to note that in both studies (A) and 
(C) there was a sli^t decrease in the mean levels of cytP450 2 hours 
after the second dose of CBZ as compared to mean control values at 
this time, suggesting that CBZ may have some sort of destructive 
effect on the cytochrome. This is argued against by the papers 
quoted above and by the fact that cytP450 was still significantly 
elevated after 12 days of treatment, even thou#i fLkS activities had 
returned to normal, table (29). If CBZ was destroying oytP450 at 
this time, when ALA-S activity was not derepressed, the levels could
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TM.E (29)
IHE EFFECTS OF CBZ OH RAT LIVER C3 
Pl|50 AFTER 5 DAIS AND AFTER 12 PAYS TREATMENT
cyt P450^ ALA-S^
LIVER WEIGHT AS 
% BODY WEIGHT
CONTROL 
5 DAYS CBZ 
12 DAYS CBZ
0.92 ± 0.18 
1.53 ± 0.29*** 
1.37 ± 0.18***
88.4 ± 3.0 
311.1 ± 177.2***
74.4 ± 18.2*
3.1 ± 0.2 
3.7 ± 0.4** 
3.6 ± 0.2***
* P<0.05, •• P<0.005 •** P<0.001 as compared to controls.
Each result is the mean + 1.S.D. for measurements from 6 animals.
a units are pmoles cytP450/g microsomal protein 
b units are nmoles ALA produced/h/g protein
not be maintained and would fall. As was just stated, this does not 
occur, leading to the conclusion that CBZ does not in fact destroy 
cytP450. The actual extent of the reductions in the levels of 
cytP450 in these studies was small (12% and 18% for studies A and C 
respectively) and could be simply a consequence of the small numbers 
used.
To return to the effects of cytP450 induction on CBZ metabolism, 
it was shown in sub-section 5,1.1 that the half-life of CBZ was 
reduced during treatment with the drug, and it was suggested that this 
may be due to induction of cytP450, leading to a faster rate of 
metabolism and consequently a faster rate of clearance. Fig. (26) 
shows this to be the case. When mean serum CBZ concentrations are 
plotted on the same graph as cytP450 levels, it can be seen that as 
the levels of cytP450 in these animals increases, the mean serum 
concentrations (two hours after the last dose in each case) fall and 
then level out once cytP450 is maximally induced. The fact that this 
rate of clearance is maintained was proven by a separate experiment in 
which mean serum CBZ concentrations were shown to be essentially the 
same after 12 days treatment as they were after 5 days treatment, 
table (24).
5.4.2 SIM4ARY AND GENERAL DISCUSSION OF SECTION 5^.4
Results from this section revealed that CBZ treatment induces 
cytP450 synthesis in rat liver and that the cytochrome produced 
belongs to the same family as that induced by phenobarbitone. The 
induction of cytP450 synthesis would appear to be the underlying 
medianism whereby ALA-S is derepressed (5.2.1). Furthermore, the 
increased levels of cytP450 provide the explanation for the increased
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rate of clearance of CBZ noted in sub-section 5.1.1. Considering 
these facts and bearing in mind that Rapeport al; (1983) showed 
that antipyrine clearance (an index of hepatic mi]œd function oxidase 
activity)» was increased during CBZ treatment in man, it would be 
reasonable to assume that the derepression of ALA-S which is found in 
man during chronic CBZ treatment (see Section 3.1) was due to 
induction of cytP450. A further point in favour of this was the 
increased 6B-hydroxycortisol excretion found in these patients. The 
mechanism of induction is unknown, but is probably not due to CBZ- 
mediated destruction of existing cytP450.
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5.5 CBZ AND GLtJTATHTQNR
Glutathione (see 4.1.5) is a cysteine containing tripeptide 
found in cells which acts as a sulphydryl buffer, maintaining the 
thiol groups of intracellular proteins in the reduced state. The 
effects of CBZ treatment on glutathione concentrations in rat liver 
were studied for two reasons, both of which were related to the fact 
that ALA-D is susceptible to loss of activity throuÿi oxidation of 
sensitive thiol groups. These reasons are (a) if CBZ or a 
metabolite caused a depletion of GSH levels this would lead to reduced 
ALA-D activity and (b) if CBZ caused a loss of ALA-D activity by 
indiscriminate reaction with thiols, then the concentration of 
glutathione would also be reduced. It could be argued that if the 
former possibility was true, activity would be restored by treatment 
with activators as described elsewhere. Althou^ no changes were 
found in glutathione concentrations of human erythrocytes, rat liver 
glutathiones were measured for completeness.
5.5.1 THE EFFECTS OF CBZ TREATMENT ON RAT LIVER GLUTATHIONE
The effects of CBZ treatment on rat liver glutathione 
concentrations were investigated. The method used measured total 
glutathione (i.e. both oxidized and reduced forms) and is described in 
sub-section 2.10.2. For the reasons described in sub-section 4.1.5, 
proposed complexes of glutathione and CBZ should not interfere with 
the assay. The results of two studies are presented in table (30). 
The first part of the table, study (A), reveals that treatment with 
lOOmg CBZ/kg body weight b.d. for 5 days reduced mean liver 
glutathione concentrations by 49% with respect to mean control values. 
ALA-D activity was also measured and, as expected, was reduced. No
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JAELE (30)
IHE EFFECTS OF CBZ TREATMENT m  RAT 
LIVER (LUTATHIONE CONCENTRATIONS
LIVER
GLUTATHIONE^ I ALA-D*)
SERUM
[CBZ]^
2.tudy..Jl
Control
CBZ
6.3 ± 2.8 
3.2 ± 0.9**
13.0 ± 3.9 
9.0 ± 2.1* 7.3 + 0.8
iStudY-J 
Control 
Group 1 
Group 2 
Group 3
7.3 ± 1.3 
6.7 ± 1.0 
5.6 ± 1.2* 
4.5 ± 1.3**
7.8 ± 0.9 
7.1 ± 0.3
6.4 ± 0.5**
5.4 ± 0.4***
3.7 ± 0.5 
5.3 ± 0.6 
8.1 ± 1.9
* P<0.05, **P<0.005» ***P<0.001 as ccmpared to controls
Each result is the mean ± I.S.D. of measurements in 6 animals.
Study A CBZ treated rats were given lOOng/kg b.d. for 5 days.
Study B rats were treated with 75 mg/kg b.d. for 7 days. The following 
doses were then administered for a further 7 days: Group 1, 50mg/kg 
b.d.; Group 2, 75mg/kg b.d.; Group 3, 150mg/kg b.d. 
a units are pmoles glutathione/g protein
b units are pmoles PBG produced/h/g protein 
c units are mg/l
correlation was found between hepatic glutathione levels and serum CBZ 
concentrations, but as was the case with rat liver ALA-D in sub­
section 5.2.1, this was probably due to the fact that CBZ 
concentrations were all very similar. The second part of table (30), 
which presents the results of study (B), shows that the extent of the 
reduction in rat liver glutathione was in fact dependent on the dose 
administered and the resultant serum CBZ concentration. These 
results would suggest that treatment with CBZ produces an 
indiscriminate reduction of intracellular thiol groups. This, 
however, contradicts the results obtained in sub-section 4.1.5. Why 
should CBZ cause depletion of glutathione in rat liver and not in 
human erythrocytes? One possible explanation is that the hi^er 
levels of epoxide or seme other CBZ metabolite in the rat cause the 
loss of glutathione, but because these are present in lower 
concentrations or absent in man, glutathione concentrations were 
unaffected. This is improbable because ALA-D activity would then be 
more severely affected in the rat and this is not the case. The most 
probable explanation for the differences lies in the nature of the 
tissues being examined. In the liver, in addition to maintaining 
intracellular thiols in the reduced state, glutathione has an 
important role to play in the detoxification of the metabolites of 
xenobiotics. This role involves conjugation of glutathione to such 
compounds by the action of glutathione transferases of which several 
are known (Ketterer âl* 1984). This renders them more easily 
eliminated. No glutathione conjugates of CBZ or its metabolites have 
been reported. This however does not exclude the possibility of 
their formation as many drug-glutathione conjugates are very unstable.
170
This proposed mechanism of glutathione depletion would not be 
applicable to erythrocytes as they lack the necessary enzymes: 
Consequently, erythrocyte glutathione concentrations were unaffected 
by treatment with CBZ.
There was no correlation between glutathione concentrations and 
the levels of ALA-D activity (or any other of the haem biosynthetic 
enzymes) in rat liver.
5.5.2 SUMMARY OF SECTION 5.5
In contrast with the findings on the effects of CBZ treatment on 
erythrocyte glutathione in man, rat liver glutathione was reduced in a 
dose dependent manner during CBZ treatment. However, it is believed 
that this was a consequence of the action of glutathione transferases 
conjugating glutathione to CBZ and its metabolites to facilitate their 
elimination, rather than an indiscriminate attack of CBZ or a 
metabolite thereof on glutathione. Bearing in mind the results from 
4.1.5, the conclusion is that ALA-D activity is not reduced as a 
consequence of glutathione depletion or a non-specific destruction of 
thiol groups by CBZ or its metabolites.
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5.6 SUMMARY OF CHAPTER 5
This chapter investigated the potential of the rat as a system 
for further study of the effects of CBZ on haem biosynthesis in man. 
The results of this chapter are summarised below.
The effects of CBZ on the enzymes of haem biosynthesis in rat 
liver were in general very similar to those observed in peripheral 
blood cells in man: a dose-dependent derepression of ALA-8; a dose-
dependent, irreversible reduction in ALA-D activity and no effects on 
PBG-D or URO-D. However, in contrast to man, there was no 
sustainment of the derepression of ALA-8 in rat liver.
With regard to the urinary excretion of porphyrins euid precursors 
in the rat, treatment with CBZ caused some changes in ALA and PBG 
excretion but did not at any time produce the large increases in the 
uroporphyrin fraction found in the early stages of treatment in man. 
No satisfactory results were obtained on the effects of CBZ treatment 
on the quantitative excretion of porphyrin.
Treatment with CBZ induced dfi. novo synthesis of cyt P450 in rat 
liver. This induction was linked to derepression of ALA-8 and was 
inversely related to the serum concentration of CBZ. This indicates 
that, in the rat, the derepression of ALA-8 produced by CBZ is 
mediated through induction of cyt P450 which is required for 
metabolism of the drug. This is probably also the case in man.
Hepatic glutathione was reduced in the rat as a result of CBZ 
treatment. This was probably due to the involvement of this compound 
in detoxification processes.
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In conclusion, these studies of the effects of CBZ on haem 
biosynthesis in the rat have shown that in some aspects at least, the 
pathway is affected in the same way as in man and have been of use in 
explaining some of the findings made in earlier diapters.
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CHAPTER 6
CARBAMAZEPINE and ALA-D;some IN VITRO STUDTES
Preceding chapters have shown that CBZ treatment results in 
reductions in the levels of ALA-D activity in both human erythrocytes 
and rat liver. However the mechanism whereby activity is lost is 
unknown. This chapter describes attempts to reproduce the depression 
of activity which occurs in vivo during CBZ treatment using several 
in Yitro. systems. The objective was to find a system which could be 
used as a model to study the mechanism whereby CBZ causes a loss of 
ALA-D activity. The problem was approached in several ways using the 
following 3 basic systems:
(1) human blood
(2) preparations of rat liver
(3) purified bovine liver ALA-D
None of the experiments in this chapter were capable of showing that 
the observed effects occurred throu^ an indirect action of CBZ or its 
metabolites, or that they were due to an alteration in the rate of 
synthesis of ALA-D. Rather, because all of the above systems are 
metabolically inert, the experiments were designed purely to test for 
a direct effect of CBZ (or the metabolites studied) on the ALA-D 
enzyme protein.
The drugs studied were CBZ and its principal metabolite, CBZ-E. 
In some experiments, 10,11-dihydrocarbamazepine (HgCBZ) was also 
included.
The chapter is split into four sections. Three of these are 
devoted to each of the aforementioned systems. The fourth summarises 
and discusses the significance of the results obtained in the chapter.
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6-1 THE IN VITRO EFFECTS OF CBZ AND METABOLITES ON ERYTHROCYTE ALA-D
The effects of added CBZ, CBZ-E and H2 CBZ on ALA-D activity in 
human blood were investigated under two sets of conditions:
(1) following addition of drugs
(2) following heating of samples to which drug had been added 
In addition to these experiments, ALA-D activity was measured in 
erythrocytes reconstituted with control plasma or plasma from CBZ 
treated patients. Each of these are discussed in the following 3 
sub-sections. The fourth and final sub-section summarises the 
results. In all experiments, the blood used was fheshly drawn and 
heparinised. When isolated erythrocytes and plasma were required, 
they were prepared from fresh heparinised blood. Two methods of 
adding drugs were tried: drugs were dissolved in either acetone or 
methanol and added directly to whole blood or were added to potassium 
phosphate buffer (0.15M,iÆ[7.2) which was added to washed erythrocytes. 
Both these methods gave identical results.
6.1.1 THE IN VITRO EFFECTS OF ADDED CBZ, CBZ-E AND HpCBZ ON ERYTHROCYTE 
OF ALA-D ACTIVITY IN WHOLE BLOOD
The effects of added CBZ, CBZ-E and HgCBZ on both circulating arrf 
restored ALA-D activities in whole and sonicated blood were 
investigated. The concentration of the drugs used varied from 
pharmacological concentrations of IOmg/1 to levels of 50mg/l, far in 
excess of any concentration liable to occur during treatment. Enzyme 
activity in both sonicated and whole blood was measured for several 
days following additions of the drugs. In all of these experiments 
there was no effect on ALA-D activity as compared to controls. Some 
typl cai results are presented in tables (31) and (32). The fact that
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table (31)
THE EFFECTS OF CBZ, CBZ-E AND HgCBZ ON ALA-D ACTIVITY 
IN WHOLE BLOOD OVER 4 DAYS
ADDITIONS
EXPOSURE TIME (HOURS)
2 26 50 74
Acetone 999 1016 850 814
CBZ^ 1002 962 887 833
CBZ-E^ 1056 1029 870 817
HgCBZ^ 1010 992 873 806
All additions were made in 30(^ acetone to 6ml whole blood.
& present at a final plasma concentration of 5(kng/l 
b present at a final plasma concentration of 25 mg/1
ALA-D activities are expressed as nmoles PBG produced/h/ml erythrocytes. 
Samples were stored at 4®C between measurements of activity.
-TABLE (32)
THE EFFECTS OF CBZ, CBZ-E AND HgCBZ ON ALA-D ACTIVITY 
IN WHOLE AND SONICATED BLOOD
ADDITIONS
CIRCULATING
ALA-DACTIVITY
ALA-D ACTIVITY IN 
SONICATEDCELLS
RESTORED 
ALA-D ACTIVITY
Acetone 1184 1080 1905
CBZ 1233 1095 1878
CBZ-E 1197 1077 1911
HgCBZ 1200 1065 1920
All additions were made in 10()pl of acetone to 2ml whole blood.
All drugs were present at final plasma concentrations of 5Qmg/l.
ALA-D activities were determined after 4 hours incubation at room temperature 
following the addition of drug.
ALA-D activity was not affected means that either CBZ, CBZ-E or HgCBZ 
do not act directly on the enzyme to reduce activity, or if they do, 
then the reaction is slow. This latter possibility is investigated 
in the following sub-section.
Conclusions on the effects of added CBZ, CBZ-E, and H^CBZ on 
arythrooYte Ala-d activity in whole blSSa
None of the compounds tested had any effect on circulating or 
restored ALA-D activity in whole or sonicated blood either immediately 
or after several days exposure to the drug.
6.1.2 THE EFFECTS OF HEAT TREATMENT ON ERYTHROCYTE ALA-D ACTIVITY IN WHOLE 
BLOOD FCT.LOWING ADDITION OF CBZ OR CBZ-E
Due to the absence of any change in ALA-D activity following the 
addition of CBZ, CBZ-E or H2 CBZ, whole blood to which CBZ or CBZ-E had 
been added was heated to investigate if this would accelerate what may 
have been a slow reaction between either of these ccmipounds and the 
enzyme. Heat treatment of whole blood usually results in an increase 
in erythrocyte ALA-D activity. (Chiba, 1976; Ushio ^ a l ,  1975). 
Reasons for this are unknown, but the most popular explanation is that 
heating results in the destruction of a heat labile inhibitory factor 
(Sakai, Yanagihara and Ushio, 1981; Trevisan æL âl» 1983; Kondo, 
Kajimoto and Urata, 1983). Preliminary studies established that when 
blood was incubated at 60°C, the maximal increase in activity occurred 
after 5 minutes. Thereafter activity declined. Therefore this 
temperature and incubation period were routinely used. Heat 
treatment also caused haemolysis therefore it was necessary to 
determine the packed cell volume beforehand. Following additions of 
drugs and heat treatment, ALA-D activity was measured in two ways.
(a) without further treatment and (b) following the addition of
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dithiothreitol (DTT) and ZnClg. Activities were determined 
immediately after heating, then again after 24 hours. Between assays 
the samples were stored at 4°C. The results of CBZ additions are 
shown in table (33) and the results of CBZ-E additions in table (34).
The results presented in these tables show that there was no 
effect of CBZ or CBZ-E on either untreated or restored enzyme 
activités following heat treatment of blood to which either compound 
had been added. Even after a further 24 hours, no loss of activities 
with respect to controls had occurred.
These findings suggest that if the loss of ALA-D activity shown 
to occur during CBZ treatment is caused by CBZ itself or CBZ-E, then 
it does not arise through a direct action of either compound on the 
enzyme. This does not exclude the possibility that the observed 
effect is a direct result of the action of some other minor 
metabolite. This possibility is explored in the following sub­
section.
Conclusions on the effects of heat-treatment. on erythrocte ALA-D 
activity in whole blood following the addition of CBZ or CBZ-E
Heat treatment of ALA-D in blood to irtiich CBZ or CBZ-E had been 
added failed to produce any effect on untreated or restored enzyme 
activities.
6.1.3 THE EFFECTS OF RECONSTITUTION WITH CONTROL AND CBZ TREATED FLÈMA 
Of ERYTHROCYTE ALA-D ACTIVITY
This sub-section looked at the effects of reconstituting control 
erythrocytes with fresh control plasma and fresh plasma from CBZ 
treated epileptic patients, on ALA-D activity. The purpose of these 
experiments was to investigate if there was some other constituent in
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table (33)
THE EFFECTS OF HEAT TREAmENT ON ALA-D ACTIVITY FCLLOWIMG 
THE ADDITION OF CBZ TO WHOLE BLOOD
CBZ^
UNTREATED ALA-D 
ACTIVITY^
RESTORED ALA-D 
ACTIVITY^
DAY 1 DAY 2 DAY 1 DAY 2
0 1110 801 1323 1383
2 1143 804 1311 1314
4 1107 777 1311 1368
6 1119 831 1299 1281
8 1113 819 1302 1389
10 1107 855 1317 1407
15 1098 789 1305 1374
20 1086 795 1311 1371
Blood was incubated at 60°C for 5 minutes following addition of CBZ.
ALA-D activities were determined immediatriy after this treatment (Day 1 
results) and after a further 24 hours at 4 C (Day 2 results).
^ units are mgCBZ/l plasma
b units are moles PBG produced/h/ml erythrocytes
TABLE (34)
THE EFFECTS OF HEAT TREATMENT (») ALA-D ACTIVITY FCLL(XmiG 
THE ADDITION OF CBZ-E TO HHCLE BLOOD
UNTREATED ALA-D 
ACTIVITY ^  i
RESTORED ALA-D 
ACTIVITY®
CBZ-E^ DAY 1 DAY 2 DAY 1 DAY 2
0 1080 768 1581 1440
1 1104 750 1641 1425
2 1089 729 1623 1413
3 1107 747 1638 1470
4 1056 759 1617 1449
5 1077 783 1617 1431
Blood was incubated at 60°C for 5 minutes following addition of CBZ-E.
ALA-D activities were determined immediately after this treatment (Day 1 
results) and after a further 24 hours at 4°C (Day 2 results).
^ units are mg CBZ—E/1 plasma
b units are moles PBG produced/h/ml erythrocytes
the blood of CBZ treated patients responsible for the loss of activity 
which occurs during treatment. It may appear that these experiments 
were unnecessary because it has been shown in earlier sections that 
even when there were high plasma concentrations of CBZ and CBZ-E, 
erythrocyte ALA-D activity was unaffected over the first few days of 
treatment. Indeed these experiments would be senseless if it was 
believed that the effect was caused directly by CBZ or CBZ-E as this 
possibility has already been tested and rejected in the two preceding 
sub-rsections of this chapter. The purpose of the experiments was to 
investigate if ALA-D activity was directly reduced by some minor 
metabolite of CBZ, only produced in effective quantities once 
induction of hepatic mixed function oxidase activity has occurred. 
If this was true, then plasma from a patient who has been receiving 
CBZ treatment for some time should contain some of this effector and 
may cause a reduction of ALA-D activity when added to control 
erythrocytes.
Experiments were conducted as follows. Plasma was prepared from 
fresh heparinised blood from control subjects and from CBZ-treated 
epileptic patients who esdiibited reduced erythrocyte ALA-D activities. 
These plasmas were used to reconstitute erythrocytes from control and 
CBZ treated subjects. Activities were determined 16 hours and 40 
hours after reconstitution. Between assays, samples were stored at 
4®C.
The results shown in table (35) are typical of all the 
experiments conducted in this sub—section. They show two things. 
The first of these is that the ALA-D activity in the erythrocytes of 
CBZ treated patients was not restored by the addition of control
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plasma. This would be expected because other attempts at reversing
the loss of activity have failed. The second is that, even after 40
hours, ALA-D activity in control erythrocytes was unaffected by
reconstitution with plasma frcxn CBZ-treated patients.
Conclusions on the effects of reconstitution with control and CBZ 
treated plasma on erythrocyte ALA-D activity
The effects of CBZ treatment on erythrocyte ALA-D activity could 
not be repeated by reconstitution of control erythrocytes with plasma 
from a CBZ-treated epileptic patient with reduced enzyme activity.
6.1.4 SOMMARY OF SECTION 6.1
Under no circumstances could a direct effect of CBZ, CBZ-E or 
HgCBZ be demonstrated on ALA-D activity in human erythrocytes. These 
j_Qcluded the use of non—sonicated and sonicated cells, the use of drug 
concentrations greatly in excess of those encountered in YiY,P» 
measurement of activity over a number of days following addition of 
drug, measurements of the effects on both untreated and restored 
activities, heating of drugs with whole blood and the use of plasma 
from chronically treated patients as a source of drug.
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6.2 IHE IN VITRO EFFECTS OF CBZ, CBZ-E AND H^CBZ ON ALA-D 
iÔÏ’IVITY IN RAT LIVER ----------
This section investigated the effects of added CBZ, CBZ-E and 
H2 CBZ on ALA-D activity in preparations of rat liver.
The experiments were performed on samples of rat liver prepared 
as described in sub-section 2.2.2 for routine determination of ALA-D 
activity. Drugs were dissolved in acetone and 50pl of these 
solutions was added to 2ml fractions of liver preparation to give 
final CBZ, CBZ-E and H2 CBZ concentrations of 250, 125 and 125mg/1 
respectively.
The results of two such experiments are presented in table (36) 
and reveal that none of these compounds had any effects on ALA-D 
activity. These results show that the depression of ALA-D activity 
in rat liver shown to occur during treatment with CBZ was not caused 
by a direct action of any of the above compounds. This provides 
confirmation of the results obtained in sub-sections 4.1.2 and 5.2.2 
where it was shown that ALA-D activities were unaffected in the 
initial stages of treatment even in the presence of high 
concentrations of CBZ and CBZ-E.
Conclnnm on the in vitro effects of CBZ, CBZ-E or HpCBZ on ALA-D 
activitv in rat liver
Neither CBZ, CBZ-E or H2 CBZ had any demonstrable effect on rat 
liver ALA-D activity in vitro even though concentrations far in excess 
of those occurring during treatment were used.
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TABLE (36)
THE IN VITRO EFFECTS OF CBZ, CBZ-E AND HgCBZ ON 
ALA-0 ACTIVITY IN PREPARATIONS OF RAT LIVER
ADDITION
ALA-D ACTIVITY^
RAT 1 RAT 2
Buffer 13.1 10.6
Acetone 12.1 10.6
CBZ^ 11.9 10.6
CBZ-E® 12.0 10.5
HgCBZ® . 12.1 10.5
^ units are umoles PBG produced/h/g protein 
^ present at a final conoefttration of 250tag/l 
® present at a final concentration of 125mg/l
6.3 TOE IN VITRO EFFECTS OF CBZ, CBZ-E AND HgCBZ ON PURIFIED 
LIVER ALA::^  ---------- -------------
The effects of added CBZ, CBZ-E or HgCBZ on the activity of ALA-D 
purified from bovine liver as described in sub-section 2,9.1 were 
investigated. Although the in vivo effects of CBZ treatment on this 
enzyme are not known, there is no reason to believe that the response 
would be any different to that observed in human erythrocytes or rat 
liver.
The results of two experiments are presented in table (37). In 
the first of these, drugs were added to a solution of enzyme as 
described in sub-section 2.7.4 and activity measured after 4 hours 
incubation at rocxn temperature. The second experiment used higher 
concentrations of drugs and the samples to which drugs had been added 
were incubated at 37®C for 30 minutes, then at room temperature for a 
further 3 hours 30 minutes before determination of activity. The 
drug concentrations used in both of these experiments are shown in the 
table. Examinations of the results reveals that none of the 
treatments described resulted in any changes in activity with respect 
to controls. This is perhaps not surprising in view of the lack of 
effect of these compounds on enzyme activity in human erythrocytes and 
rat liver as described in the previous sections. In those 
experiments, enzyme activities were determined in the absence of DTT 
and ZnClg. However it was necessary to include these compounds in 
the assay of purified enzyme otherwise no activity was detectable. 
Experiments identical to those described above but to which DTT and 
ZnClg bad been added before addition of the drugs were also performed. 
These experiments were also unable to show any effect on ALA-D 
activity.
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table (37)
THE EFFECTS OF ADDED CBZ, CBZ-E AND HgCBZ ON 
PURIFIED BOVINE LIVER ALA-D
ADDITION
STODY 1 I STUDY 2
[DRUG]^ ALA-D ACTIVITY^ [DRUG]^ ALA-D ACTIVITY^
Buffer 0 100.0 ± 6.8 0 100.0 + 2.4
Acetone 0 100.2 ± 1.9 0 100.3 ± 2.4
CBZ 50 98.3 ± 1.5 500 98.2 ± 2.6
CBZ-E 50 102.5 ± 1.5 250 99.3 ± 3.2
HgCBZ 50 99.1 + 1.9 250 99.3 ± 1.8
Study 1 Activity was measured after 4 hours incubation at room
temperature following addition of drug.
Study 2 After the addition of drugs, samples were incubated at 37®C
for 30 minutes, then at roan temperature for a further 3 
hours 30 minutes before measuring activity.
^ units are mg/1
b results expressed as percentages of controls
Conclusions on the in vitro effects of CBZ, CBZ-E and H^CBZ on 
purified bovine liver ALA-D
ALA-D purified from bovine liver was not affected by the CBZ,
CBZ-E or HgCBZ either in the presence or absence of DTT and ZnCl2 .
1 8 2
6.4 SUMMARY OF CHAPTER 6
This chapter described attempts to find an in vitro model system 
to study the mechanism of the reduction in the levels of ALA-D 
activity shown to occur during treatment with CBZ in both man and rat. 
This was done by looking for a direct action of CBZ or two of its 
metabolites on ALA-D activity in a number of different systems. It 
may be said that a direct effect of CBZ or CBZ-E on the enzyme was 
unlikely, as it has been shown in earlier sections that in both man 
and rat, ALA-D activity can be unaffected by concentrations of CBZ and 
CBZ-E which correlate with loss of activity in other patients or 
animals. However, there are many metabolic processes taking place in 
these in vitro systems which complicate the overall picture and which 
may mask a direct effect. Therefore experiments sucii as these were 
necessary to prove if in fact the effect is direct.
The conclusion of the diapter is that none of the systems studied 
provide a model for studying the effects of CBZ treatment on ALA-D 
activity. The results indicate that in all probability, the loss of 
ALA-D activity is not caused by a direct effect of CBZ, CBZ-E or HgCBZ 
on the enzyme. The possibility that it is direct but is slow was 
eliminated. The results do not exclude the possibility of the effect 
occurring throu^ a direct action of some metabolite of CBZ not tested 
here. However the results obtained would indicate that if this were 
true then this metabolite must be short lived. As was stated in the 
introduction to this chapter, these experiments did not test for 
indirect effects of CBZ or any of its metabolites. The experiments 
described in the following chapters attempt to investigate these 
possibilities.
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■CHAPTER 7
£ARBAMAZ5PINE and HAEM BI0$7NTHESIS IN CULTURED HOMAN LYMPHQCYTRR
In the preceding chapters, the effects of CBZ on several aspects 
of haem biosynthesis, in particular on ALA-D, in several different 
systems have been investigated. These included the study of the 
effects of the drug on in vivo systems, (man and rat), and on in vitro 
systems, such as isolated human erythrocytes, crude rat liver 
preparations and purified bovine liver ALA-D. Each of these has 
several drawbacks as far as elucidating the mechanism of the CBZ- 
mediated reduction in ALA-D activity is concerned. For instance, in 
complex entities such as man and the rat, there are many other 
processes taking place which may affect or be affected by ALA-D. 
There is extensive metabolism of CBZ which generates uncertainty as to 
which metabolite is responsible. The fact that individual persons and 
animals differ in their response to treatment with CBZ, shown by the 
ranges of drug concentration in plasma and the varying extent of the 
reduction in ALA-D activity, is also a complicating factor. The 
major problem with all of the in vitro systems studied so far is that 
they are metabolically inert. For example, red cells are not 
actively respiring, synthesizing proteins or performing any of the 
other processes commonly associated with living cells. The same is 
true of the preparations of rat liver and of purified enzyme. The 
use of cell culture eliminates several of these problems. For 
instance, it is possible to precisely define variables such as drug 
concentration, there are no problems due to different rates of uptake, 
metabolism and excretion of drug, and the cells are metabolically 
active. Mitogen stimulated human lymphocytes were used because the
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cells were readily available in sufficient quantities for the proposed 
experiments and also because there are many reports in the literature 
describing methods for measuring the activities of the relevant 
enzymes in these cells. Human monocytes were evaluated as a 
potential system of study» but these were not available in sufficient 
numbers. This problem could have been overcome by the use of a 
lymphocyte tumour cell line. Hiis was rejected because activities of 
enzymes were low compared to lymphocytes and without liquid nitrogen 
storage facilities it would have been both costly and troublesome to 
maintain the continuous culture which the use of these cells would 
have dictated. This latter reason also ruled out Epstein-Barr virus 
transformed lymphocytes.
The chapter is split into four sections, the first three of which 
are concerned with the effects of both CBZ and CBZ-E on (1) ALA-D 
activity, (2) PBG-D activity and (3) the capacity of the cells to 
synthesize porphyrins. As described in methods sub-section 2.2.1, 
the methods tested for the determination of ALA-8 activity in these 
cells were not satisfactory and therefore no ALA-S results are 
presented. The final section summarises the chapter.
In all the experiments described, cultures were prepared and 
mainhairiArt aa described in section 2.6 and enzyme activities were 
determined as described in the relative parts of section 2.2.
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7.1 JHE Et-ygCIg OF ÇBZ AND CBZ-E ON ALA-D ACTIVITY TN CULTDRED 
HOMAN LYMPHOCYTES
The effects of both CBZ and CBZ—E on ALA—D activity in cultured 
human lymphocytes were investigated. This section is divided into 
four sub-sections. The first of these investigates the effects of 
fixed doses of CBZ and CBZ-E on ALA-D activity, the second 
investigates the effects of varying doses of CBZ-E on enzyme activity 
and the third investigates the effects of varying the exposure time of 
cultures to CBZ-E on ALA-D activity. The fourth summarises the 
section.
7.1.1 THE EFFECTS OF CBZ AND CBZ-E ON ALA-D ACTIVITY IN COLTORED 
HOMAN LYMPHOCYTES
This section describes the first investigations into the effects 
of CBZ and CBZ-E on enzyme activity in mitogen-stimulated lymphocytes. 
The results of five experiments were collected and are presented in 
table (38). Activities are shown as percentages of mean control 
values in order to eliminate the spread of activities found in cells 
from different individuals. In all of these experiments, CBZ was 
present at a concentration of 30mg/l and CBZ-E was present at 15mg/l. 
In both instances, the cells were e3çx)sed to the drugs for 96 hours, 
after which ALA-D activity was measured. The results show that both 
CBZ and CBZ-E reduced ALA-D activity, but that CBZ-E was more 
effective in doing so. Activity in CBZ treated cells was reduced by 
a mean value of 16.9$ (P<0.001) whereas half as much CBZ-E reduced 
activity by 77.4$ (?<0.001) on average. These results would suggest 
that CBZ-E is the species responsible for the reduction in ALA-D 
activity in man and in the rat and that CBZ only results in depression
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THE EFFECTS OF CBZ AND CBZ-E ON ALA-D ACTIVITY 
IN_COLTORED HUMAN LYMPHOCYTES
CBZ CBZ-E
CONTROL (30mg/l) (15mg/l)
ALA-D 100 ± 5.3 83.1 ± 5.8* 22.6 ± 4.1*
ACTIVITY^ (n=13) (n=11) (n=10)
^ activities are ea^ressed as percentages of control values 
» P<0.001 as compared to control
' . ;■ / : V
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of the levels of ALA-D activity because it is metabolized to the 
epoxide. However, when samples of medium were analysed by HFLC, no 
metabolism of CBZ or CBZ-E had occurred. This proves that CBZ has 
the capacity to reduce ALA-D activity in its own right. The addition 
of an epoxide group potentiates this effect. These results do not 
prove whether the effects of CBZ and CBZ-E on the enzyme are direct 
or indirect.
To check that this inactivation of ALA-D was a specific property
of CBZ and CBZ-E, phenobarbitone and sodium valproate were added to
cultures to give final concentrations of IOmg/1 and 50mg/l
respectively. These two drugs do not affect ALA-D in vivo, and, as
expected, did not affect activity in these cultured lymphocytes.
■Conclusions on the effects of CBZ and CBZ-E on ALA-D activity 
in cultured human Ivmohocvtes
Both drugs caused a reduction of ALA-D activity in treated cells, 
but CBZ-E was a more potent effector than CBZ. No metabolism of the 
drugs occurred, indicating that it is the basic structure of CBZ which 
is responsible for the depression of activity. Phenobarbitone and 
sodium valproate did not affect activity. Further investigations 
using CBZ-E alone now follow. In the course of these, it was assumed 
that CBZ would act in the same way: the epoxide was used because its
effects were more potent and therefore more easily measured.
7.1.2 THE EFFECTS OF VARYING CONCENTRATIONS OF CBZ-E ON ALA-D ACTIVITY 
IN CDLTPRED HOMAN LYMPHOCYTES
The effects of a range of concentrations of CBZ-E (up to 15mg/l) 
on ALA-D activity in mitogen stimulated human lymphocytes were studied 
to investi^te if there was a relationship between drug concentration 
and enzyme activity. The results of e^osing the cells to various
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concentrations of epoxide for 96 hours are shown in fig. IZj). This 
reveals that the effect was dose dependent. It would be reasonable 
to assume, bearing in mind the results of the previous sub-section, 
that CBZ also affects activity in a dose-dependent manner. The 
largest concentrations used resulted in activity which was only 26.7* 
of control values. This compares well with the results from sub­
section 7.1.1 (see table (38)). Loss of ALA-D activity was found at 
epoxide concentrations which would occur during treatment with CBZ: 
the lowest concentration used was 3.75mg/l, and this produced a 41$ 
reduction in enzyme activity. This concentration of drug is in the 
upper range of normal plasma values. It may seem reasonable to make 
this comparison as the lymphocytes were cultured at a density which 
approximates their concentration In vivo. However it must also be 
remembered that the epoxide concentration used here may be much hi^er 
than that effectively encountered in vivo because in the plasma there 
is a hi^ degree of binding to plasma proteins which does not occur to 
the same extent in culture.
Conclusions on the effects of varving concentrations of CBZ-E 
on ALA-D activity in cultured human Ivmphocvtes
It was shown that there was a dose dependent relationship between 
the concentration of CBZ-E in the medium and the activity of ALA-D in 
the cells. Presumably this would also apply to CBZ, but as was shown 
in sub-section 7.1.1, the effects would be much less marked.
7.1.3 THE TIME COURSE OF THE CBZ-E MEDIATED REDUCTION OF ALA-D ACTIVITY 
IN COLTDRED HUMAN LYMPHOCYTE
Studies in earlier chapters demonstrated that the reduction in 
the levels of ALA-D activity produced during CBZ treatment was a slow 
process. ühls experiment investigated the rate at which activity was
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FIG.(27)
W E  EFFECT OF CBZ-E ON ALA-D ACTIVITY IN COLTORED BOMAN LÏMmOCYTES
CBZ-E was added to 10ml cultures of lymphocytes (cell density = 0.75 x 
10° cells/ml) to give final oonoentrations of 0,3.75,7.5,11.25 and 15 jig/ml. 
ALA-D activity was measured after incubation for 96 hours under the 
conditions described in sub-section 2.6.2. Each point is the mean of 3 
observations,
The figure shows that CBZ-E causes a reduction in ALA-D activity in the 
cells which is related to the concentration of the drug added.
lost in cultured cells by measuring ALA-D activity after varying
periods of exposure to CBZ-E (15mg/l). Activity was measured in
samples which had been exposed to the epoxide for periods ranging from
0 to 92 hours. DMSO was added to control cultures at the same times
as CBZ-E was added to test cultures. The results are shown in
fig. (28). The graph shows that in contrast to all the other systems
studied in previous chapters, the effects of the epoxide on enzyme
activity are detectable after short periods of time: after exposure
to CBZ-E for only 5 hours, the mean ALA-D activities in treated cells
were 7k% of the corresponding control activities. In rats there was
no detectable difference in the activity of hepatic ALA-D until 4 days
sfter initiation of treatment and in man there was no change in
erythrocyte activity for at least two days following dosage with CBZ.
The response may occur more rapidly in this system because the
concentrations of CBZ-E used were much greater than those which might
occur during treatment and also because there are no complicating
factors such as elimination or further metabolism of the drug. After
the longest period of exposure to the drug (92 hours), mean activities
were reduced to 21.9% of control values. This compares favourably
with results gained in sub-section 7.1.1 (see table (38)).
Conclusions on the time course of the CBZ-E mediated reduction of 
ALA-D activity in culturmi human lymphocytes
CBZ-E caused a reduction of ALA-D in activity at a much greater 
rate in this lymphocyte cell culture system than CBZ treatment did in 
man or in the rat.
7.1.4 SWMARY AND GENERAL DISCUSSION OF SECTION 7.1
CBZ and CBZ-E both caused a reduction in the levels of ALA-D 
activity in cultured, mitogen-stimulated human lymphocytes. CBZ-E
189
ALA-D Activity {pmoles P B G /10  *  cells/hr 
250-1
200
150
A  + DMSO
e  +DMSO+ CBZ-E 
(15>ig/ml)
100-
50-
50 100
Time Exposed to CBZ-E or DMSO (hrs)
FIG. (28)
TIME CCXJRSE OF THE EFFECT OF CBZ-E ON ALA-D ACTTIVITY 
IN CÜLTORED HUMAN LYMPHOCYTES
CBZ-E was added to 10ml cultures of lymphocytes (cell density = 0.75x10^  
cells/ml) to give a final concentration of 15pg/ml. The cultures were 
exposed to CBZ-E for 0,5,18.5,29,44,65,78.5 and 91 hours prior to assay for 
ALA-D activity, 96 hours after establishing the culture. Each point is the 
mean of 3 observations. The figure shows a progressive reduction in ALA-D 
activity during exposure to the drug.
was much more effective in reducing activity than was CBZ, and because 
of this it was used in further experiments to demonstrate that the 
depression of ALA-D activity was both dose and time dependent. 
Elffects were found at pharmacological concentrations and were evident 
after a relatively short exposure to the drug as compared to other 
systems studied. In view of this powerful effect of CBZ-E, it is 
tempting to assume that this is the species responsible for the 
inhibition of ALA-D in man and in the rat. However it was 
demonstrated that CBZ could also reduce activity, albeit to a lesser 
extent, without any detectable metabolism. Thus it would seem that 
the presence of the epoxide group potentiates the effect. While 
these results would suggest that activity is reduced directly by CBZ 
and CBZ-E, the situation cannot be that strai^tforward, otherwise the 
simple addition of these canpounds to the systems described in 
Chapter 6 would have produced a loss of activity. The fact that 
the system requires to be metabolically active suggests that some form 
of bioactivation occurs, the nature of which can only be speculative. 
This proposal would not of course be applicable if ALA-D activity was 
lost as a consequence of a reduced rate of enzyme synthesis. Indeed 
this would explain why enzyme activity was not affected in the 
experiments described in Chapter 6. However this section has 
demonstrated that this cannot be the case for the following reason 
(assuming that the lymphocyte and erythrocyte enzymes are identical). 
If ALA-D activity was depressed due to a reduction in the rate of 
synthesis, then activity could only be lost as quickly as observed in 
sub-section 7.1.3 if the enzyme had a very short half-life (17.5 hours 
from fig. (28). However this is not the case, otherwise activity
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would rapidly be irreversibly lost in erythrocytes removed from 
circulation, which it is not.
A further point which must be made is that althou^ it would seem 
frcxn the results presented in sub-section 7.1.1 that CBZ-E plays a 
more significant role in the depressson of ALA-D activity in man than 
CBZ, both probably make a significant contribution in vivo as CBZ-E
I
accounts for only 10-20$ of the total drug concentration.
The following section is concerned with the effects of CBZ and 
CBZ-E on PBG-D in cultured cells.
.s.:
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This section discusses the effects of CBZ and CBZ-E on PBG-D 
activity. It consists of 5 sub-sections. The first two examine the 
nature of the effect, the second two attempt to explain it and the 
fifth and final sub-section sumnarises the results of the section.
0" M  W,TnHRp
This sub-section presents the results of preliminary 
investigations into the effects of CBZ and CBZ-E on PBG-D activity in 
mitogen stimulated lymphocytes. The results of 5 experiments were 
collected and are presented in table (39). Activities are expressed 
as percentages of mean control values in order to eliminate the spread 
of activities found in cells from different individuals. In each of 
these e^>eriments CBZ was present at a concentration of 30mg/l and 
CBZ-E was present at 15mg/l. In both instances, cells were e3Q>osed to 
the drug for 96 hours before determination of activity. Examination 
of the results shown in table (39) reveals that CBZ-E seemed to cause 
an increase in the levels of PBG-D activity. The mean CBZ-treated 
value was not significantly different from the mean value of controls. 
The reasons why PBG-D activity should be affected by CBZ-E in this 
system but not apparently in man or the rat will be discussed in the 
final part of this section.
gonclusiops on the effects of CBZ and CBZ-E on PBG-D activity 
in cultured hvman lymphogytes
CBZ-E seemed to cause an elevation of I®G-D activities whereas 
CBZ did not. Further investigations are described in the following 
sub-sections, the objectives of which are to determine if the increase
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THE EFFECTS OF CBZ AND CBZ-E ON PBG-D ACTIVITY 
IN COLTDRED HUMAN LYMPHOCYTES
CBZ CBZ—E
CONTROL (30mg/l) (15mg/l)
PBG-D 100.0 ± 10.8 99.5 ± 29.3 130.4 ± 16.0*
ACTIVITY^ (n=12) (n=8) (n=11)
^ activities are expressed as percentages of control values. 
» P<0.001 as compared to controls.
is (a) related to drug concentration and (b) related to the 
inactivation of ALA-D described in the previous section.
7*2.2 THE lÜ-yhCTS OF VARYING CONCENTRATIONS OF CBZ-E ON PBG-D ACTTVTTY 
IN CULTURED HUMAN LWHOCYtS....
The effects of a range of concentrations of CBZ-E (up to 10mg/l) 
on PBG-D activity in mitogen stimulated human lymphocytes were studied 
to determine whether or not there was a relationship between drug 
concentration and enzyme activity. The results of exposure to the 
various concentrations of drug for 96 hours are shown in fig. (29). 
The graph shows that the increase in PBG-D activity was related to the 
concentration of CBZ-E in the incubation medium.
In conjunction with the results of the previous sub-section, 
these findings would seem to indicate that CBZ-E did indeed produce a 
rise in PBG-D activity. The only plausible way in which this could 
have occurred would be throu^ an increase in the amount of enzyme, 
i.e. an increase in enzyme synthesis. If this were the case, it 
could be produced either directly by CBZ-E or as a consequence of the 
inactivation of ALA-D. This latter possibility is investigated in the 
following sub-section.
7.2.3 INVESTIGATIONS INTO THE POTENTIAL RELATIONSHIP BETEEN INACTIVATION 
OF ALA-D AND INCREASED PBG-D A d l V m
The effects of lead and 4,6-dioxoheptanoic acid (DHA, succinyl 
acetone) on PBG-D activity in mitogen stimulated lymphocytes were 
studied to investigate if the apparent increase in the levels of PBG-D 
activity produced by CBZ-E treatment was a consequence of a reduction 
in the levels of ALA-D activity. Both of these compounds are potent
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FIG. (29)
TOE EFFECT OF CBZ-E ON PBG-D ACTIVITY IN 
COLTORED HUMAN LYMPHOCYTES
CBZ-E was added to 10ml cultures of lymphocytes (cell density 
0.75 X 10° cells/ml) to give final concentrations of 0,2.5,5.7.5 and 
IQpg/ml. PBG-D activity was measured after Incubation for 96 hours 
under the conditions described in subsection 2.6.2. Each point is 
the mean of 3 observations. TOe figure shows an apparent increase in 
PBG-D activity which is related to the concentration of the drug 
added.
inhibitors Of fi,A-D and therefore should result in an increase in
HBG-D activity if this occurs as a consequence of inactivation of 
ALA-D.
The additions were made to cultures prepared in the usual way. 
Lead was added as lead acetate to a concentration of 25 ;iM. DHA was 
added to a concentration of 5()^ . Cells treated with DBA exhibited 
subtly increased mortality, this was corrected for when calculating 
results. It had previously been established, using purified enzyme, 
that these concentrations were effective in reducing ALA-D activity.
The results of treatment with these compounds on ALA-D and PBG-D 
activities are shown in table (40). The results show that only DHA 
appeared to reduce ALA-D activity in the cultured cells: lead
appeared to have no effects. This however may be because inhibition 
of ALA-D by lead is reversible by treatment with dithiothreitol and 
Zn ions, both of which were included in the assay. In neither case 
was there any increase in the levels of PBG-D activity. Therefore 
the apparent increase in PBG-D activity noted during treatment with 
CBZ-E cannot have been due to a loss of ALA-D activity, but must have 
occurred through some other effect of the drug. This may have been 
either direct or indirect. However, it is also possible that CBZ-E 
itself interferes with the quantification of uroporphyrin produced in 
the assay resulting in an inaccurate estimation of porphyrin levels as 
shown in sub-section 5.3.2. This is investigated in the following 
sub-section.
Conclusions on investigations with the potential relationship 
between inactivation of ALA-D and increase of PBG-D actlvitv
These investigations revealed that there was no relationship 
between the loss of ALA-D activity and apparent increase in PBG-D
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TABLE (40)
THE EFFECTS OF CBZ-E. LEAD ACETATE AMD 4. 6. DIOEOHEPTAMOIC 
ACID (DHA) (M ALA-D AMD PBG-D ACTIVITIES m  COLTORED HOMAN LÎMPHOCÏTES
ADDITION ALA-D ACTIVITY^ PBG-D ACTIVITY^
DMSO
CBZ-E (15mg/1)
Lead acetate (25)M) 
ffiA (5(ÿi4)
231.1 ± 12.6 
43.2 ± 9.7 
234.3 ± 10.0 
20.9 ± 6.8*
6.7 ± 0.7
8.8 ± 1.3*
6.8 ± 0.9
6.9 ± 0.7
» P<0.001
^ units are pmoles PBG produced/10^  cells/hour 
° units are pmoles URO produced/10^  cells/hour
Each result represents the mean ± 1 S.D. of 4 measurements.
activity. This means that the inactivation of ALA-D by CBZ-E does 
not explain the apparent increase in PBG-D activity.
JHE SFFECT^ ..OF CBZ-S QN THE ASSAY USED FOR DETERMINATION OF PBG-D 
ACTIVITY IN CULTURED HOMAN LYMPHOCYTES
As was shown in sub-section 5.3.2, CBZ and CBZ-E absorb at the 
wavelengths used for measurement of porphyrins and fluoresce following 
excitation with li^t of these wavelengths. Part of the emmission 
spectrum falls in the range used for detection of porphyrin 
fluorescence. This sub-section, therefore, looked at the effects of 
CBZ-E on the assay used for determining PBG-D activity in mitogen- 
stimulated lymphocytes to investigate if, under the assay conditions 
employed, CBZ-E interfered with the fluorometric quantification of 
uroporjdiyrin which is the basis of calculating enzyme activity.
The experiment was conducted in the following way. 6 tubes were 
set up: 2 containing 25;iL DMSO, 2 containing 25^ of 20mg CBZ/ml in
DMSO, and 2 containing 25yl of lOmg CBZ-E/ml DMSO. The tubes were 
then treated as PBG-D assay blanks as described in sub-section 2.2.3, 
except that no PBG was added. At the end of the experiment, the 
fluorescence of the samples was measured at the same wavelengths used 
for calculating the amount of produced in the PBG-D assay. A 
fluorimeter expansion 10X less sensitive than that used in the assay 
was used. The results are presented in table (41) and they show that 
if CBZ-E is present, then the fluorescence of the samples is greatly 
increased. The same is true to a much lesser extent for CBZ. Thus 
the apparent increase in PBG-D activity can be explained by uptake of 
CBZ-E by the cells in the course of the incubation and retention of 
the drug during washing of the cells prior to assay. The CBZ-E
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TAH.E (41)
THE EFFECTS OF CBZ-E OS THE ASSAY USED FOB 
DETEBMIHATION OF PBG-D ACTIVITY IN CnLHJHED HOMAN LIMPHOCimS
ADDITION
MEAN
FLUORESCENCE READING»
DMSO 0.5
CBZ (25(ÿig) 0.8
CBZ-E (250pg) 7.7
* njean of 2 measurements.
CBZ or CBZ-E was added to tubes set up for FBG-D assay blanks (except 
that no PBG was added) to assess if the presence of either compound 
would interfere with the assay. The fluorescence expansion was 10 x 
less sensitive than that used in the assay.
present is sufficient to cause an artificially hi^ estimation of 
uroporphyrin produced leading to over-estimation of PBG-D activity. 
Whether or not this fluorescence of CBZ-E is a problem in the 
measurement of the porphyrin-synthesizing capacity of the cells is 
discussed in the next section.
Conclusions. Oh the effects, of CBZ-E on the assav used for the 
determination of PBG-D activity in cultured human ivmphoovtes
The presence of CBZ-E can cause an over-estimation of the
quantity of uroporphyrin produced in the assay. This fact is the
likely explanation for the apparent increase in the levels of PBG-D
activity produced following the addition of CBZ-E to cultures as
described in sub-sections 7.2.1 and 7.2.2.
7.2.5 SOMMARY OF SECTION 7.2
This section investigated the effects of CBZ and CBZ-E on PBG-D 
activity in cultured human lymphocytes. Preliminary results seemed 
to indicate an increase in PBG-D activity during CBZ-E treatment, but 
not during CBZ treatment. This result was unexpected because no 
changes in PBG-D activity had been found during CBZ treatment in 
either man or rat in the studies described in Chapters 4 and 5. 
However it is interesting to note that a positive linear correlation 
between plasma CBZ concentration and erythrocyte PBG-D activity in man 
was noted by Wright aial(1985). although there was no overall 
significant difference in the activities of control and CBZ-treated 
individuals. The possibility that the increase in activity was 
to the loss of ALA-D activity was investigated by the use of 
l^bitors of ALA-D. %ese failed to produce any increase in PBG-D 
activity. Therefore the apparent effect of CBZ-E on PBG-D activity 
was not mediated by ALA-D. This observation, coupled with the facts
196
that PBG-D activity was unaffected during CBZ treatment in man and 
rats and that CBZ-E can have some fluorescence at the wavelengths used 
for quantitative porphyrin analysis, prompted an examination of the 
effects of CBZ-E on the assay. This revealed that CB2L-E itself was 
fluorescent at the wavelengths used in the assay. The presence 
of any CBZ-E in an assay would therefore result in an overestimation 
of PBG-D activity. This would be especially true when the 
fluorimeter was set at the sensitive levels required for the 
measurement of PBG-D activity in mitogen-stimulated human lymphocytes.
In conclusion, neither CBZ nor CBZ-E had any effect on PBG-D. 
The apparent increase in activity produced by CBZ-E as described in 
sub-sections 7.2.1 and 7.2.2 was due to retention of epoxide by the 
cells with subsequent interference of the fluorimetric measurement of 
porphyrin produced.
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7*3 IHE EFFECTS OF CBZ AND CBZ-E ON PORPHYRIN SYNTHESIS TN 
gULTURED HUMAN LYMraoCYTES
This section looked at the quantitive and qualitative effects of 
CBZ and CBZ-E on porphyrin synthesis in cultured human lymphocytes 
following incubation of the cells with ALA as described in sub-section 
2,6,4, In all parts of this section, cells were prepared and 
cultured as described in 2.6.1 and 2.6.2. Drug additions were made 
in dimethyl sulphoxide (DMSO). For quantitative analyses, porphyrin 
retained in cells was determined by fluorimetry following solution in 
acid. Porphyrin which had been released into the medium Wcls first 
isolated by ion-exchange chromatography on Dowex columns and then 
measured by fluorimetry. Both these methods are described in sub­
section 2.6.4. For qualitative analyses, porphyrins in these samples 
were esterified and then separated by HFLC. The relative proportions 
of each were then calculated. The method used was as described in 
sub-section 2,3.4.
This section is composed of four sub-sections. The first of 
these presents a quantitative and qualitative comparison of the 
porphyrins retained by the cells and porphyrins released into the 
medium. The second sub-section investigates the quantitative effects 
of CBZ and CBZ-E on porphyrin synthesis and the third examines the 
qualitative effects of the same. The fourth and final sub-section 
sumnarises the results of this section.
7.3.1 QOANTITATTVE AND QUALITATIVE ANALYSES OF PORPHYRINS SYNTtffiSlZM 
BY CULTURED HUMAN LYMPHOCYTES
Before investigating the effects of drugs on porphyrin synthesis, 
quantitative and qualitative studies of the porphyrins produced by 
cultured human lymphocytes from ALA were made. As some of the
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porphyrin produced by the cells escapes into the medium, it was 
necessary to perform the analyses on both cells and medium. This 
sub-section makes a quantitative and a qualitative comparison of the 
porphyrins found in these different samples and is thus divided into 
two parts,
(i) Quantitative.analysis of pornhvrins in cells and in 
cell culture medium
The results of 3 studies are presented in table (42), The
table shows that although most porphyrin remains in the cells, a
considerable amount of the porphyrin produced is lost into the
medium. This represented 36, 30 and 25% of the total porphyrin
produced in studies 1,2 and 3 respectively, demonstrating that
there is some degree of variability in the quantity of
synthesized porphyrin lost to the medium. It would however be
correct to say that cells contained 2 to 3 times as much
porphyrin as was found in the medium. The reasons for this
variability will be discussed shortly.
(ii) Qualitative analvsis of oorohvrins in cells and in culture medium
The relative proportions of each of the porphyrins in the
mixture of porphyrins from cells and from samples of medium were
determined. Figure (30) shows typical chromatograms of the
porphyrin composition of cells and of medium. Table (43)
contains data frcxn three separate experiments. With regards
fig. (30), the most striking difference in porphyrin composition
of cells and of medium is that a considerable proportion of the
total pori^yrin in the latter was uroporphyrin (URO), whereas the
cells contained little or no URO. This would be expected
because URO in cells would be converted to coproporf*yrin (CX)PRO)
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TABLE (42)
QPAMTmTIVE ANALYSIS OF PORPHÏRIN SINTHESISED IN 
COLTORED HOMAN LYMPHOCYTES
STUDY No.
TOTAL PORPHYRIN 
IN CELLS
TOTAL PORPHYRIN 
IN MEDIUM
TOTAL PORPHYRIN 
PRODUCED
1 3.2 ± 0.4 1.8 ± 0.1 5.0 ± 0.3
2 3.7 ± 0.5 1.6 ± 0.1 5.3 ± 0.4
3 3.8 ± 0.5 1.3 ± 0.2 5.1 ± 0.6
Each value is the mean jt 1 S.D. for 4 measurements.
Results are presented as ng total porphyrin produced/10  ^oells/24 hours.
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B
XXMPARISON OF THE PORPHYRINS PODND IN CS2.S AND Df MEDIA FOLLOWING 
IN(X)BATION OF COLTORED HOMAN LYMPHOCYTES WITO ALA
Chromatogram A is a porphyrin extract from cells incubated with ALA. B 
is an extract from the medium these cells were growing in. Any porphyrin 
present in B must have been released from the cells. There is a clear 
difference in the porphyrin composition of the two extracts: in A the major
peak is PROTO, but in B the major peak is ÜRO.
A B
TIME PEAK % OF TOTAL TIME PEAK % OF TOTAL
3.16 PROTO 88.0 3.17 PROTO 38.4
4.46 COPRO 11.6 4.44 COPRO 21.2
5.14 PENTA TRACE 5.14 , PENTA TRACE
10.24 ÜRO 0.4 7.77 HEPTA TRACE
10.15 ORO 40.0
TAH.E (43)
SBALITATIVE ANALYSIS OF PORPHYRIN SÎNTHESIZED 
IN CULTURED HOMAN LBgHOCïTES
% PORPHYRIN COMPOSITION
STUDY 2-COOH 4-COOH 5-COOH 6-C0ŒÎ 7-COQH 8-COOH
CELLS 88 12 Trace
1
MEDIUM 42 20 - - - 37
CELLS 67 32 1
2
MEDIUM 5 29 - — 3 63
CELLS 80 17 _ _ 3
3
51MEDIUM 19 30
Results of HH.C analysis of porphyrins synthesized from ALA added to cultured 
human lymphocytes.
and protoporphyrin (PROTO). A further difference between the
two is that there was mudi more PROTO in cells than there was in
the medium. Again this was anticipated because COPRO in cells
would be converted to PROTO, but COPRO released into the medium
would not. Thus the relative amounts of COPRO and PROTO differ
between cells and medium. This is shown more clearly in table
(43) which also shows that althou^ the relative proportions of
these compounds may vary, the overall pattern is always the same:
considerable amounts of URO in the medium but little or none in
cells, and a higher PROTO/COPRO ratio in cells than in medium.
Discussion of Quantitative and onalitative aspects of porohvrin 
synthesis in cultured human Ivmohocvtes
These two sets of experiments have shown that, following
incubation of mitogen-stimulated lymphocytes with ALA, there are
quantitative and qualitative differences in the porphyrins found in
cells and in the medium. Furthermore the results prove that these
cells have all the enzymes necessary to synthesize PROTO from ALA.
In both sets of experiments there were differences in, for example,
the fraction of total porphyrin which was in the medium and the
proportions of the individual porphyrins. These differences can only
be attributed to slightly different relative activities of the enzymes
in each sample of lymphocytes. Having established these basic
results, the following sub-sections investigate the effects of CBZ and
CBZ-E on porphyrin synthesis.
2 0 0
y^XTATIVS ANALYSIS Qp THE EFFECTS OF cbz awd hrz-p; nf^ 
fOWPYRIN SYNTHESIS IN CULTURED HUMAN LVf^ HQCYTRS!
This sub-section investigated the effects of CBZ and CBZ-E on the 
quantities of porphyrin produced from added ALA in mitogen-stimulated 
lymphocytes.
In these experiments, cells were exposed to CBZ or CBZ-E at 
concentrations of 30mg/l and 15mg/l respectively for 96 hours prior to 
setting up porphyrin synthesis as described (2.6.4). The results of 
quantitative porphyrin determinations and ALA-D activities in these 
experiments are presented in table (44). There are several 
interesting results. The first of these is that both CBZ and CBZ-E 
significantly reduced the total amounts of porphyrin formed in both 
cells and in medium. This effect is probably due to the effects of 
these drugs on ALA-D activity. Since the starting point for 
porphyrin synthesis in these experiments was ALA, then it follows that 
the amounts of subsequent intermediate for porphyrin synthesis will be 
dependent solely on the levels of ALA-D activity. Examination of 
total poriAiyrin produced reveals that in the case of CBZ where ALA-D 
activity was only 83$ of control values, total porphyrin production 
was 79$ of control values, which supports the foregoing explanation. 
However with CBZ-E, although porphyrin synthesis was reduced, it was 
not depressed to the same extent as was ALA-D activity, treated values 
being 54$ and 23$ of control values respectively. This is almost 
certainly due to the presence of CBZ-E in the cells and in the medium, 
because as described in the previous section, CBZ-E absorbs light of 
the wavelengths used to examine porphyrins and part of the emission 
spectrum falls in the range at which porphyrin fluoresence is 
measured. However the effect is not as marked in this instance
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TABLE (M)
gOADTITATITE ANALYSIS OF THE EFFECTS OF CBZ AND 
CBZ-E ON PORPHCTIN STOHESIS IN CDLTPRED HDMAH LMPHOCÎTES
ADDITION
PORPHYRIN 
IN CELLS^
PORPHYRIN 
IN MEDIUM^
TOTAL
PORPHYRIN
PRODUCED^
ALA-D
ACTIVITYb
DMSG
CBZ
CBZ-E
3.7 ± 0.5 
3.1 ± 0.1 
2.0 + 0.1
1.6 ± 0.1 
1.1 ± 0.1 
0.9 ± 0.1
5.3 + 0.4 
4.2 ± 0.1 
2.9 ± 0.1
100 ± 5.3 
83 ± 5.8 
22.6 ± 4.1
Values are mean ± 1 S.D. for 4 determinations
CBZ and CBZ-E were present at concentrations of 30mg/l and 15mg/l 
respectively.
^ units are ng porfdiyrin produced/10^  oells/24 hours 
b ALA-D activities were expressed as percentages of control activities.
because the fluoreence reaüL,%s of the porp%r,,k produced In this 
assay were much higher than those found in the PBG-D assay.
onsequently the drug does not make such a large contribution to the 
overall fluorescence.
To further investigate this, the effects of a range of CBZ-E 
concentrations on both ALA-D activity and the quantities of porphyrin 
synthesised were examined. The results are shown in table (45). As 
before, ALA-D activities are presented as * of control activities and 
the quantities of porphryin produced are also shown as percentages of 
controls. The results show that the total quantity of porphyrin 
produced was reduced following exposure to CBZ-E. This was achieved 
by reduction in the amount synthesized in both cells and medium. 
Furthermore, the higher the concentration of CBZ-E, the less porphyrin 
was produced and less ALA-D activity remained. Both did not seem to 
be affected to the same extent: the more CBZ-E added, the greater was 
the discrepancy between the two sets of data (see table 45). This 
would suggest that CBZ-E was indeed interfering with the determination 
of the amount of porphyrin produced.
Conclusions on a quantitative analysis of the effects of CBZ 
and CBZ-E on porohvrin synthesis in cultured himian ] vmphr>nvt.f*.«4
Both CBZ and CBZ-E reduced the amount of porjrfiyrin synthesized in 
mitogen-stimulated lymphocytes. This effect was a likely consequence 
of the loss of ALA-D activity: there was a good comparison between
the effects of CBZ on ALA-D and the effects on porphyrin synthesis.
No such comparison was found with CBZ-E due to the interference of 
this compound with the fluorimetric quantitation of porphyrins. This 
resulted In an overestimation of the porphyrin content in any sample 
in which CBZ-E was present.
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.SDÆaXTATIVE ANALYSIS OF THE Ej-'i-KCTS OF CBZ AND CBZ-f nw 
BCRPHYRXN synthesis IN CULTURED HUMAN LYMPHOCYTES
The effects of CBZ and CBZ-E on the relative proportions of the 
individual porphyrins produced from ALA were investigated. The 
porphyrin ccxnposition of both medium and cells were studied. The 
results of one such experiment are shown in table (46). CBZ or CBZ-E 
were present at concentrations of 30mg/l and 15mg/l respectively for 
96 hours prior to commencement of the assay of porphyrin synthesis.
The assays were performed in duplicate and therefore the results 
shown in the table are mean values.
There was very little difference in the porphyrin canposition of 
cells treated with CBZ or CBZ-E when compared to that of control 
cells. However analysis of the porphyrins present in the medium 
revealed some changes with respect to controls. The changes were 
slight following CBZ treatment, but were great following CBZ-E 
treatment. Media to which CBZ-E had been added esdiibited a reduced 
percentage of ÜRO, but increased percentages of COPRO and PROTO when 
compared to controls. This was expected because, due to the reduced 
levels of ALA-D activity found following exposure of cells to CBZ-E, 
there would be fewer pathway intermediates. Consequently the cells 
would have been able to convert a greater proportion of the DRO 
produced to COPRO and PROTO. This would have meant that less ÜRO was 
available to diffuse into the medium, leading to an increase in the 
percentages of COPRO and PROTO. The experiment was repeated and
similar results were obtained.
The unchanged porphyrin composition in cells treated with the 
drug In the face of reduced porphyrin synthesis in the same cells
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indicates two things. Firstly, the reduction in porphyrin synthesis
is indeed due to loss of ALA-D activity, since a reduction in the
activities of any of the other enzymes in the pathway would result in
changes in the porphyrin composition. Secondly, no change in
porphyrin composition was found in this system following treatment
with CBZ and CBZ-E, but changes were found in the urinary excretion
pattern of these porphyrins during the initial stages of treatment in
man, (see sub-section 4.3.2 and Rapeport £i. 1984). This
difference could only be due to the one part of the pathway not
required for the synthesis of these porphyrins in culture but required
■HI YÎYQy namely, ALA-nS. This finding supports the theory put forward
in sub-sections 3.2.2 and 4.3.1, that the increased % DRO in human
urine during the initial stages of CBZ treatment was due to the very
hi^ levels of ALA-8 activity produced at that time.
Conclusions on a qualitative analvsis of the effects of CBZ 
and CBZ-E on oorohvrin synthesis in cultured human lymphocytes
There were no qualitative differences in porphyrin found in 
control and CBZ or CBZ-E treated cells although the quantities of 
porphyrins produced were reduced by the drugs, suggesting that 
porphyrin synthesis was indeed reduced as a consequence of ALA-D 
inactivation as was proposed in subsection 7.3.2. This further 
suggests that the altered porphyrin excretion profile found in man in 
the initial stages of CBZ treatment was due to derepression of ALA-S. 
Examination of the porphyrins released into the medium revealed a 
reduction in the DRO fraction following treatment of cells with CBZ-E. 
This could be explained by the action of CBZ-E on ALA-D.
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7.3.4 SOHKABï OF SECTION 7.1
This section has shown that there are quantitative and 
qualitative differences between the porphyrin found in cells and 
porphyrin released into the medium following incubation of mitogen- 
stimulated human lymphocytes with ALA. Furthermore, both CBZ and 
CBZ-E reduced the quantities of porphyrin synthesized and this was 
linked to the inactivation of ALA-D caused by these two compounds. 
As was found in previous sub-sections, the presence of CBZ-E can 
interfere with quantitative porphyrin determinations. Qualitative 
investigations of the effects of CBZ and CBZ-E on porphyrins produced 
frcM ALA by mitogen-stimulated lymphocytes revealed no changes in the 
porphyrins in cells but changes in the porphyrin released into the 
medium, most notably a reduction in the ÜRO fraction. This was 
particularly so in the case of CBZ-E, and was a likely consequence of 
reduced ALA-D activity. The fact that the porphyrin composition in 
cells was unchanged, althou^ the quantities produced were taken as 
evidence that the quantity of porphyrin produced in this system was 
indeed dependent on the levels of ALA-D activity. The same 
observation was also used to suggest that the altered porphyrin 
excretion profile found in man in the initial stages of CBZ treatment 
could only be due to the effects of the drug on the one enzyme not 
studied here, namely, ALA-S.
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7.4 SUMMARY OF CHAPTER 7
This chapter examined the effects of CBZ and CBZ-E on several 
aspects of ha@n biosynthesis in mitogen stimulated cultured human 
lymphocytes. Both compounds were shown to cause an irreversible 
reduction in the levels of ALA-D activity which was due to 
inactivation of existing enzyme and not to a reduced rate of 
synthesis. Althou^ it is likely that the mechanism by which enzyme 
activity was lost here is applicable to the in vivo situation, 
activity was lost at a much greater rate. This is discussed further 
in sub-section 9.1.4. Phenobarbitone and sodium valproate did not 
siffect ALA-D activity, suggesting that inactivation of the enzyme was 
a specific property of CBZ and CBZ-E. Inactivation of ALA-D was 
achieved without detectable metabolism of CBZ or CBZ-E. PBG-D 
activity was unaffected. Treatment with either CBZ or CBZ-E failed 
to produce a qualitative change in the porphyrins synthesized in the 
cells from ALA, though there were quantitative changes. This 
observation was taken as evidence that the alterations in urinary 
porphyrin excretion found in 4.3.1 and reported by Rapeport At. Ai. 
(1984) in the initial stages of CBZ treatment in man were due to 
derepression of ALA-S.
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CHAPTER 8
J3i,.yiTR0 METABOLISM OF CBZ: EFFECTS ON ALA-D AnTTVTTY
In preceding chapters it was shown that treatment with CBZ 
resulted in an irreversible reduction in ALA-D activity in both man 
and the rat. Further experiments revealed that the drop in activity 
was due to inactivation of the enzyme rather than a modification of 
activity or a reduction in the rate of synthesis. This inactivation 
was not the result of a direct action of CBZ itself or the metabolites 
CBZ-E and H2 CBZ. Results from cell culture studies showed that both 
CBZ and CBZ-E caused inactivation of ALA-D in mitogen-stimulated human 
lymphocytes with no detectable metabolism of either compound. There 
are two possible explanations for this last observation: (i) CBZ and
CBZ-E underwent some form of bio-activation in living cells which 
produced a species capable of inactivating ALA-D; or (ii) CBZ-E 
inactivated ALA-D through sane indirect mechanism, the facilities for 
which are only found in living cells. Two possible levels at which 
CBZ treatment could have indirectly affected ALA-D activity which can 
be excluded at this stage are (a) effects at the level of synthesis 
and (b) effects on glutathione concentration. This chapter was 
concerned with the effects of metabolizing CBZ, in the presence of 
purified bovine liver ALA-D, on the activity of the enzyme. These 
experiments were designed to test the hypothesis that a bio-activated 
form of CBZ inactivates ALA-D. Ihis is of interest because other 
workers have reported that trichloroethylene and bromobenzene, two 
offlnpounds which irrarersibly inhibit ALA^ iujtim but not when added 
to purified enzyme, can inhibit the enzyme injütca when they are
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metabolized by purified microsomes containing mixed function oxidase 
(m.f.o) activity (Fujita At al, 1984; Koizumi At âL 1984). The results 
of these studies suggested that some transient metabolites or 
activated states of the chemicals were responsible for the 
inactivation of ALA-D. This chapter looks at the possibility that 
this is the case with CBZ.
All of the necessary procedures and experimental details for the 
studies described in this chapter are found in section 2.8 but the 
basic details were as follows. CBZ was incubated with purified 
microsomes containing m.f.o. activity and purified bovine liver ALA-D. 
To drive the m.f.o. system it was necessary to add NADPH as a source 
of reducing power. Without this the m.f.o. system is inactive. 
Samples were tedcen from the incubation vessel at indicated times and 
ALA-D activity measured. Estimations of enzyme activity were 
performed in quadruplicate. In the sections which follow a control 
incubation m a^riR one in which there is no metabolism of CBZ taking 
place. This was usually achieved by cxnitting NADPH.
The chapter is composed by 4 sections. The first of these 
investigates if in fact CBZ is metabolized by the system and what 
effects this may have on ALA-D activity. The second looks at the 
nature of the effect of CBZ metabolism on ALA-D. The third examines 
the effect of using CBZ-E in the incubations in place of CBZ and the 
fourth and final section summarises the chapter.
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THE. EFFL'CTS QF IN VITRO CBZ METABCLTRM nw PURIFTRD AT.A-D _
SOME INITIAL STUDIES -- ------
This section presents the results of initial investigations into 
the jin..YltrQ metabolism of CBZ and the effects of this on purified 
ALA-D and consists of 5 sub-sections. Four of these are concerned 
with various aspects of CBZ metabolism and in the effects thereof on 
ALA-D. The fifth summarises the section.
8.1.1 IN VITRO METABCLISM OF CBZ
Before investigating the effects of CBZ metabolism on purified 
ALA-D activity, it was necessary to establish if metabolism of the 
drug was taking place. To this end, rat liver microsomes, CBZ and 
NADPH were added to a flask and incubated in a shaking water bath set 
at 37°C as described in sub-section 2,8.3. Aliquots were removed 
from the incubation mixture at 0, 0.5, 1 and 2 hours after initiation 
of the reaction and CBZ and its metabolites extracted and analysed by 
HPLC using the method described in sub-section 2.4.2. Fig. (31) shows 
the results of two such analyses: one at the start of the incubation
and one after 1 hour. It is clear from examination of these results 
that the above system generates several distinct metabolites of CBZ, 
the only identifiable one being CBZ-E. The nature of the other 
products is unknown, but the relative amounts of each appeared to vary 
in a randcxn fashion as the incubation progressed, sug^sting that 
they were unstable. It was therefore not possible to assign even 
arbitrary values to these species. However it is unequivocal that 
scxne form of metabolism or activation of CBZ occurs. The effects of 
this on purified ALA-D activity are investigated in the following sub­
section.
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CBZ was metabolized by the system described, resulting in the 
production of several unidentified, unstable ccxnpounds in addition to 
small quantities of CBZ-E.
8.1.2 Df VITRO METABOLISM OF CBZ: EFFECTS OW ALA-D ACTTVTTY
In the previous sub-section it was established that CBZ was 
metabolized by the In vitro system described. This sub-section 
examined the effects of this metabolism on purified bovine liver 
ALA-D. For the experiment two flasks were prepared. Each contained 
CBZ, NADPH and DTT, but only one (the test flask) contained 
microscmes. The other (the control flask) contained an equivalent 
amount of buffer. Details of the actual quantities used are listed 
in sub-section 2.8.3. DTT was included in the incubation to 
stabilize ALA-D. Aliquots were removed from the flasks 0, 0.5, 1,
1.5, 2 and 3 hours after the initiation of reaction and assayed for 
ALA-D activity. The results, expressed as percentages of activity at 
zero time, are shown in fig. (32).
In the control flask (the one lacking microsomes) there was a 
progressive loss of activity after the incubation had been going for 1 
hour. This loss of activity was found in controls in all subsequent 
studies whether microsomes, CBZ or NADPH were added alone or in a 
combination of any two of these. However when all 3 were present, as 
was the case in the test flask, activity was lost at a faster rate 
than in controls. This indicates that metabolism of CBZ caused 
inactivation of ALA-D. Another feature of interest is that in the 
later stages of the incubation, the rate of loss of ALA-D activity in 
the test flask seemed to approach that of the control. This suggests
2 1 0
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FIG. (32)
THE EFFECTS OF 
IN VITRO METABOLISM OF CBZ ON ALA-D ACT1V1IÏ
The figure shows the % of the initial ALA-D activity remaining 
0,0.5,1,1.5,2 and 3 hours after starting the experiment. The control lacked 
NADPh, therefore oould not metabolize CBZ. The test flask contained all the 
requirements for CBZ metabolism. Although activity was lost from the 
control flask, it was lost at a greater rate from the test flask, indicating 
that metabolism of CBZ caused inactivation of ALA-D.
that the metabolism of CBZ falls off with time. Unfortunately, due to 
the inability to quantify the products of the system, it was not 
possible to verify this. However analysis of the cytP450 content of 
the microsomes after 3 hours incubation revealed that less than 10$ of 
the original haemoprotein concentrations remained. Ihe mechanism 
whereby cytP450 was lost is not known.
Although these results show that metabolism of CBZ caused 
inactivation of ALA-D, they provide no evidence for the effect being 
due to CBZ or a product of the action of the m.f.o. system on the 
drug. For instance, it is possible that ALA-D was inactivated by 
reduced molecular oxygen, a highly reactive species produced by the hepatic 
m.f.o. system in the course of oxidation of substrates of the system. 
Also, the results do not show that the effect is specific for ALA-D. 
These two possibilities are examined in the following two sub­
sections.
Conclusions on the effects of in vitro CBZ metabdligffl 
on ALA^D activity
Although ALA-D activity was lost from the control, activity was 
lost at a faster rate from the test flask in which CBZ was being 
metabolized, but only over the first 1.5 - 2 hours. Thereafter 
activity was lost at the same rate as in controls. This may be 
explained by a reduction in the cytP450 content of the microsomes. 
The results do not confirm that the observed inactivation of ALA-D was 
due to CBZ metabolism in itself or that the species responsible for
inactivation was specific for ALA-D.
8.1.3 IN VITRO METABOLISM OF PRIMIDONE; EFFECTS QN ALA-P ACTiVIII
The aim of this sub-section was to determine if the loss of ALA-D 
activity found in the course of CBZ metabolism was a feature unique to
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FIG. (33)
■GOMPARISQN OF THE EFFECTS OF IN VITRO METABQLiai_QF CBZ AW .ÇBZr£
nw ALA-D ACTIVITY
% e  figure compares the effects of metabolism of CBZ and CBZ-E on the % 
of the initial ALA-D activity remaining 0.5» 1, 1.5, 2, 2.5 and 3 hours after 
starting the experiment. For each compound there was a control flask with 
no capacity for drug metabolism and a test flask with an active drug 
metabolizing system. CBZ and CBZ-E behaved identically: the activity in
both test flasks was lost at a greater rate than fhom the control flasks. 
The rates of loss of activity in both control and test flasks were the same
for both compounds.
CBZ. As stated at the end of the preceding section, it is possible 
that inactivation could have been caused by^molecular oxygen, a h i g h l y  
reactive species released as a by-product of MFC activity. If this 
was the case, then the metabolism of any drug by this in vitro system 
should result in the inactivation of ALA-D. Primidone was chosen to 
test this hypothesis because earlier results indicated that it did not 
cause inactivation of hepatic ALA-D in rat (results not shown) and 
that phenobarbitone, one of its metabolites, did not cause a loss of 
ALA-D in cultured human lymphocytes or loss of erythrocyte ALA-D in 
man. A further reason was that it was simple to check if this drug 
was metabolized by the m.f.o. system since both primidone and 
phenobarbitone can be identified using the same extraction and HFLC 
system as was used for CBZ. (See sub-section 2.4.2).
Two flasks were prepared. The control contained microsomes, 
ALA-D and primidone, the test contained all of these plus NADPH. 
These were incubated at 37^ 0 in a shaking water bath. The actual 
concentrations used are listed in methods sub-section 2.8.3. ALA-D 
activities in each flask were measured at the start of the incubation 
an<i after 2 hours. Aliquots were also analysed by HFLC. In the 
control flask, after 2 hours, mean ALA-D activities were 85$ of the 
activities at zero time and there was no detectable metabolism of 
primidone. In the test sample, there was complete metabolism of 
primidone, but after 2 hours mean activities were 86$ of activities at 
zero time. This shows that ALA-D activity is not lost as a 
consequence of the metabolism of any drug but is a specific property 
of CBZ. After two hours the cytochrome P450 content of the 
microsomes was only 23* of the starting concentrations. This
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f i g. (3%)
TM VTTBO OF ÇBZ-E
is a chromatogram of an  ^ the peaks appearing near the
of these co«fK«»5s Is uoknown.
Peak RfTWnti mn time
A £
CBZ-E 4.87 4.83
I.S. 13.08 13.04
indicates that the loss of cyt P450 is due to the incubation 
conditions since this was also shown to be the case Wien CBZ was added 
to the system (8,1,2).
Conclusions on effects of the in vitro metabolism of 
primidone ALA-P .agtivity
Metabolism of primidone by the in vitro drug metabolizing system 
described did not affect ALA-D activity whereas metabolism of CBZ did. 
Therefore the effect is not due . to the reduc.+iof\ of molecular oxygen 
or some other product of drug metabolism but is a specific property of 
CBZ.
8.1.4 INVESTIGATIONS INTO THE SPECIFICITY OF THE INACTIVATIPIi 
OF AT.A-D PROPgCED DURING IN VITRO METABOLISM OF ÇBZ
This sub-section investigated if the species responsible for the 
inactivation of ALA-D during the in vitro metabolism of CBZ was 
specific for the enzyme. If it was not, then the inclusion of 
supplementary protein In the incubation should reduce the extent of 
the inactivation. On the other hand, if it was specific, then the 
inclusion of other proteins would make no difference. The 
experiments were performed in the usual way except that bovine serum 
albumin (BSA,0.5mg/ml) was added to some of the incubations. The 
results are presented in table (47). The results from flasks 1 and 2 
confin. the results of sub-section 8.1.2: an accelerated loss of
ALA-D activity was observed when metabolism of CBZ occurred. The 
lower half of the table shows the results from flasks 3  and 4 which 
BSA. These are no different from the values obtained from 
flasks 1 and 2. This shows that the presence of BSA offered no 
protection against inactivation of ALA-D, confining that the species
213
TABLE (47)
THE EFFE(7rS OF ADDED BSA CM THE EXTEMT OF ALA-D INA(n'IVATI(M 
POKING THE m  VITRO METABOLISM OF CBZ
Flask No.
DURiVTION OF INCUBATION (HRS)
NADHi
(InM)
BSA
(0.5mg/ml)0 0.5
i
1.0 1.5
1 100 93 85 77
2 100 92 81 70 X
3 100 95 89 79 X
4 100 92 81 69 X X
Results were expressed as percentages of Initial activity remaining after a 
fixed time.
Flasks 1 and 3 were controls. Since NADffl was omitted, no metabolism of CBZ 
could occur.
Flasks 3 and 4 contained bovine s e ^  übumin to investigate if this afforded 
ALA-D any protection against inactivation.
X = present in the incubation
. . ...
\
generated during in vitro metabolism of CBZ which is responsible for 
the loss of ALA-D activity has some specificity. However, it cannot 
be said to be absolutely specific on the basis of these results.
the, specificity of the inactivation nf ALA-4) 
dwzing in vitro metabolism nf m?.
lliis sub-section has shown that the species responsible for the 
inactivation of ALA-D during in vitro metabolism of CBZ, has some 
degree of specificity for the jenzyme as the inclusion of another 
protein (BSA) in the incubation did not reduce the extent of the 
inactivation.
8.1.5 SOmARY OF SECTION 8.1
This section presented the results of initial studies on the 
effects of in. vitro CBZ metabolism on ALA-D activity. Purified 
microscxnes were shown to be capable of metabolizing CBZ to a number of 
products, including CBZ-E. The nature of these other compounds was 
not known and they appeared to be transient. When ALA-D was 
incubated with rat liver microsomes, NADPH and CBZ such that 
metabolism of CBZ took place, some inactivation of the enzyme 
occurred. Althou^ in the course of these incubations some ALA-D 
activity was lost from controls, the amount of activity lost from 
flasks in which CBZ was being metabolized was always greater. 
Further experiments showed that inactivation of ALA-D linked to drug 
metabolism did not occur with primidone, implying that this has a 
particular property of CBZ. It was also shown that the species 
responsible for the inactivation of ALA-D was specific for that 
enzyme, although it was not possible to say whether or not this
specificity was absolute.
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In conclusion, in vitro metabolism of CBZ results in the 
generation of a species, the nature of which is unknown, which 
irreversibly inactivates ALA-D. In the following section, further 
investigations on the nature of this inactivation are presented.
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8.2 FURTHER INVESTIGATIONS ON THE INACTIVATION OF ALA-D PRODUCED 
DURING IN VITRO METABOLISM OF CBZ
This section investigated several aspects of the inactivation of 
ALA-D which occurs during the in vitro metabolism of CBZ. It is 
divided into 3 sub-sections. The first of these examines the effect 
of having different concentrations of microsomes present in the 
incubation and also investigates if the presence of DTT in the 
incubation protects the enzyme against inactivation. The second sub­
section attempts to evaluate if Zn^ "^  afforded any protection against 
inactivation and the third summarises the results of this section.
8.2.1 IN VITRO METABOLISM OF CBZ : EFFECTS OF DTT AND DIFFERENT
CONCENTRATIONS OF MICROSOMES ON THE EXTENT OF ALA-D INACTIVATION
Studies in the previous section revealed that ALA-D activity was 
reduced following incubation of the enzyme with a CBZ metabolizing 
system. In those studies DTT was present to stabilize the enzyme.
This sub-section investigates the effects of emitting DTT frcm 
the incubation. If the omission of DTT resulted in an increased loss 
of ALA-D activity, it would infer that inactivation was occurring at a 
sulphydryl group. As part of the same experiment, two different 
amounts of microsomes were used to determine if the extent of 
inactivation was related to the quantity of m.f.o. activity present. 
The quantity of microsomes added is expressed as nmoles cytP450 added. 
Except for the change in the amount of microsomes added and the 
omission of DTT, the incubations were set up exactly as described in 
sub-section 2.8.3. ALA-D activities were measured at the start of 
the incubation period (zero time) and after two hours in a shaking 
water bath at 37^ C. Results were expressed on the activity remaining
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after 2 hours as a percentage of the activity at zero time. The 
results are presented in table (48). Flask No.1 was the control as it 
did not contain NAD PH and therefore could not metabolise CBZ. The 
results fran this flask show that in the absence of CBZ metabolism» 
ALA-D activities after 2 hours were 8256 of the activities at zero 
time. The results from flasks numbers 2 and 3 show that in the 
absence of DTT, even if all the components necessary for metabolism of 
CBZ were present, there was very little further inactivation of ALA-D 
compared to the control. However, in flasks numbers 4 and 5, 
identical to numbers 2 and 3 respectively except that DTT was present, 
activity was reduced by a further 10 to 20$. This shows that, 
contrary to expectation, the presence of DTT in the microsomal 
incubation actually promoted inactivation of ALA-D. This can only be 
because DTT was required for the maintenace of some component of the 
microsomal MFC system. For this reason it is not possible to assess 
whether or not DTT protects the enzyme against the inactivation 
produced during in vitro metabolism of CBZ.
As stated earlier, this experiment also investigated whether the 
extent of inactivation was related to the amount of microscmal MFC 
activity present. Examination of the results frcxn flasks numbers 4 
and 5 in table (48) reveals that the addition of microsanes containing
2.5 and 5 nmoles of cytP450 caused ALA-D activities to be reduced to 
73$ and 63$ of the activities or zero times respectively. When these 
reductions in activity are compared to the control in which 82$ of the 
original activity remained, it can be seen that CBZ metabolism 
produced additional reductions in activity of 9$ and 19$ for 
incubation containing 2.5 and 5 nmoles of cytP450 respectively. This
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IN VITRO METABCLISM OF CBZ: EFFECTS OF DTT AND DIFFERENT 
CONCENTRATIONS OF MICROSOMES ON THE EXTENT OF ALA-D INACTIVATION
Flask No.
% INITIAL 
ALA-D ACTIVITY 
REMAINING AFTER 
TWO HOURS
i
nmoles cyt P450 
added
DTT
(2nM)
NADPH
(1nM)
1 82 5 X
2 80 2.5 X
3 83 5 X
4 73 2.5 X X
5 63 5 X X
Flask 1 was the control since no metabolism of CBZ could occur.
Flasks 4 and 5 were compared to flasks 2 and 3 respectively to investigate if 
the presence of DTT afforded ALA-D any protection against inactivation.
X = present in the incubation.
shows that twice as much MFO activity results in twice as much 
inactivation.
Conclusions of sub-section 8.2.1
DTT was shown to be essential for inactivation to occur to any 
measurable degree, possibly because some component of the microsomal 
m.f.o. system is sensitive to loss of activity throu^ oxidation of 
thiol groups. The possible protective role of DTT on the enzyme,
I
therefore, could not be assessed. A correlation was found between 
the quantity of microsomes added and the extent of ALA-D inactivation.
8.2.2 IN VITRO METABCLISM OF CBZ; THE ^ EFFECT OF Zn^* IONS 
ON THE EXTENT QFJLA-D INACTIVATION
This sub-section investigated what effect the presence of Zn^"*" 
ions has the extent of the inactivation of ALA produced during the in 
vitro metabolism of CBZ. If, in the presence of Znf*, less ALA-D 
activity was lost following incubation with a CBZ metabolizing system 
than was lost in the absence of these ions, it would suggest that the 
species responsible for inactivation was attacking the enzyme at a 
zinc binding site. For each e3q>eriment two control flasks and 2 test 
flasks were prepared as described in sub-section 2.8.3. To one of 
each of these, Zn^* ions were added as ZnCl2  give a final 
concentration of 0,5mM. ALA-D activity was measured at the start of 
the experiment and after incubating the flasks for 2 hours in a 
shaking water bath at 37°C. Despite repeating this experiment 
several times, no conclusive results could be obtained. In some 
experiments the presence of Zn^"*" ions seemed to prevent any loss of 
activity from both control and test incubations even althou^ the
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results from the other two flasks whid'i did not contain Zn^* were the 
same as was found in sub-section 8.1.2. i.e. loss of activity in 
control, but greater loss of activity in the test sample in which CBZ 
was being metabolized. In other experiments, activity was lost from 
containing control and test incubations at the same rate, and in 
yet others activity was lost from Zn^* containing test incubations at 
a faster rate than it was lost from Zn^+ containing control 
incubations. In both of these circumstances however, activity was
i
lost at a slower rate than it was in the corresponding incubations 
which lacked Zn^"*", The reasons for this extensive variation in the 
effects of Zn^* on ALA-D activity in the presence of a CBZ- 
metabolising system are unknown.
Conclusions on the effect of Zn^* ions on the extent of ALA-D 
inactivation produced during in vitro metabolism of CBZ
No conclusions can be drawn about whether or not Zn^* protects
against inactivation of ALA-D by a species generated during the
in vitro metabolism of CBZ.
8.2.3 SDtflARY OF SECTIW 8.2
In this section it was shown that the extent of ALA-D 
inactivation was dependent on the quantity of m.f.o. activity (as 
judged by the amount of cytP450 present) added to the incubation. 
Experiments aimed at determining the nature of the site on the enzyme 
at which the event leading to inactivation occurs were also performed. 
However, no conclusions can be made as to whether or not the presence 
of DTT or Zn^'*' ions offered any protection against inactivation by the 
species generated in the course of the incubations.
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3 m i l R Q  METABOLISM OF CBZ-E: EFFECTS ON ALA-D ACTIVITY
In section 7.1, it was shown that the addition of CBZ or CBZ-E to 
cultures of mitogen stimulated human lymphocytes produce inactivation 
of ALA-D in the cells, and furthermore, that CBZ-E was much more 
effective than CBZ at inactivating the enzyme. The effect of 
incubating CBZ-E with the drug metabolizing system on ALA-D activity 
was investigated. The aim of the experiment was to determine if under 
these conditions CBZ-E would cause inactivation of ALA-D and then to 
compare the results with those obtained with CBZ. Four flasks were 
set up: two control flasks containing microsomes and ALA-D auid two
test flasks containing microsomes, ALA-D and NADPH. One control 
flask and one test flask contained CBZ (50mg/l) and the others 
contained CBZ-E (50mg/1). The flasks were incubated at 37®C in a 
shaking water bath. Aliquots were removed at 0, 0.5, 1, 1.5, 2, 2.5 
and 3 hours and the percentage of ALA-D activity remaining determined. 
The results are presented in fig.(33) and show that in both controls 
(containing CBZ or CBZ-E) activity was lost at the same rate and that 
in both tests activity was lost at the same rate, thou^ the rate of 
loss of activity was faster in these than it was in controls. 
Aliquots from the reaction mixture were also analysed by the HFLC 
method described in sub-section 2.4.3 to investigate if any metabolism 
of the epoxide took place. The resultant chromatograms showed the 
appearance of several new peaks following incubation of the epoxide 
with microsomes and NADPH but not with microsomes alone. Two of 
these chromatograms are shown in fig. (34). The nature of these 
products is unknown.
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One puzzling feature of these results is that CBZ-E caused the
same amount of inactivation of the enzyme at the same rate as CBZ but
in cultured lymphocytes, CBZ-E caused much greater inactivation more
quickly than CBZ. The reasons for this difference are unknown. It
may be that CBZ and CBZ-E were activated in different ways in the two
different systems, or it may be that CBZ-E was activated to the same
extent in the drug metabolising system as it was in cell culture, but
that greater activation of CBZ occurs in the drug metabolizing system.
Whatever the mechanism, it is clear that CBZ-E is activated or
metabolised by the in vitro drug metabolising system used for these
studies and this results in inactivation of ALA-D.
SQQclugjpDs i?D .tlie..-gff,ect? in xitiza-iaataboiism of CBZ-g gn 
ALA-D activity
CBZ-E was metabolized to unknown products by the purified 
microsomes used in these studies, causing inactivation of ALA-D 
present in the incubation at the same rate as was found with CBZ.
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SUMMARY OF CHAPTER 8
This chapter investigated if metabolism or bioactivation of CBZ 
by purified microsomes containing m.f.o. activity would result in the 
inactivation of ALA-D. This was indeed the case, although the 
species actually responsible for the inactivation of the enzyme 
remains unknown. The effect occurred only with CBZ and was not 
caused by some by-product of the m.f.o system. The inactivating 
species reacted selectively ; with ALA-D. The extent of the 
inactivation of ALA-D was related to the levels of microsomal m.f.o. 
activity present in the incubation. Further experiments which 
attempted to elucidate the nature of the site upon which the 
inactivator acts produced no conclusive results. Surprisingly, CBZ-E 
was also transformed to some extent by this in vitro drug metabolizing 
system and this also resulted in inactivation of ALA-D. However, in 
contrast to the results of Chapter 7, CBZ and CBZ-E were equally 
effective at inactivating ALA-D. The reasons for this can only be 
speculative, but it is probable that the inactivating species produced 
here were different from those produced in the lymphocyte culture 
systan.
The most significant conclusion of the chapter is that the 
microsomal m.f.o. system acted on CBZ and CBZ-E to generate a 
metabolite or activated intermediate which inactivated ALA-D. It is 
likely that this is the mechanism by which ALA-D was inactivated in 
rat liver, but whether the loss of activity in erythrocytes in man was 
due to activated species from the m.f.o. system or from other 
metabolically active cells (which presumably would respond in the same 
way as cultured lymphocytes) is unknown.
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CHAPTER 9 
SUMMARY AND GENERAL DISCUSSION
This thesis was primarily concerned with determining and 
explaining the effects of the anticonvulsant drug carbamazepine on 
haem biosynthesis in man, although the effects of sodium valproate, 
idienytoin and phenobarbitone were also studied. Initial studies were 
concerned with the long-term effects of these drugs on the pathway. 
These were followed by more detailed investigations into the effects 
of CBZ itself. This final chapter summarises and discusses the 
significance of all of these investigations before assessing if the 
objectives of this thesis, described in section 1.4, were attained.
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9.1 mmmY and discussion of results
In the discussion of these results, two issues must be taken into 
consideration. Firstly, althou^ the effects of drugs were studied 
in different systems, the primary aim of all of the experiments was a 
fuller understanding of the effects of the drugs on haem biosynthesis 
in man. Secondly, the effects of the drugs on haem biosynthesis in 
peripheral blood cells in man were assumed to be representative of the 
effects on haem biosynthesis in the liver, the major site of haem 
biosynthesis in the body.
The effects of each of the drugs studied on haem biosynthesis are 
now discussed.
9.1.1 PHENOBARBITQNE
Only a small number of patients taking phenobarbitone (PB) were 
studied and consequently the results are limited, but no effect was 
found on ALA-D, PBG-D or URO-D activities. Whether or not chronic 
derepression of ALA-8 occurs, as was found with VPA and CBZ, was not 
assessed. However, it is well known that PB is a very potent inducer 
of the m.f.o. system and would therefore be expected to cause dironic 
derepression of the enzyme.
9.1.2 PHEWrrOIN
The results of all enzyme analyses in patients taking phenytoin 
were no different from controls, although there was a sli^t change in 
the urinary excretion of PBG. However no definitive statements on 
the effects of long term phenytoin therapy on haem biosynthesis can be 
made because of the low plasma levels of the drug in the patients 
studied. The fact that these plasma concentrations were much lower
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than expected from the supposed dose suggests a lack of canpliance in 
these patients.
9.1.3 SODIUM VALPROATE
The effects of sodium valproate (VPA) are discussed under 
individual headings.
Æ A -g
ALA-S activity was increas^ during long-term treatment with VPA. 
It was also found that short-term treatment with VPA produced 
increases in ALA-S activity. The mechanism by which most drugs 
increase ALA-S activity is through an increased haem requirement for 
the de novo synthesis of cytP450 which is usually required for 
metabolism of the drug. This may not seem likely in the case of VPA 
because this drug is not primarily metabolized by the MFO system of 
which cytP450 is a part. However, the fact that chronic VPA therapy 
produces increased 6B-0HC excretion (an in vivo index of hepatic 
m.f.o. activity) suggests that an increased cyt P450 requirement is 
indeed the mechanism by which ALA-S is derepressed in these patients. 
VPA is known to have inhibitory effects on the m.f.o. system. 
Therefore the increase in the activity of this system observed here is 
probably the result of overcompensating for the inhibitory effects of 
VPA.
ALA-D, PBG-D and URO-D
These enzymes were unaffected by treatment with VPA.
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Urinary excretion of porphyrins and precursors
There were increases of the urinary excretion of ALA, PBG and 
total porphyrin during treatment with VPA, although the increase was 
only significant as regards PBG and total porphyrin. These increases 
were believed to be due to increased ALA-S activity. There was no 
correlation between drug levels and the excretion of any of these. 
Qualitative analysis of urinary porohvrins
Long term treatment with VPA resulted in a slight change in the 
urinary porphyrin excretion profile characterized by an increase in 
the % coproporphyrin. This was explained by the increased 
availability of pathway intermediates due to derepression of ALA-S and 
a difference in the relative activities of URO-D and COPRO-0.
9.1.4 CARBAMAZEPINE
The effects of carbamazepine (CBZ) on haem biosynthesis are 
discussed under individual headings.
ALA-S
Rapeport jgt. âL (1983) have shown that short term treatment with 
CBZ in man resulted in an elevation of ALA-S activity. Results 
presented in this thesis revealed that the increase in ALA-S activity 
was sustained during long term treatment with CBZ, althou^ activities 
were not as hi^ as during the initial stages of treatment. CBZ is 
metabolized prior to excretion by cytP450 dependent m.f.o. system. 
It is therefore hi^ly probable that ALA-S was derepressed to produce 
enou^ haem to satisfy the increased haem requirements generated by 
increased synthesis of cytP450 apoprotein according to the mechanism 
described in sub-section 1.3.9. In support of this, 6B-0HC 
excretion, (an in vivo index of hepatic m.f.o. activity) was increased
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in patients receiving CBZ. Further evidence that cytP450 dependent 
m.f.o. activity was induced in man was noted by Rapeport sL ai. (1983). 
In subsequent studies in the rat, induction of cyt P450 was shown to 
be linked to the derepression of ALA-S. Rat liver did not prove to 
be an ideal system for modelling the effects of CBZ treatment in man 
since activity soon returned to control levels. This may be due to 
differences in the relative activités of the other enzymes in the 
pathway and m.f.o. system or to the fact that activity was measured in 
a different tissue. The mechanism by which CBZ stimulated the 
production of cytP450 in the rat and presumably in man is not known, 
but it was probably not due to CBZ-mediated destruction of cypP450. 
To return to man, it is possible that in some of the patients studied, 
the derepression of ALA-S was partly due to an impairment of the flow 
of metabolites throu^ the pathway as a consequence of reduced ALA-D 
activity. This was not true for the majority of the patients 
studied. However, even in those where it may have been applicable, 
it would not have been as significant as the effect of increased 
cytP450 requirement. In support of this there was no correlation 
between ALA-S and ALA-D activities. There was no correlation between 
ALA-S activity and plasma CBZ, CBZ-E or free CBZ concentrations.
ALA-D.
Long term treatment with CBZ caused a substantial reduction in 
the activity of erythrocyte ALA-D in man. The reduced activity in 
these patients was not due to a coincidental hi^ blood lead level. 
The reduction in activity was irreversible. The Km values for ALA 
and the optimum assay pH of ALA-D in CBZ-treated patients were 
identical to controls. These facts suggested that the low activities 
were probably due to a reduced amount of normal enzyme rather than the
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alternative explanation: a normal amount of modified enzyme. In
these patients there were correlations between plasma "total" CBZ and 
CBZ-E concentrations and ALA-D activity» but not between free CBZ 
levels and ALA-D. Activities were not affected for some time, even 
after several days in the presence of plasma concentrations of CBZ and 
CBZ-E found in patients with reduced ALA-D. This suggested that 
enzyme activity was not lost as a consequence of a direct effect of 
CBZ or CBZ-E on the enzyme. Lc^s of activity was not due to a loss 
of glutathione, a tripeptide responsible for the maintenance of thiol 
groups sensitive to oxidation in the reduced state. ALA-D has 
several such groups.
Studies in rats confirmed that CBZ treatment produced an 
irreversible loss of ALA-D activity and that the extent of the loss 
was dependent on the dose of CBZ administered. As was the case in 
man, activity was not immediately affected, even in the presence of 
hi^ CBZ and CBZ-E concentrations, providing further evidence that 
activity was not reduced throu^ a direct action of CBZ or CBZ-E on 
the enzyme. This was confirmed by In vitro studies which also showed 
that the loss of ALA-D activity was not caused by a direct action of 
any metabolite of CBZ present in plasma or erythrocytes unless the 
metabolite was very short lived.
In further studies using mitogen-stimulated human lymphocytes, 
it was shown that both CBZ and CBZ-E caused a specific, irreversible 
loss of ALA-D activity without detectable metabolism of drug. CBZ-E 
was much more effective than CBZ. The loss of ALA-D activity in this 
system could only be explained by inactivation of existing enzyme and 
not by a reduction in enzyme synthesis. The fact that this occurs
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here but does not occur when these compounds are added to 
metabolically inactive preparations of the enzyme suggests that the 
inactivating species is produced throu^ seme bioactivation of the 
drugs which occurs in living cells. The nature of this activated 
species is not known.
Data from jjl vitro drug metabolism studies showed that the action 
of the cytP450 dependent MFO system on CBZ and CBZ-E generated species 
which caused inactivation of ALA-D. Whether the species responsible 
were metabolites or transient intermediates is not known, but it is 
unlikely that they were the same as those responsible for inactivation 
of ALA-D in cultured cells. The inactivating species were only 
generated from CBZ or CBZ-E and showed specificity for ALA-D. The 
relevance of these results to the in vivo situation is doubtful.
In the absence of metabolism, CBZ and CBZ-E only caused 
inactivation of ALA-D in metabolically active cells. This provides 
a possible explanation for the length of time taken for erythrocyte 
ALA-D activities to be affected in vivo. Since any bioactivated form 
of CBZ or CBZ-E must be unstable, it is unlikely that they would be 
found outwith cells and could therefore only inactivate ALA-D in 
active cells. ALA-D activity in mature erythrocytes therefore, would 
be unaffected. However, ALA-D in developing erythroblasts would be 
inactivated but it would take seme time for affected cells to mature 
and make up a significant proportion of the erythrocyte population. 
This hypothesis would suggest that ALA-D should have been rapidly 
inactivated in rat liver. This was not so. Possible explanations 
for this are the faster rate of enzyme turnover in the rat and the 
fact that rat liver is very efficient at removing toxic xenobiotics 
throu^ further metabolism and conjugation. Whereas the relevance of
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inactivation of ALA-D in the course of metabolism of CBZ is uncertain 
(except perhaps in the liver) the activation of these compounds by 
metabolically active cells with the result inactivation of ALA-D 
almost certainly occurs in vivo.
Previously Rapeport fit âl (1984) and Yeung fit (1983(B)) had 
reported a loss of PBG-D activity during treatment with CBZ. These 
claims were refuted by Doss and Shafar (1983); Rideout fit fit (1983) 
and Shanley, (1983).
Initial results showed that PBG-D activities seemed to be reduced 
by CBZ and that the loss of activity was related to plasma 
concentrations of the drug. Subsequent studies however revealed that 
PBG-D activity was not affected by CBZ and that these earlier results 
were artifacts produced by the fact that the assay used relied on 
normal levels of ALA-D activity (not present in CBZ treated patients) 
to generate sufficient substrate for PBG-D. In support of this, 
PBG-D activity was unaffected in rats during CBZ treatment. CBZ 
itself did not affect PBG-D in cultured lymphocytes, but the effects 
of CBZ-E could not be assessed because it interfered with the assay.
This result is important because it demonstrates how the use of a 
coupled enzyme system can produce false results if the activity of the 
coupling enzyme is inadequate.
URO-D
URO-D activity was not affected by CBZ treatment.
Urinarv excretion of nornhvrins and precursors
The urinary excretion of ALA, PBG and total porphyrin was 
increased by long term CBZ treatment, but not to a significant level.
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This was probably due to the derepression of ALA-S already described. 
The fact that PBG and porphyrin excretion were sli^tly increased 
shows that ALA-D activity in general was not reduced to an extent 
where flux throu^ the pathway was disturbed. There was however a 
subtle change in the relationship between ALA and PBG concentrations.
The results of studies on the effects of CBZ on ALA, PBG and 
total porphyrin excretion in rat urine showed changes in ALA and PBG 
excretion which could be parti^ly explained by the alterations in 
ALA-S and ALA-D activities. However no conclusions of the effects of 
CBZ on total porphyrin excretion were made for reasons described in 
the text.
In tissue culture, both CBZ and CBZ-E caused a reduction in the 
amount of total porphyrin synthesized frcxn ALA, which correlated with 
the loss of ALA-D activity. However porphyrin synthesis would not be 
affected in this way in. vivo, even if ALA-D activity was reduced to 
the same extent. This was confirmed by the finding that all the 
urines studied from CBZ treated patients had normal or sli^tly raised 
total porfdiyrin excretion. The reasons for this difference in the in. 
vivo and in vitro models is that in vitro the rate of porphyrin 
synthesis depends on the amount of ALA-D activity (since ALA is 
present in saturating amounts), whereas in vivo the rate limiting 
factor is the amount of ALA produced for ALA-D to act upon. Normally 
this is well below the km of ALA-D and therefore the rate of porphyrin 
synthesis is not dependent on the amount of ALA-D present but on the 
level of ALA-S activity.
Qualitative analysis of urinary.-PQrPhyring
No differences were found in the relative proportions of 
porphyrins in urine from long term CBZ-treated patients and controls,
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indicating no changes in COPRO-0, PROTO-0 or FERRO-C activity. This 
did not fit in with the findings of Rapeport fit. âl» (1984) who 
reported large increases in the ÜRO fraction following short term 
treatment with the drug. This result was confirmed. Since these 
changes were transient and occurred at the start of treatment, it may 
be that they were a consequence of the very high levels of ALA-S 
present at this time. This would have caused more PBG to be produced 
than PBG-D could cope with, with the result that the excess would be 
excreted in the urine where it could undergo non-enzymatic 
condensation and cyclization to produce ÜRO-I. No increase in the $ 
ÜRO was found in the rat urine. Possible reasons for this are 
discussed in the text*.
In cell culture, the la vivo effects of CBZ and CBZ-E on ALA-D 
were shown to occur. This did not result in any change in the 
relative proportions of porphyrins produced from ALA in these cells. 
This would therefore suggest that the change in urine porphyrin 
composition la vivo must be due to the one other enzyme shown to be 
affected by CBZ treatment vrtiich would have no effect on this assay, 
namely ALA-S.
These findings would imply that derepression of ALA-S by other 
drugs to the very high levels produced by CBZ would also cause an 
increase in the % ÜRO in the urinary porphyrin excretion profile. It 
would therefore be prudent when screening for porphyria by analysis of 
urinary porphyrins to check that the subject is not taking any drugs 
known to induce m.f.o.activity and consequently raise the levels of 
ALA-S activity.
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APPLICATION OF THESE RESULTS TO THE FINDINGS OF RAPEPORT AND YEUNG
The results presented in this thesis regarding the effects of CBZ 
on haem biosynthesis can explain the findings made by Rapeport fit. al 
(1984) in their study of the effects of CBZ on the pathway, i.e. 
elevated ALA-S activity, an apparent reduction in PBG-D activity, 
slightly increased urinary excretion of ALA, PBG and porphyrin and an 
altered urinary porphyrin excretion profile. However they do not 
explain some of the results published by Yeung fit fit (1983). In that 
paper a patient taking carbamazepine was shown to have a moderately 
raised ALA-S activity (395 nmolALA/h/g protein) an ^parently reduced 
PBG-D activity (9 nmolURO/h/ml erythrocytes) and elevated urinary 
excretion of ALA, PBG and ÜRO (171 jomol/l, 194 pmol/1 and 1022 nmol/1 
respectively). Unfortunately values for 24 hour excretions of these 
compounds are not given and consequently it is difficult to gauge the 
extent of the increased excretion. The patient also experienced 
severe abdominal pain for which no cause could be found and passed 
dark urine.
The ALA-S activity in this patient was not greatly derepressed: 
many of the patients taking CBZ who were studied as part of this 
thesis had activities in excess of this. Therefore this effect of 
CBZ is not unusual. Nor is the apparent reduction in PBG-D activity, 
which was presumably due to the effects of CBZ on ALA-D as discussed 
previously. The finding that it took 3-4 weeks for PBG-D activity to 
return to normal after cessation of CBZ therapy fits in nicely with 
the observation that it would take this time to renew the erythrocyte 
population with cells containing unaffected ALA-D. What is difficult 
to explain is the increased urinary excretion of ALA, PBG and URO. 
There are two possible explanations. The first is that the excretion
233
of these compounds was not greatly increased at all, but that the 
urine was very concentrated. This would also explain the dark colour 
of the urine and cannot be ruled out as a possibility since 24 hour 
urine volumes were not given. The second is that the excretion of 
these compounds was increased because of an impairment of the flow of 
metabolites further on in the pathway or because the low levels of 
PBG-D detected were not entirely due to the effects of CBZ on ALA-D. 
Whichever of these is the case, it would appear that the clinical 
response of this patient to CBZ treatment was atypical of all of the 
other patients studied. His many clinical symptoms may have simply 
been due to extreme sensitivity to the side-effects of CBZ.
. . •
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9.2 GENERAL CONCLUSIONS
This thesis investi^ted the effects of CBZ, VPA, DPH and PB on 
haem biosynthesis in man. As stated in the introduction, the 
objectives were:
(i) to establish if CBZ, VPA or DPH could be safely used for 
seizure prophylaxis in individuals with porphyria 
(ii) to investigate and elucidate the mechanism(s) whereby CBZ 
treatment produced an apparent acute intermittent porphyria 
(AIP) syndrome 
and
(iii) to assess the suitability of CBZ treatment as a model for 
studying AIP
These aims have been satisfied and allow the following general 
conclusions to be drawn.
(1) CBZ and VPA are contra-indicated in the porphyrias due to the 
sustained derepression of ALA-S produced by chronic treatment 
with these drugs. However, they may be tolerated in some 
patients without adverse effect (Lai, 1981; Peters, 1981; Sergay, 
1979 and Brodie fit fil, 1977,B). Such results reflect the fact 
that even in the presence of ALA and PBG levels which could be 
associated with an acute porphyric attack, some individuals 
remain asymptomatic. Thou^ it was not proven here, other work 
has shown that DPH is probably unsafe to use for treatment of 
seizures in porphyria (McColl fit fii? 1980).
(2) In light of the effects of CBZ on ALA-D, it would be unwise to 
prescribe this drug to individuals whose levels of ALA-D activity 
are already chronically reduced by pathological conditions such 
as lead-poisoning, severe alcoholism or hereditary tyrosinemia.
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(3) The altered porphyrin excretion profile in the initial stages of 
CBZ treatment was a consequence of extreme derepression of ALA-S. 
Presumably, therefore, other drugs which cause derepression of 
the enzyme to the same degree would also cause dhanges in the 
urinary porphyrin excretion profile. In view of the increasing 
interestinscreening for porphyria by qualitative analysis of 
urinary porphyrins, it is important to ensure that the subjects 
are not taking any such drugs, otherwise a mis-diagnosis of 
porphyria may result.
(4) CBZ does not cause a loss of PBG-D activity as reported by Yeung 
fitaL (1983) and Rapeport fit âl ( 1984). These findings were 
erroneous due to the use of a coupled assay system in which ALA-D 
was the coupling enzyme, (ALA-D activity is reduced by CBZ).
(5) The effects of CBZ on rat liver and on cultured human lymphocytes 
were in general the same as in man. The use of these systems 
allowed further probing of the nature of the effects of CBZ on 
haem biosynthesis.
(6) CBZ treatment is not a suitable model for studying AIP.
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APPENDIX I
PATIENT DETAILS
Control males CBZ-treated males
No. Age No. Age Type of epilepsy*
1 14 1 15 I
2 23 2 18 I
3 23 3 I
4 24 4 1 20 I
3 24 5 21 PC
6 24 6 25 PC
7 24 7 26 I
8 25 8 27 I
9 23 9 27 PC
10 26 10 28 PC
11 26 11 29 PC
12 26 12 29 I
13 27 13 30 PC
14 28 14 30 PC
15 31 15 30 PC
16 32 16 30 PC
17 32 17 32 I
18 35 18 32 PC
19 39 19 33 I
20 39 20 33 PC
21 39 21 35 I
22 39 22 36 I
23 49 23 37 PC
24 51 24 37 PC
25 71 25 43 PC
26 43 • I
27 46 PC
28 55 I
29 59 PC
30 62 I
* PC = Partial complex 
I = Idiopathic
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APPENDIX I (cont)
Control females CBZ-treated females
No. Arc No. Age Type of epilepsy *
1 14 1 1 3 PC
2 16 2 14 I
3 1 7 3 ^7 PC
4 20 4 1 8 I
3 2 0 5 1 8 PC
6 24 6 1 9 PC
7 2 5 7 2 0 I
8 2 5 8 2 1 PC
9 2 6 9 2 3 PC
1 0 2 9 1 0 2 3 PC
1 1 2 8 1 1 24 PC
1 2 3 2 1 2 24 I
1 3 42 1 3 2 6 PC
14 44 14 2 6 PC
1 5 4 9 1 5 3 0 PC
1 6 5 0 1 6 37 PC
1 7 57 1 7 4 5 I
1 8 4 7 PC
1 9 57 I
2 0 57 PC
2 1 58 PC
2 2 64 PC
2 3 75 I
.
* PC = Partial complex 
I s= Idiopathic
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APPENDIX I (contd) 
Phenytoin-treated subjects
No. Sex Age Type of epilepsy *
1 M 20 PC
2 M 27 PC
3 M 27 PC
4 M 42 I
3 M 43 1 I
6 M 43 I
7 M 33 I
8 F 34 PC
9 F 39 PC
10 M 61 I
11 F 69 PC
Sodium valproate-treated subjects
No. Sex Age Type of epilepsy *
1 F 13 I
2 F 14 I
3 M 14 I
4 F 16 PC
3 M 16 I
6 F 1 8 I
7 . M 24 I
8 M 23 I
9 F 23 I
10 M 28 I
11 F 30 I
12 F 57 I
* PC = Partial complex 
I = Idiopathic
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